AN ACT 
To reauthorize certain programs under the Public Health 
Service Act and the Federal Food, Drug, and Cosmetic 
Act with respect to public health security and all-hazards 
preparedness and response, to clarify the regulatory 
framework with respect to certain nonprescription drugs 
that are marketed without an approved drug application, 
and for other purposes. 
2 
•HR 269 EH
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) SHORT TITLE.—This Act may be cited as the 
4
‘‘Pandemic and All-Hazards Preparedness and Advancing 
5
Innovation Act of 2019’’. 
6
(b) TABLE OF CONTENTS.—The table of contents for 
7
this Act is as follows: 
8
Sec. 1. Short title; table of contents. 
DIVISION A—PANDEMIC AND ALL-HAZARDS PREPAREDNESS AND 
ADVANCING INNOVATION 
Sec. 100. References in division. 
TITLE I—STRENGTHENING THE NATIONAL HEALTH SECURITY 
STRATEGY 
Sec. 101. National Health Security Strategy. 
TITLE II—IMPROVING PREPAREDNESS AND RESPONSE 
Sec. 201. Improving benchmarks and standards for preparedness and response. 
Sec. 202. Amendments to preparedness and response programs. 
Sec. 203. Regional health care emergency preparedness and response systems. 
Sec. 204. Military and civilian partnership for trauma readiness. 
Sec. 205. Public health and health care system situational awareness and bio-
surveillance capabilities. 
Sec. 206. Strengthening and supporting the public health emergency rapid re-
sponse fund. 
Sec. 207. Improving all-hazards preparedness and response by public health 
emergency volunteers. 
Sec. 208. Clarifying State liability law for volunteer health care professionals. 
Sec. 209. Report on adequate national blood supply. 
Sec. 210. Report on the public health preparedness and response capabilities 
and capacities of hospitals, long-term care facilities, and other 
health care facilities. 
TITLE III—REACHING ALL COMMUNITIES 
Sec. 301. Strengthening and assessing the emergency response workforce. 
Sec. 302. Health system infrastructure to improve preparedness and response. 
Sec. 303. Considerations for at-risk individuals. 
Sec. 304. Improving emergency preparedness and response considerations for 
children. 
Sec. 305. National advisory committees on disasters. 
Sec. 306. Guidance for participation in exercises and drills. 
3 
•HR 269 EH
TITLE IV—PRIORITIZING A THREAT-BASED APPROACH 
Sec. 401. Assistant Secretary for Preparedness and Response. 
Sec. 402. Public Health Emergency Medical Countermeasures Enterprise. 
Sec. 403. Strategic National Stockpile. 
Sec. 404. Preparing for pandemic influenza, antimicrobial resistance, and other 
significant threats. 
Sec. 405. Reporting on the Federal Select Agent Program. 
TITLE V—INCREASING COMMUNICATION IN MEDICAL 
COUNTERMEASURE ADVANCED RESEARCH AND DEVELOPMENT 
Sec. 501. Medical countermeasure budget plan. 
Sec. 502. Material threat and medical countermeasure notifications. 
Sec. 503. Availability of regulatory management plans. 
Sec. 504. The Biomedical Advanced Research and Development Authority and 
the BioShield Special Reserve Fund. 
Sec. 505. Additional strategies for combating antibiotic resistance. 
TITLE VI—ADVANCING TECHNOLOGIES FOR MEDICAL 
COUNTERMEASURES 
Sec. 601. Administration of countermeasures. 
Sec. 602. Updating definitions of other transactions. 
Sec. 603. Medical countermeasure master files. 
Sec. 604. Animal rule report. 
Sec. 605. Review of the benefits of genomic engineering technologies and their 
potential role in national security. 
Sec. 606. Report on vaccines development. 
Sec. 607. Strengthening mosquito abatement for safety and health. 
TITLE VII—MISCELLANEOUS PROVISIONS 
Sec. 701. Reauthorizations and extensions. 
Sec. 702. Location of materials in the stockpile. 
Sec. 703. Cybersecurity. 
Sec. 704. Strategy and report. 
Sec. 705. Technical amendments. 
DIVISION B—OVER-THE-COUNTER MONOGRAPH SAFETY, 
INNOVATION, AND REFORM 
Sec. 1000. Short title; references in division. 
TITLE I—OTC DRUG REVIEW 
Sec. 1001. Regulation of certain nonprescription drugs that are marketed with-
out an approved drug application. 
Sec. 1002. Misbranding. 
Sec. 1003. Drugs excluded from the over-the-counter drug review. 
Sec. 1004. Treatment of Sunscreen Innovation Act. 
Sec. 1005. Annual update to Congress on appropriate pediatric indication for 
certain OTC cough and cold drugs. 
Sec. 1006. Technical corrections. 
TITLE II—USER FEES 
4 
•HR 269 EH
Sec. 2001. Short title; finding. 
Sec. 2002. Fees relating to over-the-counter drugs. 
DIVISION 
A—PANDEMIC 
AND 
1
ALL-HAZARDS 
PREPARED-
2
NESS AND ADVANCING INNO-
3
VATION 
4
SEC. 100. REFERENCES IN DIVISION. 
5
Except as otherwise specified— 
6
(1) amendments made by this division to a sec-
7
tion or other provision of law are amendments to 
8
such section or other provision of the Public Health 
9
Service Act (42 U.S.C. 201 et seq.); and 
10
(2) any reference to ‘‘this Act’’ contained in 
11
this division shall be treated as referring only to the 
12
provisions of this division. 
13
TITLE I—STRENGTHENING THE 
14
NATIONAL HEALTH SECURITY 
15
STRATEGY 
16
SEC. 101. NATIONAL HEALTH SECURITY STRATEGY. 
17
Section 2802 (42 U.S.C. 300hh–1) is amended— 
18
(1) in subsection (a)— 
19
(A) in paragraph (1)— 
20
(i) by striking ‘‘2014’’ and inserting 
21
‘‘2018’’; and 
22
(ii) by striking the second sentence 
23
and inserting the following: ‘‘Such Na-
24
5 
•HR 269 EH
tional Health Security Strategy shall de-
1
scribe potential emergency health security 
2
threats and identify the process for achiev-
3
ing the preparedness goals described in 
4
subsection (b) to be prepared to identify 
5
and respond to such threats and shall be 
6
consistent with the national preparedness 
7
goal (as described in section 504(a)(19) of 
8
the Homeland Security Act of 2002), the 
9
National Incident Management System (as 
10
defined in section 501(7) of such Act), and 
11
the National Response Plan developed pur-
12
suant to section 504 of such Act, or any 
13
successor plan.’’; 
14
(B) in paragraph (2), by inserting before 
15
the period at the end of the second sentence the 
16
following: ‘‘, and an analysis of any changes to 
17
the evidence-based benchmarks and objective 
18
standards under sections 319C–1 and 319C–2’’; 
19
and 
20
(C) in paragraph (3)— 
21
(i) by striking ‘‘2009’’ and inserting 
22
‘‘2022’’; 
23
(ii) by inserting ‘‘(including gaps in 
24
the environmental health and animal 
25
6 
•HR 269 EH
health workforces, as applicable), describ-
1
ing the status of such workforce’’ after 
2
‘‘gaps in such workforce’’; 
3
(iii) by striking ‘‘and identifying strat-
4
egies’’ and inserting ‘‘identifying strate-
5
gies’’; and 
6
(iv) by inserting before the period at 
7
the end ‘‘, and identifying current capabili-
8
ties to meet the requirements of section 
9
2803’’; and 
10
(2) in subsection (b)— 
11
(A) in paragraph (2)— 
12
(i) in subparagraph (A), by striking 
13
‘‘and investigation’’ and inserting ‘‘inves-
14
tigation, and related information tech-
15
nology activities’’; 
16
(ii) in subparagraph (B), by striking 
17
‘‘and decontamination’’ and inserting ‘‘de-
18
contamination, relevant health care serv-
19
ices and supplies, and transportation and 
20
disposal of medical waste’’; and 
21
(iii) by adding at the end the fol-
22
lowing: 
23
‘‘(E) Response to environmental hazards.’’; 
24
(B) in paragraph (3)— 
25
7 
•HR 269 EH
(i) in the matter preceding subpara-
1
graph (A), by striking ‘‘including mental 
2
health’’ and inserting ‘‘including phar-
3
macies, mental health facilities,’’; and 
4
(ii) in subparagraph (F), by inserting 
5
‘‘or exposures to agents that could cause a 
6
public health emergency’’ before the pe-
7
riod; 
8
(C) in paragraph (5), by inserting ‘‘and 
9
other applicable compacts’’ after ‘‘Compact’’; 
10
and 
11
(D) by adding at the end the following: 
12
‘‘(9) ZOONOTIC
DISEASE, FOOD, AND
AGRI-
13
CULTURE.—Improving coordination among Federal, 
14
State, local, Tribal, and territorial entities (including 
15
through consultation with the Secretary of Agri-
16
culture) to prevent, detect, and respond to outbreaks 
17
of plant or animal disease (including zoonotic dis-
18
ease) that could compromise national security result-
19
ing from a deliberate attack, a naturally occurring 
20
threat, the intentional adulteration of food, or other 
21
public health threats, taking into account inter-
22
actions between animal health, human health, and 
23
animals’ and humans’ shared environment as di-
24
8 
•HR 269 EH
rectly related to public health emergency prepared-
1
ness and response capabilities, as applicable. 
2
‘‘(10) GLOBAL HEALTH SECURITY.—Assessing 
3
current or potential health security threats from 
4
abroad to inform domestic public health prepared-
5
ness and response capabilities.’’. 
6
TITLE II—IMPROVING 
7
PREPAREDNESS AND RESPONSE 
8
SEC. 201. IMPROVING BENCHMARKS AND STANDARDS FOR 
9
PREPAREDNESS AND RESPONSE. 
10
(a) EVALUATING MEASURABLE EVIDENCE-BASED 
11
BENCHMARKS
AND
OBJECTIVE
STANDARDS.—Section 
12
319C–1 (42 U.S.C. 247d–3a) is amended by inserting 
13
after subsection (j) the following: 
14
‘‘(k) EVALUATION.— 
15
‘‘(1) IN
GENERAL.—Not later than 2 years 
16
after the date of enactment of the Pandemic and 
17
All-Hazards Preparedness and Advancing Innovation 
18
Act of 2019 and every 2 years thereafter, the Sec-
19
retary shall conduct an evaluation of the evidence- 
20
based benchmarks and objective standards required 
21
under subsection (g). Such evaluation shall be sub-
22
mitted to the congressional committees of jurisdic-
23
tion together with the National Health Security 
24
9 
•HR 269 EH
Strategy under section 2802, at such time as such 
1
strategy is submitted. 
2
‘‘(2) CONTENT.—The evaluation under this 
3
paragraph shall include— 
4
‘‘(A) a review of evidence-based bench-
5
marks and objective standards, and associated 
6
metrics and targets; 
7
‘‘(B) a discussion of changes to any evi-
8
dence-based benchmarks and objective stand-
9
ards, and the effect of such changes on the abil-
10
ity to track whether entities are meeting or 
11
making progress toward the goals under this 
12
section and, to the extent practicable, the appli-
13
cable goals of the National Health Security 
14
Strategy under section 2802; 
15
‘‘(C) a description of amounts received by 
16
eligible entities described in subsection (b) and 
17
section 319C–2(b), and amounts received by 
18
subrecipients and the effect of such funding on 
19
meeting evidence-based benchmarks and objec-
20
tive standards; and 
21
‘‘(D) recommendations, as applicable and 
22
appropriate, to improve evidence-based bench-
23
marks and objective standards to more accu-
24
rately assess the ability of entities receiving 
25
10 
•HR 269 EH
awards under this section to better achieve the 
1
goals under this section and section 2802.’’. 
2
(b) EVALUATING THE PARTNERSHIP FOR STATE AND 
3
REGIONAL HOSPITAL PREPAREDNESS.—Section 319C– 
4
2(i)(1) (42 U.S.C. 247–3b(i)(1)) is amended by striking 
5
‘‘section 319C–1(g), (i), and (j)’’ and inserting ‘‘section 
6
319C–1(g), (i), (j), and (k)’’. 
7
SEC. 202. AMENDMENTS TO PREPAREDNESS AND RE-
8
SPONSE PROGRAMS. 
9
(a) COOPERATIVE AGREEMENT APPLICATIONS FOR 
10
IMPROVING STATE AND LOCAL PUBLIC HEALTH SECU-
11
RITY.—Section 319C–1 (42 U.S.C. 247d–3a) is amend-
12
ed— 
13
(1) in subsection (a), by inserting ‘‘, acting 
14
through the Director of the Centers for Disease 
15
Control and Prevention,’’ after ‘‘the Secretary’’; and 
16
(2) in subsection (b)(2)(A)— 
17
(A) in clause (vi), by inserting ‘‘, including 
18
public health agencies with specific expertise 
19
that may be relevant to public health security, 
20
such as environmental health agencies,’’ after 
21
‘‘stakeholders’’; 
22
(B) by redesignating clauses (vii) through 
23
(ix) as clauses (viii) through (x); 
24
11 
•HR 269 EH
(C) by inserting after clause (vi) the fol-
1
lowing: 
2
‘‘(vii) a description of how, as applica-
3
ble, such entity may integrate information 
4
to account for individuals with behavioral 
5
health needs following a public health 
6
emergency;’’; 
7
(D) in clause (ix), as so redesignated, by 
8
striking ‘‘; and’’ and inserting a semicolon; and 
9
(E) by adding at the end the following: 
10
‘‘(xi) a description of how the entity 
11
will partner with health care facilities, in-
12
cluding hospitals and nursing homes and 
13
other long-term care facilities, to promote 
14
and improve public health preparedness 
15
and response; and 
16
‘‘(xii) a description of how, as appro-
17
priate and practicable, the entity will in-
18
clude critical infrastructure partners, such 
19
as utility companies within the entity’s ju-
20
risdiction, in planning pursuant to this 
21
subparagraph to help ensure that critical 
22
infrastructure will remain functioning dur-
23
ing, or return to function as soon as prac-
24
ticable after, a public health emergency;’’. 
25
12 
•HR 269 EH
(b) EXCEPTION RELATING TO APPLICATION OF CER-
1
TAIN REQUIREMENTS.— 
2
(1) IN
GENERAL.—Section 319C–1(g) (42 
3
U.S.C. 247d–3a(g)) is amended— 
4
(A) in paragraph (5)— 
5
(i) in the matter preceding subpara-
6
graph (A), by striking ‘‘Beginning with fis-
7
cal year 2009’’ and inserting ‘‘Beginning 
8
with fiscal year 2019’’; and 
9
(ii) in subparagraph (A)— 
10
(I) by striking ‘‘for the imme-
11
diately preceding fiscal year’’ and in-
12
serting ‘‘for either of the 2 imme-
13
diately preceding fiscal years’’; and 
14
(II) by striking ‘‘2008’’ and in-
15
serting ‘‘2018’’; and 
16
(B) in paragraph (6), by amending sub-
17
paragraph (A) to read as follows: 
18
‘‘(A) IN
GENERAL.—The amounts de-
19
scribed in this paragraph are the following 
20
amounts that are payable to an entity for ac-
21
tivities described in this section or section 
22
319C–2: 
23
‘‘(i) For no more than 1 of each of 
24
the first 2 fiscal years immediately fol-
25
13 
•HR 269 EH
lowing a fiscal year in which an entity ex-
1
perienced a failure described in subpara-
2
graph (A) or (B) of paragraph (5), an 
3
amount equal to 10 percent of the amount 
4
the entity was eligible to receive for the re-
5
spective fiscal year. 
6
‘‘(ii) For no more than 1 of the first 
7
2 fiscal years immediately following the 
8
third consecutive fiscal year in which an 
9
entity experienced such a failure, in lieu of 
10
applying clause (i), an amount equal to 15 
11
percent of the amount the entity was eligi-
12
ble to receive for the respective fiscal 
13
year.’’. 
14
(2) EFFECTIVE DATE.—The amendments made 
15
by paragraph (1) shall apply with respect to cooper-
16
ative agreements awarded on or after the date of en-
17
actment of this Act. 
18
(c) PARTNERSHIP FOR STATE AND REGIONAL HOS-
19
PITAL PREPAREDNESS TO IMPROVE SURGE CAPACITY.— 
20
Section 319C–2 (42 U.S.C. 247d–3b) is amended— 
21
(1) in subsection (a)— 
22
(A) by inserting ‘‘, acting through the As-
23
sistant Secretary for Preparedness and Re-
24
sponse,’’ after ‘‘The Secretary’’; and 
25
14 
•HR 269 EH
(B) by striking ‘‘preparedness for public 
1
health emergencies’’ and inserting ‘‘prepared-
2
ness for, and response to, public health emer-
3
gencies in accordance with subsection (c)’’; 
4
(2) in subsection (b)(1)(A)— 
5
(A) by striking ‘‘partnership consisting of’’ 
6
and inserting ‘‘coalition that includes’’; 
7
(B) in clause (ii), by striking ‘‘; and’’ and 
8
inserting a semicolon; and 
9
(C) by adding at the end the following: 
10
‘‘(iv) one or more emergency medical serv-
11
ice organizations or emergency management or-
12
ganizations; and’’; 
13
(3) in subsection (d)— 
14
(A) in paragraph (1)(B), by striking ‘‘part-
15
nership’’ each place it appears and inserting 
16
‘‘coalition’’; and 
17
(B) in paragraph (2)(C), by striking ‘‘med-
18
ical preparedness’’ and inserting ‘‘preparedness 
19
and response’’; 
20
(4) in subsection (f), by striking ‘‘partnership’’ 
21
and inserting ‘‘coalition’’; 
22
(5) in subsection (g)(2)— 
23
(A) by striking ‘‘Partnerships’’ and insert-
24
ing ‘‘Coalitions’’; 
25
15 
•HR 269 EH
(B) by striking ‘‘partnerships’’ and insert-
1
ing ‘‘coalitions’’; and 
2
(C) by inserting ‘‘and response’’ after 
3
‘‘preparedness’’; and 
4
(6) in subsection (i)(1)— 
5
(A) by striking ‘‘An entity’’ and inserting 
6
‘‘A coalition’’; and 
7
(B) by striking ‘‘such partnership’’ and in-
8
serting ‘‘such coalition’’. 
9
(d) PUBLIC HEALTH SECURITY GRANTS AUTHORIZA-
10
TION
OF
APPROPRIATIONS.—Section 319C–1(h)(1)(A) 
11
(42 U.S.C. 247d–3a(h)(1)(A)) is amended by striking 
12
‘‘$641,900,000 for fiscal year 2014’’ and all that follows 
13
through 
the 
period 
at 
the 
end 
and 
inserting 
14
‘‘$685,000,000 for each of fiscal years 2019 through 2023 
15
for awards pursuant to paragraph (3) (subject to the au-
16
thority of the Secretary to make awards pursuant to para-
17
graphs (4) and (5)).’’. 
18
(e) PARTNERSHIP FOR STATE AND REGIONAL HOS-
19
PITAL PREPAREDNESS AUTHORIZATION OF APPROPRIA-
20
TIONS.—Section 319C–2(j) (42 U.S.C. 247d–3b(j)) is 
21
amended— 
22
(1) by amending paragraph (1) to read as fol-
23
lows: 
24
‘‘(1) IN GENERAL.— 
25
16 
•HR 269 EH
‘‘(A) 
AUTHORIZATION
OF
APPROPRIA-
1
TIONS.—For purposes of carrying out this sec-
2
tion and section 319C–3, in accordance with 
3
subparagraph (B), there is authorized to be ap-
4
propriated $385,000,000 for each of fiscal years 
5
2019 through 2023. 
6
‘‘(B) RESERVATION OF AMOUNTS FOR RE-
7
GIONAL SYSTEMS.— 
8
‘‘(i) IN GENERAL.—Subject to clause 
9
(ii), of the amount appropriated under sub-
10
paragraph (A) for a fiscal year, the Sec-
11
retary may reserve up to 5 percent for the 
12
purpose of carrying out section 319C–3. 
13
‘‘(ii) RESERVATION
CONTINGENT
ON 
14
CONTINUED
APPROPRIATIONS
FOR
THIS 
15
SECTION.—If for fiscal year 2019 or a sub-
16
sequent fiscal year, the amount appro-
17
priated under subparagraph (A) is such 
18
that, after application of clause (i), the 
19
amount remaining for the purpose of car-
20
rying out this section would be less than 
21
the amount available for such purpose for 
22
the previous fiscal year, the amount that 
23
may be reserved under clause (i) shall be 
24
reduced such that the amount remaining 
25
17 
•HR 269 EH
for the purpose of carrying out this section 
1
is not less than the amount available for 
2
such purpose for the previous fiscal year. 
3
‘‘(iii) SUNSET.—The authority to re-
4
serve amounts under clause (i) shall expire 
5
on September 30, 2023.’’; 
6
(2) in paragraph (2), by striking ‘‘paragraph 
7
(1) for a fiscal year’’ and inserting ‘‘paragraph 
8
(1)(A) for a fiscal year and not reserved for the pur-
9
pose described in paragraph (1)(B)(i)’’; and 
10
(3) in paragraph (3)(A), by striking ‘‘paragraph 
11
(1) and not reserved under paragraph (2)’’ and in-
12
serting ‘‘paragraph (1)(A) and not reserved under 
13
paragraph (1)(B)(i) or (2)’’. 
14
SEC. 203. REGIONAL HEALTH CARE EMERGENCY PRE-
15
PAREDNESS AND RESPONSE SYSTEMS. 
16
(a) IN GENERAL.—Part B of title III (42 U.S.C. 243 
17
et seq.) is amended by inserting after section 319C–2 the 
18
following: 
19
‘‘SEC. 319C–3. GUIDELINES FOR REGIONAL HEALTH CARE 
20
EMERGENCY PREPAREDNESS AND RESPONSE 
21
SYSTEMS. 
22
‘‘(a) PURPOSE.—It is the purpose of this section to 
23
identify and provide guidelines for regional systems of hos-
24
pitals, health care facilities, and other public and private 
25
18 
•HR 269 EH
sector entities, with varying levels of capability to treat 
1
patients and increase medical surge capacity during, in ad-
2
vance of, and immediately following a public health emer-
3
gency, including threats posed by one or more chemical, 
4
biological, radiological, or nuclear agents, including emerg-
5
ing infectious diseases. 
6
‘‘(b) GUIDELINES.—The Assistant Secretary for Pre-
7
paredness and Response, in consultation with the Director 
8
of the Centers for Disease Control and Prevention, the Ad-
9
ministrator of the Centers for Medicare & Medicaid Serv-
10
ices, the Administrator of the Health Resources and Serv-
11
ices Administration, the Commissioner of Food and 
12
Drugs, the Assistant Secretary for Mental Health and 
13
Substance Use, the Assistant Secretary of Labor for Occu-
14
pational Safety and Health, the Secretary of Veterans Af-
15
fairs, the heads of such other Federal agencies as the Sec-
16
retary determines to be appropriate, and State, local, 
17
Tribal, and territorial public health officials, shall, not 
18
later than 2 years after the date of enactment of this sec-
19
tion— 
20
‘‘(1) identify and develop a set of guidelines re-
21
lating to practices and protocols for all-hazards pub-
22
lic health emergency preparedness and response for 
23
hospitals and health care facilities to provide appro-
24
priate patient care during, in advance of, or imme-
25
19 
•HR 269 EH
diately following, a public health emergency, result-
1
ing from one or more chemical, biological, radio-
2
logical, or nuclear agents, including emerging infec-
3
tious diseases (which may include existing practices, 
4
such as trauma care and medical surge capacity and 
5
capabilities), with respect to— 
6
‘‘(A) a regional approach to identifying 
7
hospitals and health care facilities based on 
8
varying capabilities and capacity to treat pa-
9
tients affected by such emergency, including— 
10
‘‘(i) the manner in which the system 
11
will coordinate with and integrate the part-
12
nerships and health care coalitions estab-
13
lished under section 319C–2(b); and 
14
‘‘(ii) informing and educating appro-
15
priate first responders and health care sup-
16
ply chain partners of the regional emer-
17
gency preparedness and response capabili-
18
ties and medical surge capacity of such 
19
hospitals and health care facilities in the 
20
community; 
21
‘‘(B) physical and technological infrastruc-
22
ture, laboratory capacity, staffing, blood supply, 
23
and other supply chain needs, taking into ac-
24
20 
•HR 269 EH
count resiliency, geographic considerations, and 
1
rural considerations; 
2
‘‘(C) protocols or best practices for the 
3
safety and personal protection of workers who 
4
handle human remains and health care workers 
5
(including with respect to protective equipment 
6
and supplies, waste management processes, and 
7
decontamination), sharing of specialized experi-
8
ence among the health care workforce, behav-
9
ioral health, psychological resilience, and train-
10
ing of the workforce, as applicable; 
11
‘‘(D) in a manner that allows for disease 
12
containment (within the meaning of section 
13
2802(b)(2)(B)), coordinated medical triage, 
14
treatment, and transportation of patients, based 
15
on patient medical need (including patients in 
16
rural areas), to the appropriate hospitals or 
17
health care facilities within the regional system 
18
or, as applicable and appropriate, between sys-
19
tems in different States or regions; and 
20
‘‘(E) the needs of children and other at- 
21
risk individuals; 
22
‘‘(2) make such guidelines available on the 
23
internet website of the Department of Health and 
24
21 
•HR 269 EH
Human Services in a manner that does not com-
1
promise national security; and 
2
‘‘(3) update such guidelines as appropriate, in-
3
cluding based on input received pursuant to sub-
4
sections (c) and (e) and information resulting from 
5
applicable reports required under the Pandemic and 
6
All-Hazards Preparedness and Advancing Innovation 
7
Act of 2019 (including any amendments made by 
8
such Act), to address new and emerging public 
9
health threats. 
10
‘‘(c) CONSIDERATIONS.—In identifying, developing, 
11
and updating guidelines under subsection (b), the Assist-
12
ant Secretary for Preparedness and Response shall— 
13
‘‘(1) include input from hospitals and health 
14
care facilities (including health care coalitions under 
15
section 319C–2), State, local, Tribal, and territorial 
16
public health departments, and health care or sub-
17
ject matter experts (including experts with relevant 
18
expertise in chemical, biological, radiological, or nu-
19
clear threats, including emerging infectious dis-
20
eases), as the Assistant Secretary determines appro-
21
priate, to meet the goals under section 2802(b)(3); 
22
‘‘(2) consult and engage with appropriate 
23
health care providers and professionals, including 
24
physicians, nurses, first responders, health care fa-
25
22 
•HR 269 EH
cilities (including hospitals, primary care clinics, 
1
community health centers, mental health facilities, 
2
ambulatory care facilities, and dental health facili-
3
ties), pharmacies, emergency medical providers, 
4
trauma care providers, environmental health agen-
5
cies, public health laboratories, poison control cen-
6
ters, blood banks, tissue banks, and other experts 
7
that the Assistant Secretary determines appropriate, 
8
to meet the goals under section 2802(b)(3); 
9
‘‘(3) consider feedback related to financial im-
10
plications for hospitals, health care facilities, public 
11
health agencies, laboratories, blood banks, tissue 
12
banks, and other entities engaged in regional pre-
13
paredness planning to implement and follow such 
14
guidelines, as applicable; and 
15
‘‘(4) consider financial requirements and poten-
16
tial incentives for entities to prepare for, and re-
17
spond to, public health emergencies as part of the 
18
regional health care emergency preparedness and re-
19
sponse system. 
20
‘‘(d) TECHNICAL ASSISTANCE.—The Assistant Sec-
21
retary for Preparedness and Response, in consultation 
22
with the Director of the Centers for Disease Control and 
23
Prevention and the Assistant Secretary of Labor for Occu-
24
pational Safety and Health, may provide technical assist-
25
23 
•HR 269 EH
ance and consultation toward meeting the guidelines de-
1
scribed in subsection (b). 
2
‘‘(e) DEMONSTRATION
PROJECT
FOR
REGIONAL 
3
HEALTH CARE PREPAREDNESS
AND RESPONSE SYS-
4
TEMS.— 
5
‘‘(1) IN GENERAL.—The Assistant Secretary for 
6
Preparedness and Response may establish a dem-
7
onstration project pursuant to the development and 
8
implementation of guidelines under subsection (b) to 
9
award grants to improve medical surge capacity for 
10
all hazards, build and integrate regional medical re-
11
sponse capabilities, improve specialty care expertise 
12
for all-hazards response, and coordinate medical pre-
13
paredness and response across State, local, Tribal, 
14
territorial, and regional jurisdictions. 
15
‘‘(2) SUNSET.—The authority under this sub-
16
section shall expire on September 30, 2023.’’. 
17
(b) GAO REPORT TO CONGRESS.— 
18
(1) REPORT.—Not later than 3 years after the 
19
date of enactment of this Act, the Comptroller Gen-
20
eral of the United States (referred to in this sub-
21
section as the ‘‘Comptroller General’’) shall submit 
22
to the Committee on Health, Education, Labor, and 
23
Pensions and the Committee on Finance of the Sen-
24
ate and the Committee on Energy and Commerce 
25
24 
•HR 269 EH
and the Committee on Ways and Means of the 
1
House of Representatives, a report on the extent to 
2
which hospitals and health care facilities have imple-
3
mented the recommended guidelines under section 
4
319C–3(b) of the Public Health Service Act (as 
5
added by subsection (a)), including an analysis and 
6
evaluation of any challenges hospitals or health care 
7
facilities experienced in implementing such guide-
8
lines. 
9
(2) CONTENT.—The Comptroller General shall 
10
include in the report under paragraph (1)— 
11
(A) data on the preparedness and response 
12
capabilities that have been informed by the 
13
guidelines under section 319C–3(b) of the Pub-
14
lic Health Service Act to improve regional emer-
15
gency health care preparedness and response 
16
capability, including hospital and health care 
17
facility capacity and medical surge capabilities 
18
to prepare for, and respond to, public health 
19
emergencies; and 
20
(B) recommendations to reduce gaps in in-
21
centives for regional health partners, including 
22
hospitals and health care facilities, to improve 
23
capacity and medical surge capabilities to pre-
24
pare for, and respond to, public health emer-
25
25 
•HR 269 EH
gencies, consistent with subsection (a), which 
1
may include consideration of facilities partici-
2
pating in programs under section 319C–2 of 
3
the Public Health Service Act (42 U.S.C. 
4
247d–3b) or in programs under the Centers for 
5
Medicare & Medicaid Services (including inno-
6
vative health care delivery and payment mod-
7
els), and input from private sector financial in-
8
stitutions. 
9
(3) CONSULTATION.—In carrying out para-
10
graphs (1) and (2), the Comptroller General shall 
11
consult with the heads of appropriate Federal agen-
12
cies, including— 
13
(A) the Assistant Secretary for Prepared-
14
ness and Response; 
15
(B) the Director of the Centers for Disease 
16
Control and Prevention; 
17
(C) the Administrator of the Centers for 
18
Medicare & Medicaid Services; 
19
(D) the Assistant Secretary for Mental 
20
Health and Substance Use; 
21
(E) the Assistant Secretary of Labor for 
22
Occupational Safety and Health; and 
23
(F) the Secretary of Veterans Affairs. 
24
26 
•HR 269 EH
(c) ANNUAL REPORTS.—Section 319C–2(i)(1) (42 
1
U.S.C. 247d–3b(i)(1)) is amended by inserting after the 
2
first sentence the following: ‘‘In submitting reports under 
3
this paragraph, a coalition shall include information on the 
4
progress that the coalition has made toward the implemen-
5
tation of section 319C–3 (or barriers to progress, if 
6
any).’’. 
7
(d) NATIONAL HEALTH SECURITY STRATEGY INCOR-
8
9
NESS
AND RESPONSE.—Subparagraph (G) of section 
10
2802(b)(3) (42 U.S.C. 300hh–1(b)(3)) is amended to read 
11
as follows: 
12
‘‘(G) Optimizing a coordinated and flexible 
13
approach to the emergency response and med-
14
ical surge capacity of hospitals, other health 
15
care facilities, critical care, trauma care (which 
16
may include trauma centers), and emergency 
17
medical systems.’’. 
18
(e) IMPROVING STATE AND LOCAL PUBLIC HEALTH 
19
SECURITY.— 
20
(1) STATE
AND
LOCAL
SECURITY.—Section 
21
319C–1(e) (42 U.S.C. 247d–3a(e)) is amended by 
22
striking ‘‘, and local emergency plans.’’ and inserting 
23
‘‘, local emergency plans, and any regional health 
24
care emergency preparedness and response system 
25
27 
•HR 269 EH
established pursuant to the applicable guidelines 
1
under section 319C–3.’’. 
2
(2) PARTNERSHIPS.—Section 319C–2(d)(1)(A) 
3
(42 U.S.C. 247d–3b(d)(1)(A)) is amended— 
4
(A) in clause (i), by striking ‘‘; and’’ and 
5
inserting ‘‘;’’; 
6
(B) by redesignating clause (ii) as clause 
7
(iii); and 
8
(C) by inserting after clause (i) the fol-
9
lowing: 
10
‘‘(ii) among one or more facilities in a 
11
regional health care emergency system 
12
under section 319C–3; and’’. 
13
SEC. 204. MILITARY AND CIVILIAN PARTNERSHIP FOR 
14
TRAUMA READINESS. 
15
Title XII (42 U.S.C. 300d et seq.) is amended by 
16
adding at the end the following new part: 
17
‘‘PART I—MILITARY AND CIVILIAN PARTNERSHIP 
18
FOR TRAUMA READINESS GRANT PROGRAM 
19
‘‘SEC. 1291. MILITARY AND CIVILIAN PARTNERSHIP FOR 
20
TRAUMA READINESS GRANT PROGRAM. 
21
‘‘(a) MILITARY TRAUMA TEAM PLACEMENT PRO-
22
GRAM.— 
23
‘‘(1) IN
GENERAL.—The Secretary, acting 
24
through the Assistant Secretary for Preparedness 
25
28 
•HR 269 EH
and Response and in consultation with the Secretary 
1
of Defense, shall award grants to not more than 20 
2
eligible high-acuity trauma centers to enable military 
3
trauma teams to provide, on a full-time basis, trau-
4
ma care and related acute care at such trauma cen-
5
ters. 
6
‘‘(2) LIMITATIONS.—In the case of a grant 
7
awarded under paragraph (1) to an eligible high- 
8
acuity trauma center, such grant— 
9
‘‘(A) shall be for a period of at least 3 
10
years and not more than 5 years (and may be 
11
renewed at the end of such period); and 
12
‘‘(B) shall be in an amount that does not 
13
exceed $1,000,000 per year. 
14
‘‘(3) 
AVAILABILITY
OF
FUNDS.—Notwith-
15
standing section 1552 of title 31, United States 
16
Code, or any other provision of law, funds available 
17
to the Secretary for obligation for a grant under this 
18
subsection shall remain available for expenditure for 
19
100 days after the last day of the performance pe-
20
riod of such grant. 
21
‘‘(b) MILITARY TRAUMA CARE PROVIDER PLACE-
22
MENT PROGRAM.— 
23
‘‘(1) IN
GENERAL.—The Secretary, acting 
24
through the Assistant Secretary for Preparedness 
25
29 
•HR 269 EH
and Response and in consultation with the Secretary 
1
of Defense, shall award grants to eligible trauma 
2
centers to enable military trauma care providers to 
3
provide trauma care and related acute care at such 
4
trauma centers. 
5
‘‘(2) LIMITATIONS.—In the case of a grant 
6
awarded under paragraph (1) to an eligible trauma 
7
center, such grant— 
8
‘‘(A) shall be for a period of at least 1 year 
9
and not more than 3 years (and may be re-
10
newed at the end of such period); and 
11
‘‘(B) shall be in an amount that does not 
12
exceed, in a year— 
13
‘‘(i) $100,000 for each military trau-
14
ma care provider that is a physician at 
15
such eligible trauma center; and 
16
‘‘(ii) $50,000 for each other military 
17
trauma care provider at such eligible trau-
18
ma center. 
19
‘‘(c) GRANT REQUIREMENTS.— 
20
‘‘(1) DEPLOYMENT AND PUBLIC HEALTH EMER-
21
GENCIES.—As a condition of receipt of a grant 
22
under this section, a grant recipient shall agree to 
23
allow military trauma care providers providing care 
24
pursuant to such grant to— 
25
30 
•HR 269 EH
‘‘(A) be deployed by the Secretary of De-
1
fense for military operations, for training, or 
2
for response to a mass casualty incident; and 
3
‘‘(B) be deployed by the Secretary of De-
4
fense, in consultation with the Secretary of 
5
Health and Human Services, for response to a 
6
public health emergency pursuant to section 
7
319. 
8
‘‘(2) USE OF FUNDS.—Grants awarded under 
9
this section to an eligible trauma center may be used 
10
to train and incorporate military trauma care pro-
11
viders into such trauma center, including incorpora-
12
tion into operational exercises and training drills re-
13
lated to public health emergencies, expenditures for 
14
malpractice insurance, office space, information 
15
technology, specialty education and supervision, 
16
trauma programs, research, and applicable license 
17
fees for such military trauma care providers. 
18
‘‘(d) RULE OF CONSTRUCTION.—Nothing in this sec-
19
tion shall be construed to affect any other provision of law 
20
that preempts State licensing requirements for health care 
21
professionals, including with respect to military trauma 
22
care providers. 
23
‘‘(e) REPORTING REQUIREMENTS.— 
24
31 
•HR 269 EH
‘‘(1) REPORT
TO
THE
SECRETARY
AND
THE 
1
SECRETARY
OF
DEFENSE.—Each eligible trauma 
2
center or eligible high-acuity trauma center awarded 
3
a grant under subsection (a) or (b) for a year shall 
4
submit to the Secretary and the Secretary of De-
5
fense a report for such year that includes informa-
6
tion on— 
7
‘‘(A) the number and types of trauma 
8
cases managed by military trauma teams or 
9
military trauma care providers pursuant to such 
10
grant during such year; 
11
‘‘(B) the ability to maintain the integration 
12
of the military trauma providers or teams of 
13
providers as part of the trauma center, includ-
14
ing the financial effect of such grant on the 
15
trauma center; 
16
‘‘(C) the educational effect on resident 
17
trainees in centers where military trauma teams 
18
are assigned; 
19
‘‘(D) any research conducted during such 
20
year supported by such grant; and 
21
‘‘(E) any other information required by the 
22
Secretaries for the purpose of evaluating the ef-
23
fect of such grant. 
24
32 
•HR 269 EH
‘‘(2) REPORT
TO
CONGRESS.—Not less than 
1
once every 2 years, the Secretary, in consultation 
2
with the Secretary of Defense, shall submit a report 
3
to the congressional committees of jurisdiction that 
4
includes information on the effect of placing military 
5
trauma care providers in trauma centers awarded 
6
grants under this section on— 
7
‘‘(A) maintaining military trauma care 
8
providers’ readiness and ability to respond to 
9
and treat battlefield injuries; 
10
‘‘(B) providing health care to civilian trau-
11
ma patients in urban and rural settings; 
12
‘‘(C) the capability of trauma centers and 
13
military trauma care providers to increase med-
14
ical surge capacity, including as a result of a 
15
large-scale event; 
16
‘‘(D) the ability of grant recipients to 
17
maintain the integration of the military trauma 
18
providers or teams of providers as part of the 
19
trauma center; 
20
‘‘(E) efforts to incorporate military trauma 
21
care providers into operational exercises and 
22
training and drills for public health emer-
23
gencies; and 
24
33 
•HR 269 EH
‘‘(F) the capability of military trauma care 
1
providers to participate as part of a medical re-
2
sponse during or in advance of a public health 
3
emergency, as determined by the Secretary, or 
4
a mass casualty incident. 
5
‘‘(f) DEFINITIONS.—For purposes of this part: 
6
‘‘(1) ELIGIBLE
HIGH-ACUITY
TRAUMA
CEN-
7
TER.—The term ‘eligible high-acuity trauma center’ 
8
means a Level I trauma center that satisfies each of 
9
the following: 
10
‘‘(A) Such trauma center has an agree-
11
ment with the Secretary of Defense to enable 
12
military trauma teams to provide trauma care 
13
and related acute care at such trauma center. 
14
‘‘(B) At least 20 percent of patients treat-
15
ed at such trauma center in the most recent 3- 
16
month period for which data are available are 
17
treated for a major trauma at such trauma cen-
18
ter. 
19
‘‘(C) Such trauma center utilizes a risk-ad-
20
justed benchmarking system and metrics to 
21
measure performance, quality, and patient out-
22
comes. 
23
‘‘(D) Such trauma center is an academic 
24
training center— 
25
34 
•HR 269 EH
‘‘(i) affiliated with a medical school; 
1
‘‘(ii) that maintains residency pro-
2
grams and fellowships in critical trauma 
3
specialties and subspecialties, and provides 
4
education and supervision of military trau-
5
ma team members according to those spe-
6
cialties and subspecialties; and 
7
‘‘(iii) that undertakes research in the 
8
prevention and treatment of traumatic in-
9
jury. 
10
‘‘(E) Such trauma center serves as a med-
11
ical and public health preparedness and re-
12
sponse leader for its community, such as by 
13
participating in a partnership for State and re-
14
gional hospital preparedness established under 
15
section 319C–2 or 319C–3. 
16
‘‘(2) ELIGIBLE
TRAUMA
CENTER.—The term 
17
‘eligible trauma center’ means a Level I, II, or III 
18
trauma center that satisfies each of the following: 
19
‘‘(A) Such trauma center has an agree-
20
ment with the Secretary of Defense to enable 
21
military trauma care providers to provide trau-
22
ma care and related acute care at such trauma 
23
center. 
24
35 
•HR 269 EH
‘‘(B) Such trauma center utilizes a risk-ad-
1
justed benchmarking system and metrics to 
2
measure performance, quality, and patient out-
3
comes. 
4
‘‘(C) Such trauma center demonstrates a 
5
need for integrated military trauma care pro-
6
viders to maintain or improve the trauma clin-
7
ical capability of such trauma center. 
8
‘‘(3) MAJOR TRAUMA.—The term ‘major trau-
9
ma’ means an injury that is greater than or equal 
10
to 15 on the injury severity score. 
11
‘‘(4) MILITARY
TRAUMA
TEAM.—The term 
12
‘military trauma team’ means a complete military 
13
trauma team consisting of military trauma care pro-
14
viders. 
15
‘‘(5) MILITARY TRAUMA CARE PROVIDER.—The 
16
term ‘military trauma care provider’ means a mem-
17
ber of the Armed Forces who furnishes emergency, 
18
critical care, and other trauma acute care services 
19
(including a physician, surgeon, physician assistant, 
20
nurse, nurse practitioner, respiratory therapist, 
21
flight paramedic, combat medic, or enlisted medical 
22
technician) or other military trauma care provider as 
23
the Secretary determines appropriate. 
24
36 
•HR 269 EH
‘‘(g) AUTHORIZATION
OF
APPROPRIATIONS.—To 
1
carry out this section, there is authorized to be appro-
2
priated $11,500,000 for each of fiscal years 2019 through 
3
2023.’’. 
4
SEC. 205. PUBLIC HEALTH AND HEALTH CARE SYSTEM SIT-
5
UATIONAL 
AWARENESS 
AND 
BIOSURVEIL-
6
LANCE CAPABILITIES. 
7
(a) FACILITIES, CAPACITIES, AND BIOSURVEILLANCE 
8
CAPABILITIES.—Section 319D (42 U.S.C. 247d–4) is 
9
amended— 
10
(1) in the section heading, by striking ‘‘REVI-
11
TALIZING’’ and inserting ‘‘FACILITIES AND CA-
12
PACITIES OF’’; 
13
(2) in subsection (a)— 
14
(A) in the subsection heading, by striking 
15
‘‘FACILITIES; CAPACITIES’’ and inserting ‘‘IN 
16
GENERAL’’; 
17
(B) in paragraph (1), by striking ‘‘and im-
18
proved’’ and inserting ‘‘, improved, and appro-
19
priately maintained’’; 
20
(C) in paragraph (3), in the matter pre-
21
ceding subparagraph (A), by striking ‘‘expand, 
22
enhance, and improve’’ and inserting ‘‘expand, 
23
improve, enhance, and appropriately maintain’’; 
24
and 
25
37 
•HR 269 EH
(D) by adding at the end the following: 
1
‘‘(4) STUDY
OF
RESOURCES
FOR
FACILITIES 
2
AND CAPACITIES.—Not later than June 1, 2022, the 
3
Comptroller General of the United States shall con-
4
duct a study on Federal spending in fiscal years 
5
2013 through 2018 for activities authorized under 
6
this subsection. Such study shall include a review 
7
and assessment of obligations and expenditures di-
8
rectly related to each activity under paragraphs (2) 
9
and (3), including a specific accounting of, and de-
10
lineation between, obligations and expenditures in-
11
curred for the construction, renovation, equipping, 
12
and security upgrades of facilities and associated 
13
contracts under this subsection, and the obligations 
14
and expenditures incurred to establish and improve 
15
the situational awareness and biosurveillance net-
16
work under subsection (b), and shall identify the 
17
agency or agencies incurring such obligations and 
18
expenditures.’’; 
19
(3) in subsection (b)— 
20
(A) in the subsection heading, by striking 
21
‘‘NATIONAL’’ and inserting ‘‘ESTABLISHMENT 
22
OF SYSTEMS OF PUBLIC HEALTH’’; 
23
38 
•HR 269 EH
(B) in paragraph (1)(B), by inserting ‘‘im-
1
munization information systems,’’ after ‘‘cen-
2
ters,’’; 
3
(C) in paragraph (2)— 
4
(i) by inserting ‘‘develop a plan to, 
5
and’’ after ‘‘The Secretary shall’’; and 
6
(ii) by inserting ‘‘and in a form read-
7
ily usable for analytical approaches’’ after 
8
‘‘in a secure manner’’; and 
9
(D) by amending paragraph (3) to read as 
10
follows: 
11
‘‘(3) STANDARDS.— 
12
‘‘(A) IN GENERAL.—Not later than 1 year 
13
after the date of the enactment of the Pan-
14
demic and All-Hazards Preparedness and Ad-
15
vancing Innovation Act of 2019, the Secretary, 
16
in cooperation with health care providers, State, 
17
local, Tribal, and territorial public health offi-
18
cials, and relevant Federal agencies (including 
19
the Office of the National Coordinator for 
20
Health Information Technology and the Na-
21
tional Institute of Standards and Technology), 
22
shall, as necessary, adopt technical and report-
23
ing standards, including standards for inter-
24
operability as defined by section 3000, for net-
25
39 
•HR 269 EH
works under paragraph (1) and update such 
1
standards as necessary. Such standards shall be 
2
made available on the internet website of the 
3
Department of Health and Human Services, in 
4
a manner that does not compromise national se-
5
curity. 
6
‘‘(B) DEFERENCE TO STANDARDS DEVEL-
7
OPMENT ORGANIZATIONS.—In adopting and im-
8
plementing standards under this subsection and 
9
subsection (c), the Secretary shall give def-
10
erence to standards published by standards de-
11
velopment organizations and voluntary con-
12
sensus-based standards entities.’’; 
13
(4) in subsection (c)— 
14
(A) in paragraph (1)— 
15
(i) by striking ‘‘Not later than 2 years 
16
after the date of enactment of the Pan-
17
demic and All-Hazards Preparedness Re-
18
authorization Act of 2013, the Secretary’’ 
19
and inserting ‘‘The Secretary’’; 
20
(ii) by inserting ‘‘, and improve as ap-
21
plicable and appropriate,’’ after ‘‘shall es-
22
tablish’’; 
23
(iii) by striking ‘‘of rapid’’ and insert-
24
ing ‘‘of, rapid’’; and 
25
40 
•HR 269 EH
(iv) by striking ‘‘such connectivity’’ 
1
and inserting ‘‘such interoperability’’; 
2
(B) by amending paragraph (2) to read as 
3
follows: 
4
‘‘(2) COORDINATION AND CONSULTATION.—In 
5
establishing and improving the network under para-
6
graph (1), the Secretary shall— 
7
‘‘(A) facilitate coordination among agencies 
8
within the Department of Health and Human 
9
Services that provide, or have the potential to 
10
provide, information and data to, and analyses 
11
for, the situational awareness and biosurveil-
12
lance network under paragraph (1), including 
13
coordination among relevant agencies related to 
14
health care services, the facilitation of health 
15
information exchange (including the Office of 
16
the National Coordinator for Health Informa-
17
tion Technology), and public health emergency 
18
preparedness and response; and 
19
‘‘(B) consult with the Secretary of Agri-
20
culture, the Secretary of Commerce (and the 
21
Director of the National Institute of Standards 
22
and Technology), the Secretary of Defense, the 
23
Secretary of Homeland Security, the Secretary 
24
of Veterans Affairs, and the heads of other 
25
41 
•HR 269 EH
Federal agencies, as the Secretary determines 
1
appropriate.’’; 
2
(C) in paragraph (3)— 
3
(i) by redesignating subparagraphs 
4
(A) through (E) as clauses (i) through (v), 
5
respectively, and adjusting the margins ac-
6
cordingly; 
7
(ii) in clause (iv), as so redesig-
8
nated— 
9
(I) by inserting ‘‘immunization 
10
information systems,’’ after ‘‘poison 
11
control,’’; and 
12
(II) by striking ‘‘and clinical lab-
13
oratories’’ and inserting ‘‘, clinical 
14
laboratories, and public environmental 
15
health agencies’’; 
16
(iii) by striking ‘‘The network’’ and 
17
inserting the following: 
18
‘‘(A) IN GENERAL.—The network’’; and 
19
(iv) by adding at the end the fol-
20
lowing: 
21
‘‘(B) REVIEW.—Not later than 2 years 
22
after the date of the enactment of the Pan-
23
demic and All-Hazards Preparedness and Ad-
24
vancing Innovation Act of 2019 and every 6 
25
42 
•HR 269 EH
years thereafter, the Secretary shall conduct a 
1
review of the elements described in subpara-
2
graph (A). Such review shall include a discus-
3
sion of the addition of any elements pursuant to 
4
clause (v), including elements added to advanc-
5
ing new technologies, and identify any chal-
6
lenges in the incorporation of elements under 
7
subparagraph (A). The Secretary shall provide 
8
such review to the congressional committees of 
9
jurisdiction.’’; 
10
(D) in paragraph (5)— 
11
(i) by redesignating subparagraphs 
12
(A) through (D) as clauses (i) through 
13
(iv), respectively, and adjusting the mar-
14
gins accordingly; 
15
(ii) by striking ‘‘In establishing’’ and 
16
inserting the following: 
17
‘‘(A) IN GENERAL.—In establishing’’; 
18
(iii) by adding at the end the fol-
19
lowing: 
20
‘‘(B) PUBLIC MEETING.— 
21
‘‘(i) IN
GENERAL.—Not later than 
22
180 days after the date of enactment of 
23
the Pandemic and All-Hazards Prepared-
24
ness and Advancing Innovation Act of 
25
43 
•HR 269 EH
2019, the Secretary shall convene a public 
1
meeting for purposes of discussing and 
2
providing input on the potential goals, 
3
functions, and uses of the network de-
4
scribed in paragraph (1) and incorporating 
5
the 
elements 
described 
in 
paragraph 
6
(3)(A). 
7
‘‘(ii) EXPERTS.—The public meeting 
8
shall include representatives of relevant 
9
Federal agencies (including representatives 
10
from the Office of the National Coordi-
11
nator for Health Information Technology 
12
and the National Institute of Standards 
13
and Technology); State, local, Tribal, and 
14
territorial public health officials; stake-
15
holders with expertise in biosurveillance 
16
and situational awareness; stakeholders 
17
with expertise in capabilities relevant to 
18
biosurveillance and situational awareness, 
19
such as experts in informatics and data 
20
analytics (including experts in prediction, 
21
modeling, or forecasting); and other rep-
22
resentatives as the Secretary determines 
23
appropriate. 
24
44 
•HR 269 EH
‘‘(iii) TOPICS.—Such public meeting 
1
shall include a discussion of— 
2
‘‘(I) data elements, including 
3
minimal or essential data elements, 
4
that are voluntarily provided for such 
5
network, which may include elements 
6
from public health and public and pri-
7
vate health care entities, to the extent 
8
practicable; 
9
‘‘(II) standards and implementa-
10
tion specifications that may improve 
11
the collection, analysis, and interpre-
12
tation of data during a public health 
13
emergency; 
14
‘‘(III) strategies to encourage the 
15
access, exchange, and use of informa-
16
tion; 
17
‘‘(IV) considerations for State, 
18
local, Tribal, and territorial capabili-
19
ties and infrastructure related to data 
20
exchange and interoperability; 
21
‘‘(V) privacy and security protec-
22
tions provided at the Federal, State, 
23
local, Tribal, and territorial levels, 
24
45 
•HR 269 EH
and by nongovernmental stakeholders; 
1
and 
2
‘‘(VI) opportunities for the incor-
3
poration of innovative technologies to 
4
improve the network.’’; and 
5
(iv) in subparagraph (A), as so des-
6
ignated by clause (ii)— 
7
(I) in clause (i), as so redesig-
8
nated— 
9
(aa) by striking ‘‘as deter-
10
mined’’ and inserting ‘‘as adopt-
11
ed’’; and 
12
(bb) by inserting ‘‘and the 
13
National Institute of Standards 
14
and Technology’’ after ‘‘Office of 
15
the National Coordinator for 
16
Health Information Technology’’; 
17
(II) in clause (iii), as so redesig-
18
nated, by striking ‘‘; and’’ and insert-
19
ing a semicolon; 
20
(III) in clause (iv), as so redesig-
21
nated, by striking the period and in-
22
serting ‘‘; and’’; and 
23
(IV) by adding at the end the fol-
24
lowing: 
25
46 
•HR 269 EH
‘‘(v) pilot test standards and imple-
1
mentation specifications, consistent with 
2
the 
process 
described 
in 
section 
3
3002(b)(3)(C), which State, local, Tribal, 
4
and territorial public health entities may 
5
utilize, on a voluntary basis, as a part of 
6
the network.’’; 
7
(E) by redesignating paragraph (6) as 
8
paragraph (7); 
9
(F) by inserting after paragraph (5) the 
10
following: 
11
‘‘(6) 
STRATEGY
AND
IMPLEMENTATION 
12
PLAN.— 
13
‘‘(A) IN
GENERAL.—Not later than 18 
14
months after the date of enactment of the Pan-
15
demic and All-Hazards Preparedness and Ad-
16
vancing Innovation Act of 2019, the Secretary 
17
shall submit to the congressional committees of 
18
jurisdiction a coordinated strategy and an ac-
19
companying implementation plan that— 
20
‘‘(i) is informed by the public meeting 
21
under paragraph (5)(B); 
22
‘‘(ii) includes a review and assessment 
23
of existing capabilities of the network and 
24
related infrastructure, including input pro-
25
47 
•HR 269 EH
vided by the public meeting under para-
1
graph (5)(B); 
2
‘‘(iii) identifies and demonstrates the 
3
measurable steps the Secretary will carry 
4
out to— 
5
‘‘(I) develop, implement, and 
6
evaluate the network described in 
7
paragraph (1), utilizing elements de-
8
scribed in paragraph (3)(A); 
9
‘‘(II) modernize and enhance bio-
10
surveillance activities, including strat-
11
egies to include innovative tech-
12
nologies and analytical approaches 
13
(including prediction and forecasting 
14
for pandemics and all-hazards) from 
15
public and private entities; 
16
‘‘(III) improve information shar-
17
ing, coordination, and communication 
18
among disparate biosurveillance sys-
19
tems supported by the Department of 
20
Health and Human Services, includ-
21
ing the identification of methods to 
22
improve accountability, better utilize 
23
resources and workforce capabilities, 
24
and 
incorporate 
innovative 
tech-
25
48 
•HR 269 EH
nologies within and across agencies; 
1
and 
2
‘‘(IV) test and evaluate capabili-
3
ties of the interoperable network of 
4
systems to improve situational aware-
5
ness and biosurveillance capabilities; 
6
‘‘(iv) includes performance measures 
7
and the metrics by which performance 
8
measures will be assessed with respect to 
9
the measurable steps under clause (iii); 
10
and 
11
‘‘(v) establishes dates by which each 
12
measurable step under clause (iii) will be 
13
implemented. 
14
‘‘(B) ANNUAL BUDGET PLAN.—Not later 
15
than 2 years after the date of enactment of the 
16
Pandemic and All-Hazards Preparedness and 
17
Advancing Innovation Act of 2019 and on an 
18
annual basis thereafter, in accordance with the 
19
strategy and implementation plan under this 
20
paragraph, the Secretary shall, taking into ac-
21
count recommendations provided by the Na-
22
tional Biodefense Science Board, develop a 
23
budget plan based on the strategy and imple-
24
49 
•HR 269 EH
mentation plan under this section. Such budget 
1
plan shall include— 
2
‘‘(i) a summary of resources pre-
3
viously expended to establish, improve, and 
4
utilize the nationwide public health situa-
5
tional awareness and biosurveillance net-
6
work under paragraph (1); 
7
‘‘(ii) estimates of costs and resources 
8
needed to establish and improve the net-
9
work under paragraph (1) according to the 
10
strategy and implementation plan under 
11
subparagraph (A); 
12
‘‘(iii) the identification of gaps and in-
13
efficiencies in nationwide public health sit-
14
uational awareness and biosurveillance ca-
15
pabilities, resources, and authorities need-
16
ed to address such gaps; and 
17
‘‘(iv) a strategy to minimize and ad-
18
dress such gaps and improve inefficien-
19
cies.’’; 
20
(G) in paragraph (7), as so redesignated— 
21
(i) in subparagraph (A), by inserting 
22
‘‘(taking into account zoonotic disease, in-
23
cluding gaps in scientific understanding of 
24
the interactions between human, animal, 
25
50 
•HR 269 EH
and environmental health)’’ after ‘‘human 
1
health’’; 
2
(ii) in subparagraph (B)— 
3
(I) by inserting ‘‘and gaps in sur-
4
veillance programs’’ after ‘‘surveil-
5
lance programs’’; and 
6
(II) by striking ‘‘; and’’ and in-
7
serting a semicolon; 
8
(iii) in subparagraph (C)— 
9
(I) by inserting ‘‘, animal health 
10
organizations related to zoonotic dis-
11
ease,’’ after ‘‘health care entities’’; 
12
and 
13
(II) by striking the period and 
14
inserting ‘‘; and’’; and 
15
(iv) by adding at the end the fol-
16
lowing: 
17
‘‘(D) provide recommendations to the Sec-
18
retary on policies and procedures to complete 
19
the steps described in this paragraph in a man-
20
ner that is consistent with section 2802.’’; and 
21
(H) by adding at the end the following: 
22
‘‘(8) 
SITUATIONAL
AWARENESS
AND
BIO-
23
SURVEILLANCE
AS
A
NATIONAL
SECURITY
PRI-
24
ORITY.—The Secretary, on a periodic basis as appli-
25
51 
•HR 269 EH
cable and appropriate, shall meet with the Director 
1
of National Intelligence to inform the development 
2
and capabilities of the nationwide public health situ-
3
ational awareness and biosurveillance network.’’; 
4
(5) in subsection (d)— 
5
(A) in paragraph (1)— 
6
(i) by inserting ‘‘environmental health 
7
agencies,’’ after ‘‘public health agencies,’’; 
8
and 
9
(ii) by inserting ‘‘immunization pro-
10
grams,’’ after ‘‘poison control centers,’’; 
11
(B) in paragraph (2)— 
12
(i) in subparagraph (B), by striking 
13
‘‘and’’ at the end; 
14
(ii) in subparagraph (C), by striking 
15
the period and inserting ‘‘; and’’; and 
16
(iii) by adding after subparagraph (C) 
17
the following: 
18
‘‘(D) an implementation plan that may in-
19
clude measurable steps to achieve the purposes 
20
described in paragraph (1).’’; and 
21
(C) by striking paragraph (5) and insert-
22
ing the following: 
23
‘‘(5) TECHNICAL ASSISTANCE.—The Secretary 
24
may provide technical assistance to States, localities, 
25
52 
•HR 269 EH
Tribes, and territories or a consortium of States, lo-
1
calities, Tribes, and territories receiving an award 
2
under this subsection regarding interoperability and 
3
the technical standards set forth by the Secretary.’’; 
4
(6) by redesignating subsections (f) and (g) as 
5
subsections (i) and (j), respectively; and 
6
(7) by inserting after subsection (e) the fol-
7
lowing: 
8
‘‘(f) PERSONNEL AUTHORITIES.— 
9
‘‘(1) SPECIALLY
QUALIFIED
PERSONNEL.—In 
10
addition to any other personnel authorities, to carry 
11
out subsections (b) and (c), the Secretary may— 
12
‘‘(A) appoint highly qualified individuals to 
13
scientific or professional positions at the Cen-
14
ters for Disease Control and Prevention, not to 
15
exceed 30 such employees at any time (specific 
16
to positions authorized by this subsection), with 
17
expertise in capabilities relevant to biosurveil-
18
lance and situational awareness, such as experts 
19
in informatics and data analytics (including ex-
20
perts in prediction, modeling, or forecasting), 
21
and other related scientific or technical fields; 
22
and 
23
‘‘(B) compensate individuals appointed 
24
under subparagraph (A) in the same manner 
25
53 
•HR 269 EH
and subject to the same terms and conditions in 
1
which individuals appointed under 9903 of title 
2
5, United States Code, are compensated, with-
3
out regard to the provisions of chapter 51 and 
4
subchapter III of chapter 53 of such title relat-
5
ing to classification and General Schedule pay 
6
rates. 
7
‘‘(2) LIMITATIONS.—The Secretary shall exer-
8
cise the authority under paragraph (1) in a manner 
9
that is consistent with the limitations described in 
10
section 319F–1(e)(2). 
11
‘‘(g) TIMELINE.—The Secretary shall accomplish the 
12
purposes under subsections (b) and (c) no later than Sep-
13
tember 30, 2023, and shall provide a justification to the 
14
congressional committees of jurisdiction for any missed or 
15
delayed implementation of measurable steps identified 
16
under subsection (c)(6)(A)(iii). 
17
‘‘(h) INDEPENDENT EVALUATION.—Not later than 3 
18
years after the date of enactment of the Pandemic and 
19
All-Hazards Preparedness and Advancing Innovation Act 
20
of 2019, the Comptroller General of the United States 
21
shall conduct an independent evaluation and submit to the 
22
Secretary and the congressional committees of jurisdiction 
23
a report concerning the activities conducted under sub-
24
sections (b) and (c), and provide recommendations, as ap-
25
54 
•HR 269 EH
plicable and appropriate, on necessary improvements to 
1
the biosurveillance and situational awareness network.’’. 
2
(b) AUTHORIZATION
OF
APPROPRIATIONS.—Sub-
3
section (i) of section 319D (42 U.S.C. 247d–4), as redes-
4
ignated by subsection (a)(6), is amended by striking 
5
‘‘$138,300,000 for each of fiscal years 2014 through 
6
2018’’ and inserting ‘‘$161,800,000 for each of fiscal 
7
years 2019 through 2023’’. 
8
(c) BIOLOGICAL THREAT DETECTION REPORT.—The 
9
Secretary of Health and Human Services shall, in coordi-
10
nation with the Secretary of Defense and the Secretary 
11
of Homeland Security, not later than 180 days after the 
12
date of enactment of this Act, report to the Committee 
13
on Energy and Commerce, the Committee on Armed Serv-
14
ices, and the Committee on Homeland Security of the 
15
House of Representatives and the Committee on Health, 
16
Education, Labor, and Pensions, the Committee on Armed 
17
Services, and the Committee on Homeland Security and 
18
Governmental Affairs of the Senate on the state of Fed-
19
eral biological threat detection efforts, including the fol-
20
lowing: 
21
(1) An identification of technological, oper-
22
ational, and programmatic successes and failures of 
23
domestic detection programs supported by Federal 
24
departments and agencies for intentionally intro-
25
55 
•HR 269 EH
duced or accidentally released biological threat 
1
agents and naturally occurring infectious diseases. 
2
(2) A description of Federal efforts to facilitate 
3
the exchange of information related to the informa-
4
tion described in paragraph (1) among Federal de-
5
partments and agencies that utilize biological threat 
6
detection technology. 
7
(3) A description of the capabilities of detection 
8
systems in use by Federal departments and agencies 
9
including the capability to— 
10
(A) rapidly detect, identify, characterize, 
11
and confirm the presence of biological threat 
12
agents; 
13
(B) recover live biological agents from col-
14
lection devices; 
15
(C) determine the geographical distribution 
16
of biological agents; 
17
(D) determine the extent of environmental 
18
contamination and persistence of biological 
19
agents; and 
20
(E) provide advanced molecular diagnostics 
21
to State, local, Tribal, and territorial public 
22
health and other laboratories that support bio-
23
logical threat detection activities. 
24
56 
•HR 269 EH
(4) A description of Federal interagency coordi-
1
nation related to biological threat detection. 
2
(5) A description of efforts by Federal depart-
3
ments and agencies that utilize biological threat de-
4
tection technology to collaborate with State, local, 
5
Tribal, and territorial public health laboratories and 
6
other users of biological threat detection systems, in-
7
cluding collaboration regarding the development of— 
8
(A) biological threat detection require-
9
ments or standards; 
10
(B) a standardized integration strategy; 
11
(C) training requirements or guidelines; 
12
(D) guidelines for a coordinated public 
13
health response, including preparedness capa-
14
bilities, and, as applicable, for coordination with 
15
public health surveillance systems; and 
16
(E) a coordinated environmental remedi-
17
ation plan, as applicable. 
18
(6) Recommendations related to research, ad-
19
vanced research, development, and procurement for 
20
Federal departments and agencies to improve and 
21
enhance biological threat detection systems, includ-
22
ing recommendations on the transfer of biological 
23
threat detection technology among Federal depart-
24
ments and agencies, as necessary and appropriate. 
25
57 
•HR 269 EH
SEC. 206. STRENGTHENING AND SUPPORTING THE PUBLIC 
1
HEALTH 
EMERGENCY 
RAPID 
RESPONSE 
2
FUND. 
3
Section 319 (42 U.S.C. 247d) is amended— 
4
(1) in subsection (b)— 
5
(A) in paragraph (1)— 
6
(i) in the first sentence, by inserting 
7
‘‘or if the Secretary determines there is the 
8
significant potential for a public health 
9
emergency, to allow the Secretary to rap-
10
idly respond to the immediate needs result-
11
ing from such public health emergency or 
12
potential public health emergency’’ before 
13
the period; and 
14
(ii) by inserting ‘‘The Secretary shall 
15
plan for the expedited distribution of funds 
16
to appropriate agencies and entities.’’ after 
17
the first sentence; 
18
(B) by redesignating paragraph (2) as 
19
paragraph (3); 
20
(C) by inserting after paragraph (1) the 
21
following: 
22
‘‘(2) USES.—The Secretary may use amounts 
23
in the Fund established under paragraph (1), to— 
24
‘‘(A) facilitate coordination between and 
25
among Federal, State, local, Tribal, and terri-
26
58 
•HR 269 EH
torial entities and public and private health 
1
care entities that the Secretary determines may 
2
be affected by a public health emergency or po-
3
tential public health emergency referred to in 
4
paragraph (1) (including communication of 
5
such entities with relevant international enti-
6
ties, as applicable); 
7
‘‘(B) make grants, provide for awards, 
8
enter into contracts, and conduct supportive in-
9
vestigations pertaining to a public health emer-
10
gency or potential public health emergency, in-
11
cluding further supporting programs under sec-
12
tion 319C–1, 319C–2, or 319C–3; 
13
‘‘(C) facilitate and accelerate, as applica-
14
ble, advanced research and development of secu-
15
rity countermeasures (as defined in section 
16
319F–2), qualified countermeasures (as defined 
17
in section 319F–1), or qualified pandemic or 
18
epidemic products (as defined in section 319F– 
19
3), that are applicable to the public health 
20
emergency or potential public health emergency 
21
under paragraph (1); 
22
‘‘(D) strengthen biosurveillance capabilities 
23
and laboratory capacity to identify, collect, and 
24
analyze information regarding such public 
25
59 
•HR 269 EH
health emergency or potential public health 
1
emergency, including the systems under section 
2
319D; 
3
‘‘(E) support initial emergency operations 
4
and assets related to preparation and deploy-
5
ment of intermittent disaster response per-
6
sonnel under section 2812 and the Medical Re-
7
serve Corps under section 2813; and 
8
‘‘(F) carry out other activities, as the Sec-
9
retary determines applicable and appropriate.’’; 
10
and 
11
(D) by inserting after paragraph (3), as so 
12
redesignated, the following: 
13
‘‘(4) REVIEW.—Not later than 2 years after the 
14
date of enactment of the Pandemic and All-Hazards 
15
Preparedness and Advancing Innovation Act of 
16
2019, the Secretary, in coordination with the Assist-
17
ant Secretary for Preparedness and Response, shall 
18
conduct a review of the Fund under this section and 
19
provide recommendations to the Committee on 
20
Health, Education, Labor, and Pensions and the 
21
Committee on Appropriations of the Senate and the 
22
Committee on Energy and Commerce and the Com-
23
mittee on Appropriations of the House of Represent-
24
60 
•HR 269 EH
atives on policies to improve such Fund for the uses 
1
described in paragraph (2). 
2
‘‘(5) GAO REPORT.—Not later than 4 years 
3
after the date of enactment of the Pandemic and 
4
All-Hazards Preparedness and Advancing Innovation 
5
Act of 2019, the Comptroller General of the United 
6
States shall— 
7
‘‘(A) conduct a review of the Fund under 
8
this section, including its uses and the re-
9
sources available in the Fund; and 
10
‘‘(B) submit to the Committee on Health, 
11
Education, Labor, and Pensions of the Senate 
12
and the Committee on Energy and Commerce 
13
of the House of Representatives a report on 
14
such review, including recommendations related 
15
to such review, as applicable.’’; and 
16
(2) in subsection (c)— 
17
(A) by inserting ‘‘rapidly respond to public 
18
health emergencies or potential public health 
19
emergencies and’’ after ‘‘used to’’; and 
20
(B) by striking ‘‘section.’’ and inserting 
21
‘‘Act or funds otherwise provided for emergency 
22
response.’’. 
23
61 
•HR 269 EH
SEC. 207. IMPROVING ALL-HAZARDS PREPAREDNESS AND 
1
RESPONSE BY PUBLIC HEALTH EMERGENCY 
2
VOLUNTEERS. 
3
(a) IN GENERAL.—Section 319I (42 U.S.C. 247d– 
4
7b) is amended— 
5
(1) in the section heading, by striking 
6
‘‘HEALTH PROFESSIONS VOLUNTEERS’’ and in-
7
serting ‘‘VOLUNTEER HEALTH PROFESSIONAL’’; 
8
(2) in subsection (a), by adding at the end the 
9
following: ‘‘Such health care professionals may in-
10
clude members of the National Disaster Medical 
11
System, members of the Medical Reserve Corps, and 
12
individual health care professionals.’’; 
13
(3) in subsection (i), by adding at the end the 
14
following: ‘‘In order to inform the development of 
15
such mechanisms by States, the Secretary shall 
16
make available information and material provided by 
17
States that have developed mechanisms to waive the 
18
application of licensing requirements to applicable 
19
health professionals seeking to provide medical serv-
20
ices during a public health emergency. Such infor-
21
mation shall be made publicly available in a manner 
22
that does not compromise national security.’’; and 
23
(4) in subsection (k), by striking ‘‘2014 through 
24
2018’’ and inserting ‘‘2019 through 2023’’. 
25
62 
•HR 269 EH
(b) ALL-HAZARDS PUBLIC HEALTH EMERGENCY 
1
PREPAREDNESS AND RESPONSE PLAN.—Section 319C– 
2
1(b)(2)(A)(iv) 
(42 
U.S.C. 
247d–3a(b)(2)(A)(iv)) 
is 
3
amended to read as follows: 
4
‘‘(iv) a description of the mechanism the 
5
entity will implement to utilize the Emergency 
6
Management Assistance Compact, or other mu-
7
tual aid agreement, for medical and public 
8
health mutual aid, and, as appropriate, the ac-
9
tivities such entity will implement pursuant to 
10
section 319I to improve enrollment and coordi-
11
nation of volunteer health care professionals 
12
seeking to provide medical services during a 
13
public health emergency, which may include— 
14
‘‘(I) providing a public method of 
15
communication for purposes of volunteer 
16
coordination (such as a phone number); 
17
‘‘(II) providing for optional registra-
18
tion to participate in volunteer services 
19
during processes related to State medical 
20
licensing, registration, or certification or 
21
renewal of such licensing, registration, or 
22
certification; or 
23
‘‘(III) other mechanisms as the State 
24
determines appropriate;’’. 
25
63 
•HR 269 EH
SEC. 208. CLARIFYING STATE LIABILITY LAW FOR VOLUN-
1
TEER HEALTH CARE PROFESSIONALS. 
2
(a) IN GENERAL.—Title II (42 U.S.C. 202 et seq.) 
3
is amended by inserting after section 224 the following: 
4
‘‘SEC. 225. HEALTH CARE PROFESSIONALS ASSISTING DUR-
5
ING A PUBLIC HEALTH EMERGENCY. 
6
‘‘(a) LIMITATION ON LIABILITY.—Notwithstanding 
7
any other provision of law, a health care professional who 
8
is a member of the Medical Reserve Corps under section 
9
2813 or who is included in the Emergency System for Ad-
10
vance Registration of Volunteer Health Professionals 
11
under section 319I and who— 
12
‘‘(1) is responding— 
13
‘‘(A) to a public health emergency deter-
14
mined under section 319(a), during the initial 
15
period of not more than 90 days (as determined 
16
by the Secretary) of the public health emer-
17
gency determination (excluding any period cov-
18
ered by a renewal of such determination); or 
19
‘‘(B) to a major disaster or an emergency 
20
as declared by the President under section 401 
21
of the Robert T. Stafford Disaster Relief and 
22
Emergency Assistance Act (42 U.S.C. 5170) or 
23
under section 201 of the National Emergencies 
24
Act (50 U.S.C. 1621) during the initial period 
25
of such declaration; 
26
64 
•HR 269 EH
‘‘(2) is alleged to be liable for an act or omis-
1
sion— 
2
‘‘(A) during the initial period of a deter-
3
mination or declaration described in paragraph 
4
(1) and related to the treatment of individuals 
5
in need of health care services due to such pub-
6
lic health emergency, major disaster, or emer-
7
gency; 
8
‘‘(B) in the State or States for which such 
9
determination or declaration is made; 
10
‘‘(C) in the health care professional’s ca-
11
pacity as a member of the Medical Reserve 
12
Corps or a professional included in the Emer-
13
gency System for Advance Registration of Vol-
14
unteer Health Professionals under section 319I; 
15
and 
16
‘‘(D) in the course of providing services 
17
that are within the scope of the license, reg-
18
istration, or certification of the professional, as 
19
defined by the State of licensure, registration, 
20
or certification; and 
21
‘‘(3) prior to the rendering of such act or omis-
22
sion, was authorized by the State’s authorization of 
23
deploying such State’s Emergency System for Ad-
24
vance Registration of Volunteer Health Professionals 
25
65 
•HR 269 EH
described in section 319I or the Medical Reserve 
1
Corps established under section 2813, to provide 
2
health care services, 
3
shall be subject only to the State liability laws of the State 
4
in which such act or omission occurred, in the same man-
5
ner and to the same extent as a similar health care profes-
6
sional who is a resident of such State would be subject 
7
to such State laws, except with respect to the licensure, 
8
registration, and certification of such individual. 
9
‘‘(b) VOLUNTEER PROTECTION ACT.—Nothing in 
10
this section shall be construed to affect an individual’s 
11
right to protections under the Volunteer Protection Act 
12
of 1997. 
13
‘‘(c) PREEMPTION.—This section shall supersede the 
14
laws of any State that would subject a health care profes-
15
sional described in subsection (a) to the liability laws of 
16
any State other than the State liability laws to which such 
17
individual is subject pursuant to such subsection. 
18
‘‘(d) DEFINITIONS.—In this section: 
19
‘‘(1) The term ‘health care professional’ means 
20
an individual licensed, registered, or certified under 
21
Federal or State laws or regulations to provide 
22
health care services. 
23
‘‘(2) The term ‘health care services’ means any 
24
services provided by a health care professional, or by 
25
66 
•HR 269 EH
any individual working under the supervision of a 
1
health care professional, that relate to— 
2
‘‘(A) the diagnosis, prevention, or treat-
3
ment of any human disease or impairment; or 
4
‘‘(B) the assessment or care of the health 
5
of human beings. 
6
‘‘(e) EFFECTIVE DATE.— 
7
‘‘(1) IN GENERAL.—This section shall take ef-
8
fect 90 days after the date of the enactment of the 
9
Pandemic and All-Hazards Preparedness and Ad-
10
vancing Innovation Act of 2019. 
11
‘‘(2) APPLICATION.—This section shall apply to 
12
a claim for harm only if the act or omission that 
13
caused such harm occurred on or after the effective 
14
date described in paragraph (1).’’. 
15
(b) GAO STUDY.—Not later than one year after the 
16
date of enactment of this Act, the Comptroller General 
17
of the United States shall conduct a review of— 
18
(1) the number of health care providers who 
19
register under the Emergency System for Advance 
20
Registration of Volunteer Health Professionals 
21
under section 319I of the Public Health Service Act 
22
(42 U.S.C. 247d–7b) in advance to provide services 
23
during a public health emergency; 
24
67 
•HR 269 EH
(2) the number of health care providers who are 
1
credentialed to provide services during the period of 
2
a public health emergency declaration, including 
3
those who are credentialed though programs estab-
4
lished in the Emergency System for Advance Reg-
5
istration of Volunteer Health Professionals under 
6
such section 319I and those credentialed by authori-
7
ties within the State in which the emergency oc-
8
curred; 
9
(3) the average time to verify the credentials of 
10
a health care provider during the period of a public 
11
health emergency declaration, including the average 
12
time pursuant to the Emergency System for Ad-
13
vance Registration of Volunteer Health Professionals 
14
under such section 319I and for an individual’s cre-
15
dentials to be verified by an authority within the 
16
State; and 
17
(4) the Emergency System for Advance Reg-
18
istration of Volunteer Health Professionals program 
19
in States, including whether physician or medical 
20
groups, associations, or other relevant provider orga-
21
nizations utilize such program for purposes of volun-
22
teering during public health emergencies. 
23
68 
•HR 269 EH
SEC. 209. REPORT ON ADEQUATE NATIONAL BLOOD SUP-
1
PLY. 
2
Not later than 1 year after the date of the enactment 
3
of this Act, the Secretary of Health and Human Services 
4
shall submit to Congress a report containing recommenda-
5
tions related to maintaining an adequate national blood 
6
supply, including— 
7
(1) challenges associated with the continuous 
8
recruitment of blood donors (including those newly 
9
eligible to donate); 
10
(2) ensuring the adequacy of the blood supply 
11
in the case of public health emergencies; 
12
(3) implementation of the transfusion trans-
13
mission monitoring system; and 
14
(4) other measures to promote safety and inno-
15
vation, such as the development, use, or implementa-
16
tion of new technologies, processes, and procedures 
17
to improve the safety and reliability of the blood 
18
supply. 
19
SEC. 210. REPORT ON THE PUBLIC HEALTH PREPARED-
20
NESS AND RESPONSE CAPABILITIES AND CA-
21
PACITIES OF HOSPITALS, LONG-TERM CARE 
22
FACILITIES, AND OTHER HEALTH CARE FA-
23
CILITIES. 
24
(a) STUDY.— 
25
69 
•HR 269 EH
(1) IN
GENERAL.—Not later than one year 
1
after the date of enactment of this Act, the Sec-
2
retary of Health and Human Services shall enter 
3
into an agreement with an appropriate entity to con-
4
duct a study regarding the public health prepared-
5
ness and response capabilities and medical surge ca-
6
pacities of hospitals, long-term care facilities, and 
7
other health care facilities to prepare for, and re-
8
spond to, public health emergencies, including nat-
9
ural disasters. 
10
(2) CONSULTATION.—In conducting the study 
11
under paragraph (1), the entity shall consult with 
12
Federal, State, local, Tribal, and territorial public 
13
health officials (as appropriate), and health care 
14
providers and facilities with experience in public 
15
health preparedness and response activities. 
16
(3) EVALUATION.—The study under paragraph 
17
(1) shall include— 
18
(A) an evaluation of the current bench-
19
marks and objective standards, as applicable, 
20
related to programs that support hospitals, 
21
long-term care facilities, and other health care 
22
facilities, and their effect on improving public 
23
health preparedness and response capabilities 
24
and medical surge capacities, including the 
25
70 
•HR 269 EH
Hospital Preparedness Program, the Public 
1
Health Emergency Preparedness cooperative 
2
agreements, and the Regional Health Care 
3
Emergency Preparedness and Response Sys-
4
tems under section 319C–3 of the Public 
5
Health Service Act (as added by section 203); 
6
(B) the identification of gaps in prepared-
7
ness, including with respect to such benchmarks 
8
and objective standards, such as those identified 
9
during recent public health emergencies, for 
10
hospitals, long-term care facilities, and other 
11
health care facilities to address future potential 
12
public health threats; 
13
(C) an evaluation of coordination efforts 
14
between the recipients of Federal funding for 
15
programs described in subparagraph (A) and 
16
entities with expertise in emergency power sys-
17
tems and other critical infrastructure partners 
18
during a public health emergency, to ensure a 
19
functioning critical infrastructure, to the great-
20
est extent practicable, during a public health 
21
emergency; 
22
(D) an evaluation of coordination efforts 
23
between the recipients of Federal funding for 
24
programs described in subparagraph (A) and 
25
71 
•HR 269 EH
environmental health agencies with expertise in 
1
emergency preparedness and response planning 
2
for hospitals, long-term care facilities, and other 
3
health care facilities; and 
4
(E) an evaluation of current public health 
5
preparedness and response capabilities and 
6
medical surge capacities related to at-risk indi-
7
viduals during public health emergencies, in-
8
cluding an identification of gaps in such pre-
9
paredness as they relate to such individuals. 
10
(b) REPORT.— 
11
(1) IN GENERAL.—The agreement under sub-
12
section (a) shall require the entity to submit to the 
13
Secretary of Health and Human Services and the 
14
congressional committees of jurisdiction, not later 
15
than 3 years after the date of enactment of this Act, 
16
a report on the results of the study conducted pur-
17
suant to this section. 
18
(2) CONTENTS.—The report under paragraph 
19
(1) shall— 
20
(A) describe the findings and conclusions 
21
of the evaluation conducted pursuant to sub-
22
section (a); and 
23
(B) provide recommendations for improv-
24
ing public health preparedness and response ca-
25
72 
•HR 269 EH
pability and medical surge capacity for hos-
1
pitals, long-term care facilities, and other health 
2
care facilities, including— 
3
(i) improving the existing benchmarks 
4
and objective standards for the Federal 
5
grant programs described in subsection 
6
(a)(3)(A) or developing new benchmarks 
7
and standards for such programs; and 
8
(ii) identifying best practices for im-
9
proving public health preparedness and re-
10
sponse programs and medical surge capac-
11
ity at hospitals, long-term care facilities, 
12
and other health care facilities, including 
13
recommendations for the evaluation under 
14
subparagraphs (C) and (D) of subsection 
15
(a)(3). 
16
TITLE III—REACHING ALL 
17
COMMUNITIES 
18
SEC. 301. STRENGTHENING AND ASSESSING THE EMER-
19
GENCY RESPONSE WORKFORCE. 
20
(a) NATIONAL DISASTER MEDICAL SYSTEM.— 
21
(1) STRENGTHENING THE NATIONAL DISASTER 
22
MEDICAL
SYSTEM.—Clause 
(ii) 
of 
section 
23
2812(a)(3)(A) (42 U.S.C. 300hh–11(a)(3)(A)) is 
24
amended to read as follows: 
25
73 
•HR 269 EH
‘‘(ii) be present at locations, and for 
1
limited periods of time, specified by the 
2
Secretary on the basis that the Secretary 
3
has determined that a location is at risk of 
4
a public health emergency during the time 
5
specified, or there is a significant potential 
6
for a public health emergency.’’. 
7
(2) REVIEW OF THE NATIONAL DISASTER MED-
8
ICAL
SYSTEM.—Section 2812(b)(2) (42 U.S.C. 
9
300hh–11(b)(2)) is amended to read as follows: 
10
‘‘(2) JOINT REVIEW AND MEDICAL SURGE CA-
11
PACITY STRATEGIC PLAN.— 
12
‘‘(A) REVIEW.—Not later than 180 days 
13
after the date of enactment of the Pandemic 
14
and All-Hazards Preparedness and Advancing 
15
Innovation Act of 2019, the Secretary, in co-
16
ordination with the Secretary of Homeland Se-
17
curity, the Secretary of Defense, and the Sec-
18
retary of Veterans Affairs, shall conduct a joint 
19
review of the National Disaster Medical System. 
20
Such review shall include— 
21
‘‘(i) an evaluation of medical surge ca-
22
pacity, as described in section 2803(a); 
23
‘‘(ii) an assessment of the available 
24
workforce of the intermittent disaster re-
25
74 
•HR 269 EH
sponse personnel described in subsection 
1
(c); 
2
‘‘(iii) the capacity of the workforce de-
3
scribed in clause (ii) to respond to all haz-
4
ards, including capacity to simultaneously 
5
respond to multiple public health emer-
6
gencies and the capacity to respond to a 
7
nationwide public health emergency; 
8
‘‘(iv) the effectiveness of efforts to re-
9
cruit, retain, and train such workforce; and 
10
‘‘(v) gaps that may exist in such 
11
workforce and recommendations for ad-
12
dressing such gaps. 
13
‘‘(B) UPDATES.—As part of the National 
14
Health Security Strategy under section 2802, 
15
the Secretary shall update the findings from the 
16
review under subparagraph (A) and provide rec-
17
ommendations to modify the policies of the Na-
18
tional Disaster Medical System as necessary.’’. 
19
(3) NOTIFICATION
OF
SHORTAGE.—Section 
20
2812(c) (42 U.S.C. 300hh–11(c)) is amended by 
21
adding at the end the following: 
22
‘‘(3) NOTIFICATION.—Not later than 30 days 
23
after the date on which the Secretary determines the 
24
number of intermittent disaster-response personnel 
25
75 
•HR 269 EH
of the National Disaster Medical System is insuffi-
1
cient to address a public health emergency or poten-
2
tial public health emergency, the Secretary shall sub-
3
mit to the congressional committees of jurisdiction a 
4
notification detailing— 
5
‘‘(A) the impact such shortage could have 
6
on meeting public health needs and emergency 
7
medical personnel needs during a public health 
8
emergency; and 
9
‘‘(B) any identified measures to address 
10
such shortage. 
11
‘‘(4) CERTAIN APPOINTMENTS.— 
12
‘‘(A) IN GENERAL.—If the Secretary deter-
13
mines that the number of intermittent disaster 
14
response personnel within the National Disaster 
15
Medical System under this section is insuffi-
16
cient to address a public health emergency or 
17
potential public health emergency, the Secretary 
18
may appoint candidates directly to personnel 
19
positions for intermittent disaster response 
20
within such system. The Secretary shall provide 
21
updates on the number of vacant or unfilled po-
22
sitions within such system to the congressional 
23
committees of jurisdiction each quarter for 
24
which this authority is in effect. 
25
76 
•HR 269 EH
‘‘(B) SUNSET.—The authority under this 
1
paragraph shall expire on September 30, 
2
2021.’’. 
3
(4) AUTHORIZATION
OF
APPROPRIATIONS.— 
4
Section 2812(g) (42 U.S.C. 300hh–11(g)) is amend-
5
ed by striking ‘‘$52,700,000 for each of fiscal years 
6
2014 through 2018’’ and inserting ‘‘$57,400,000 for 
7
each of fiscal years 2019 through 2023’’. 
8
(b) VOLUNTEER MEDICAL RESERVE CORPS.— 
9
(1) IN GENERAL.—Section 2813(a) (42 U.S.C. 
10
42 U.S.C. 300hh–15(a)) is amended by striking the 
11
second sentence and inserting ‘‘The Secretary may 
12
appoint a Director to head the Corps and oversee 
13
the activities of the Corps chapters that exist at the 
14
State, local, Tribal, and territorial levels.’’. 
15
(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
16
Section 2813(i) (42 U.S.C. 300hh–15(i)) is amended 
17
by striking ‘‘2014 through 2018’’ and inserting 
18
‘‘2019 through 2023’’. 
19
(c) STRENGTHENING THE EPIDEMIC INTELLIGENCE 
20
SERVICE.—Section 317F (42 U.S.C. Sec. 247b–7) is 
21
amended— 
22
(1) in subsection (a)— 
23
(A) in paragraph (1)— 
24
77 
•HR 269 EH
(i) by inserting ‘‘or preparedness and 
1
response activities, including rapid re-
2
sponse to public health emergencies and 
3
significant public health threats’’ after 
4
‘‘conduct prevention activities’’; and 
5
(ii) by striking ‘‘$35,000’’ and insert-
6
ing ‘‘$50,000’’; and 
7
(B) in paragraph (2)(B), by striking ‘‘3 
8
years’’ and inserting ‘‘2 years’’; and 
9
(2) in subsection (c)— 
10
(A) by striking ‘‘For the purpose of car-
11
rying out this section’’ and inserting the fol-
12
lowing: 
13
‘‘(1) IN
GENERAL.—For the purpose of car-
14
rying out this section, except as described in para-
15
graph (2)’’; and 
16
(B) by adding at the end the following: 
17
‘‘(2) EPIDEMIC
INTELLIGENCE
SERVICE
PRO-
18
GRAM.—For purposes of carrying out this section 
19
with respect to qualified health professionals serving 
20
in the Epidemic Intelligence Service, as authorized 
21
under section 317G, there is authorized to be appro-
22
priated $1,000,000 for each of fiscal years 2019 
23
through 2023.’’. 
24
78 
•HR 269 EH
(d) SERVICE BENEFIT
FOR NATIONAL DISASTER 
1
MEDICAL SYSTEM VOLUNTEERS.— 
2
(1) IN GENERAL.—Section 2812(c) (42 U.S.C. 
3
300hh–11(c)), as amended by subsection (a)(3), is 
4
further amended by adding at the end the following: 
5
‘‘(5) SERVICE BENEFIT.—Individuals appointed 
6
to serve under this subsection shall be considered eli-
7
gible for benefits under part L of title I of the Om-
8
nibus Crime Control and Safe Streets Act of 1968. 
9
The Secretary shall provide notification to any eligi-
10
ble individual of any effect such designation may 
11
have on other benefits for which such individual is 
12
eligible, including benefits from private entities.’’. 
13
(2) PUBLIC SAFETY OFFICER BENEFITS.—Sec-
14
tion 1204(9) of title I of the Omnibus Crime Control 
15
and Safe Streets Act of 1968 (34 U.S.C. 10284(9)) 
16
is amended— 
17
(A) in subparagraph (C)(ii), by striking 
18
‘‘or’’ at the end; 
19
(B) in subparagraph (D), by striking the 
20
period and inserting ‘‘; or’’; and 
21
(C) by inserting after subparagraph (D) 
22
the following: 
23
‘‘(E) an individual appointed to the Na-
24
tional Disaster Medical System under section 
25
79 
•HR 269 EH
2812 of the Public Health Service Act (42 
1
U.S.C. 300hh–11) who is performing official 
2
duties of the Department of Health and Human 
3
Services, if those official duties are— 
4
‘‘(i) related to responding to a public 
5
health emergency or potential public health 
6
emergency, or other activities for which the 
7
Secretary of Health and Human Services 
8
has activated such National Disaster Med-
9
ical System; and 
10
‘‘(ii) determined by the Secretary of 
11
Health and Human Services to be haz-
12
ardous.’’. 
13
(3) SUNSET.—The amendments made by para-
14
graphs (1) and (2) shall cease to have force or effect 
15
on October 1, 2021. 
16
(e) MISSION READINESS REPORT TO CONGRESS.— 
17
(1) REPORT.—Not later than one year after the 
18
date of enactment of this section, the Comptroller 
19
General of the United States (referred to in this 
20
subsection as the ‘‘Comptroller General’’) shall sub-
21
mit to the Committee on Health, Education, Labor, 
22
and Pensions of the Senate and the Committee on 
23
Energy and Commerce of the House of Representa-
24
tives, a report on the medical surge capacity of the 
25
80 
•HR 269 EH
United States in the event of a public health emer-
1
gency, including the capacity and capability of the 
2
current health care workforce to prepare for, and re-
3
spond to, the full range of public health emergencies 
4
or potential public health emergencies, and rec-
5
ommendations to address any gaps identified in such 
6
workforce. 
7
(2) CONTENTS.—The Comptroller General shall 
8
include in the report under paragraph (1)— 
9
(A) the number of health care providers 
10
who have volunteered to provide health care 
11
services during a public health emergency, in-
12
cluding members of the National Disaster Med-
13
ical System, the Disaster Medical Assistant 
14
Teams, the Medical Reserve Corps, and other 
15
volunteer health care professionals in the 
16
verification network pursuant to section 319I of 
17
the Public Health Service Act (42 U.S.C. 
18
247d–7b); 
19
(B) the capacity of the workforce described 
20
in subparagraph (A) to respond to a public 
21
health emergency or potential public health 
22
emergency, including the capacity to respond to 
23
multiple concurrent public health emergencies 
24
81 
•HR 269 EH
and the capacity to respond to a nationwide 
1
public health emergency; 
2
(C) the preparedness and response capa-
3
bilities and mission readiness of the workforce 
4
described in subparagraph (A) taking into ac-
5
count areas of health care expertise and consid-
6
erations for at-risk individuals (as defined in 
7
section 2802(b)(4)(B) of the Public Health 
8
Service Act (42 U.S.C. 300hh–1(b)(4)(B))); 
9
(D) an assessment of the effectiveness of 
10
efforts to recruit, retain, and train such work-
11
force; and 
12
(E) identification of gaps that may exist in 
13
such workforce and recommendations for ad-
14
dressing such gaps, the extent to which the As-
15
sistant Secretary for Preparedness and Re-
16
sponse plans to address such gaps, and any rec-
17
ommendations from the Comptroller General to 
18
address such gaps. 
19
SEC. 302. HEALTH SYSTEM INFRASTRUCTURE TO IMPROVE 
20
PREPAREDNESS AND RESPONSE. 
21
(a) COORDINATION
OF
PREPAREDNESS.—Section 
22
2811(b)(5) (42 U.S.C. 300hh–10(b)(5)) is amended by 
23
adding at the end the following: ‘‘Such logistical support 
24
shall include working with other relevant Federal, State, 
25
82 
•HR 269 EH
local, Tribal, and territorial public health officials and pri-
1
vate sector entities to identify the critical infrastructure 
2
assets, systems, and networks needed for the proper func-
3
tioning of the health care and public health sectors that 
4
need to be maintained through any emergency or disaster, 
5
including entities capable of assisting with, responding to, 
6
and mitigating the effect of a public health emergency, 
7
including a public health emergency determined by the 
8
Secretary pursuant to section 319(a) or an emergency or 
9
major disaster declared by the President under the Robert 
10
T. Stafford Disaster Relief and Emergency Assistance Act 
11
or the National Emergencies Act, including by estab-
12
lishing methods to exchange critical information and de-
13
liver products consumed or used to preserve, protect, or 
14
sustain life, health, or safety, and sharing of specialized 
15
expertise.’’. 
16
(b) 
MANUFACTURING
CAPACITY.—Section 
17
2811(d)(2)(C) (42 U.S.C. 300hh–10(d)(2)(C)) is amended 
18
by inserting ‘‘, and ancillary medical supplies to assist 
19
with the utilization of such countermeasures or products,’’ 
20
after ‘‘products’’. 
21
(c) EVALUATION OF BARRIERS TO RAPID DELIVERY 
22
OF MEDICAL COUNTERMEASURES.— 
23
(1) RAPID
DELIVERY
STUDY.—The Assistant 
24
Secretary for Preparedness and Response may con-
25
83 
•HR 269 EH
duct a study on issues that have the potential to ad-
1
versely affect the handling and rapid delivery of 
2
medical countermeasures to individuals during public 
3
health emergencies occurring in the United States. 
4
(2) NOTICE TO CONGRESS.—Not later than 9 
5
months after the date of the enactment of this Act, 
6
the Assistant Secretary for Preparedness and Re-
7
sponse shall notify the Committee on Energy and 
8
Commerce of the House of Representatives and the 
9
Committee on Health, Education, Labor, and Pen-
10
sions of the Senate if the Assistant Secretary for 
11
Preparedness and Response does not plan to conduct 
12
the study under paragraph (1) and shall provide 
13
such committees a summary explanation for such de-
14
cision. 
15
(3) REPORT TO CONGRESS.—Not later than 1 
16
year after the Assistant Secretary for Preparedness 
17
and Response conducts the study under paragraph 
18
(1), such Assistant Secretary shall submit a report 
19
to the Committee on Energy and Commerce of the 
20
House of Representatives and the Committee on 
21
Health, Education, Labor, and Pensions of the Sen-
22
ate containing the findings of such study. 
23
84 
•HR 269 EH
SEC. 303. CONSIDERATIONS FOR AT-RISK INDIVIDUALS. 
1
(a) AT-RISK
INDIVIDUALS
IN
THE
NATIONAL 
2
HEALTH SECURITY STRATEGY.—Section 2802(b)(4)(B) 
3
(42 U.S.C. 300hh–1(b)(4)(B)) is amended— 
4
(1) by striking ‘‘this section and sections 319C– 
5
1, 319F, and 319L,’’ and inserting ‘‘this Act,’’; and 
6
(2) by striking ‘‘special’’ and inserting ‘‘access 
7
or functional’’. 
8
(b) COUNTERMEASURE CONSIDERATIONS.—Section 
9
319L(c)(6) (42 U.S.C. 247d–7e(c)(6)) is amended— 
10
(1) by striking ‘‘elderly’’ and inserting ‘‘older 
11
adults’’; and 
12
(2) by inserting ‘‘with relevant characteristics 
13
that warrant consideration during the process of re-
14
searching and developing such countermeasures and 
15
products’’ before the period. 
16
(c) 
BIOSURVEILLANCE
OF
EMERGING
PUBLIC 
17
HEALTH THREATS.—Section 2814 is amended— 
18
(1) in paragraph (7), by striking ‘‘; and’’ and 
19
inserting a semicolon; 
20
(2) in paragraph (8), by striking the period and 
21
inserting ‘‘; and’’; and 
22
(3) by adding at the end the following: 
23
‘‘(9) facilitate coordination to ensure that, in 
24
implementing the situational awareness and bio-
25
surveillance network under section 319D, the Sec-
26
85 
•HR 269 EH
retary considers incorporating data and information 
1
from Federal, State, local, Tribal, and territorial 
2
public health officials and entities relevant to detect-
3
ing emerging public health threats that may affect 
4
at-risk individuals, such as pregnant and postpartum 
5
women and infants, including adverse health out-
6
comes of such populations related to such emerging 
7
public health threats.’’. 
8
SEC. 304. IMPROVING EMERGENCY PREPAREDNESS AND 
9
RESPONSE 
CONSIDERATIONS 
FOR 
CHIL-
10
DREN. 
11
Part B of title III (42 U.S.C. 243 et seq.) is amended 
12
by inserting after section 319D the following: 
13
‘‘SEC. 319D–1. CHILDREN’S PREPAREDNESS UNIT. 
14
‘‘(a) ENHANCING EMERGENCY PREPAREDNESS FOR 
15
CHILDREN.—The Secretary, acting through the Director 
16
of the Centers for Disease Control and Prevention (re-
17
ferred to in this subsection as the ‘Director’), shall main-
18
tain an internal team of experts, to be known as the Chil-
19
dren’s Preparedness Unit (referred to in this subsection 
20
as the ‘Unit’), to work collaboratively to provide guidance 
21
on the considerations for, and the specific needs of, chil-
22
dren before, during, and after public health emergencies. 
23
The Unit shall inform the Director regarding emergency 
24
86 
•HR 269 EH
preparedness and response efforts pertaining to children 
1
at the Centers for Disease Control and Prevention. 
2
‘‘(b) EXPERTISE.—The team described in subsection 
3
(a) shall include one or more pediatricians, which may be 
4
a developmental-behavioral pediatrician, and may also in-
5
clude behavioral scientists, child psychologists, epidemiolo-
6
gists, biostatisticians, health communications staff, and 
7
individuals with other areas of expertise, as the Secretary 
8
determines appropriate. 
9
‘‘(c) DUTIES.—The team described in subsection (a) 
10
may— 
11
‘‘(1) assist State, local, Tribal, and territorial 
12
emergency planning and response activities related 
13
to children, which may include developing, identi-
14
fying, and sharing best practices; 
15
‘‘(2) provide technical assistance, training, and 
16
consultation to Federal, State, local, Tribal, and ter-
17
ritorial public health officials to improve prepared-
18
ness and response capabilities with respect to the 
19
needs of children, including providing such technical 
20
assistance, training, and consultation to eligible enti-
21
ties in order to support the achievement of measur-
22
able evidence-based benchmarks and objective stand-
23
ards applicable to sections 319C–1 and 319C–2; 
24
87 
•HR 269 EH
‘‘(3) improve the utilization of methods to in-
1
corporate the needs of children in planning for and 
2
responding to a public health emergency, including 
3
public awareness of such methods; 
4
‘‘(4) coordinate with, and improve, public-pri-
5
vate partnerships, such as health care coalitions pur-
6
suant to sections 319C–2 and 319C–3, to address 
7
gaps and inefficiencies in emergency preparedness 
8
and response efforts for children; 
9
‘‘(5) provide expertise and input during the de-
10
velopment of guidance and clinical recommendations 
11
to address the needs of children when preparing for, 
12
and responding to, public health emergencies, includ-
13
ing pursuant to section 319C–3; and 
14
‘‘(6) carry out other duties related to prepared-
15
ness and response activities for children, as the Sec-
16
retary determines appropriate.’’. 
17
SEC. 305. NATIONAL ADVISORY COMMITTEES ON DISAS-
18
TERS. 
19
(a) REAUTHORIZING THE NATIONAL ADVISORY COM-
20
MITTEE ON CHILDREN AND DISASTERS.—Section 2811A 
21
(42 U.S.C. 300hh–10a) is amended— 
22
(1) in subsection (b)(2), by inserting ‘‘, mental 
23
and behavioral,’’ after ‘‘medical’’; 
24
(2) in subsection (d)— 
25
88 
•HR 269 EH
(A) in paragraph (1), by striking ‘‘15’’ and 
1
inserting ‘‘25’’; and 
2
(B) by striking paragraph (2) and insert-
3
ing the following: 
4
‘‘(2) REQUIRED NON-FEDERAL MEMBERS.—The 
5
Secretary, in consultation with such other heads of 
6
Federal agencies as may be appropriate, shall ap-
7
point to the Advisory Committee under paragraph 
8
(1) at least 13 individuals, including— 
9
‘‘(A) at least 2 non-Federal professionals 
10
with expertise in pediatric medical disaster 
11
planning, preparedness, response, or recovery; 
12
‘‘(B) at least 2 representatives from State, 
13
local, Tribal, or territorial agencies with exper-
14
tise in pediatric disaster planning, prepared-
15
ness, response, or recovery; 
16
‘‘(C) at least 4 members representing 
17
health care professionals, which may include 
18
members with expertise in pediatric emergency 
19
medicine; pediatric trauma, critical care, or sur-
20
gery; the treatment of pediatric patients af-
21
fected by chemical, biological, radiological, or 
22
nuclear agents, including emerging infectious 
23
diseases; pediatric mental or behavioral health 
24
89 
•HR 269 EH
related to children affected by a public health 
1
emergency; or pediatric primary care; and 
2
‘‘(D) other members as the Secretary de-
3
termines appropriate, of whom— 
4
‘‘(i) at least one such member shall 
5
represent a children’s hospital; 
6
‘‘(ii) at least one such member shall 
7
be an individual with expertise in schools 
8
or child care settings; 
9
‘‘(iii) at least one such member shall 
10
be an individual with expertise in children 
11
and youth with special health care needs; 
12
and 
13
‘‘(iv) at least one such member shall 
14
be an individual with expertise in the needs 
15
of parents or family caregivers, including 
16
the parents or caregivers of children with 
17
disabilities. 
18
‘‘(3) FEDERAL MEMBERS.—The Advisory Com-
19
mittee under paragraph (1) shall include the fol-
20
lowing Federal members or their designees (who 
21
may be nonvoting members, as determined by the 
22
Secretary): 
23
‘‘(A) The Assistant Secretary for Pre-
24
paredness and Response. 
25
90 
•HR 269 EH
‘‘(B) The Director of the Biomedical Ad-
1
vanced Research and Development Authority. 
2
‘‘(C) The Director of the Centers for Dis-
3
ease Control and Prevention. 
4
‘‘(D) The Commissioner of Food and 
5
Drugs. 
6
‘‘(E) The Director of the National Insti-
7
tutes of Health. 
8
‘‘(F) The Assistant Secretary of the Ad-
9
ministration for Children and Families. 
10
‘‘(G) The Administrator of the Health Re-
11
sources and Services Administration. 
12
‘‘(H) The Administrator of the Federal 
13
Emergency Management Agency. 
14
‘‘(I) The Administrator of the Administra-
15
tion for Community Living. 
16
‘‘(J) The Secretary of Education. 
17
‘‘(K) Representatives from such Federal 
18
agencies (such as the Substance Abuse and 
19
Mental Health Services Administration and the 
20
Department of Homeland Security) as the Sec-
21
retary determines appropriate to fulfill the du-
22
ties of the Advisory Committee under sub-
23
sections (b) and (c). 
24
91 
•HR 269 EH
‘‘(4) TERM OF APPOINTMENT.—Each member 
1
of the Advisory Committee appointed under para-
2
graph (2) shall serve for a term of 3 years, except 
3
that the Secretary may adjust the terms of the Advi-
4
sory Committee appointees serving on the date of 
5
enactment of the Pandemic and All-Hazards Pre-
6
paredness and Advancing Innovation Act of 2019, or 
7
appointees who are initially appointed after such 
8
date of enactment, in order to provide for a stag-
9
gered term of appointment for all members. 
10
‘‘(5) CONSECUTIVE APPOINTMENTS; MAXIMUM 
11
TERMS.—A member appointed under paragraph (2) 
12
may serve not more than 3 terms on the Advisory 
13
Committee, and not more than 2 of such terms may 
14
be served consecutively.’’; 
15
(3) in subsection (e), by adding at the end ‘‘At 
16
least one meeting per year shall be an in-person 
17
meeting.’’; 
18
(4) by redesignating subsection (f) as sub-
19
section (g); 
20
(5) by inserting after subsection (e) the fol-
21
lowing: 
22
‘‘(f) COORDINATION.—The Secretary shall coordinate 
23
duties and activities authorized under this section in ac-
24
cordance with section 2811D.’’; and 
25
92 
•HR 269 EH
(6) in subsection (g), as so redesignated, by 
1
striking ‘‘2018’’ and inserting ‘‘2023’’. 
2
(b) AUTHORIZING THE NATIONAL ADVISORY COM-
3
MITTEE ON SENIORS AND DISASTERS.—Subtitle B of title 
4
XXVIII (42 U.S.C. 300hh et seq.) is amended by inserting 
5
after section 2811A the following: 
6
‘‘SEC. 2811B. NATIONAL ADVISORY COMMITTEE ON SEN-
7
IORS AND DISASTERS. 
8
‘‘(a) ESTABLISHMENT.—The Secretary, in consulta-
9
tion with the Secretary of Homeland Security and the Sec-
10
retary of Veterans Affairs, shall establish an advisory com-
11
mittee to be known as the National Advisory Committee 
12
on Seniors and Disasters (referred to in this section as 
13
the ‘Advisory Committee’). 
14
‘‘(b) DUTIES.—The Advisory Committee shall— 
15
‘‘(1) provide advice and consultation with re-
16
spect to the activities carried out pursuant to section 
17
2814, as applicable and appropriate; 
18
‘‘(2) evaluate and provide input with respect to 
19
the medical and public health needs of seniors re-
20
lated to preparation for, response to, and recovery 
21
from all-hazards emergencies; and 
22
‘‘(3) provide advice and consultation with re-
23
spect to State emergency preparedness and response 
24
activities relating to seniors, including related drills 
25
93 
•HR 269 EH
and exercises pursuant to the preparedness goals 
1
under section 2802(b). 
2
‘‘(c) ADDITIONAL DUTIES.—The Advisory Committee 
3
may provide advice and recommendations to the Secretary 
4
with respect to seniors and the medical and public health 
5
grants and cooperative agreements as applicable to pre-
6
paredness and response activities under this title and title 
7
III. 
8
‘‘(d) MEMBERSHIP.— 
9
‘‘(1) IN GENERAL.—The Secretary, in consulta-
10
tion with such other heads of agencies as appro-
11
priate, shall appoint not more than 17 members to 
12
the Advisory Committee. In appointing such mem-
13
bers, the Secretary shall ensure that the total mem-
14
bership of the Advisory Committee is an odd num-
15
ber. 
16
‘‘(2) 
REQUIRED
MEMBERS.—The 
Advisory 
17
Committee shall include Federal members or their 
18
designees (who may be nonvoting members, as deter-
19
mined by the Secretary) and non-Federal members, 
20
as follows: 
21
‘‘(A) The Assistant Secretary for Pre-
22
paredness and Response. 
23
‘‘(B) The Director of the Biomedical Ad-
24
vanced Research and Development Authority. 
25
94 
•HR 269 EH
‘‘(C) The Director of the Centers for Dis-
1
ease Control and Prevention. 
2
‘‘(D) The Commissioner of Food and 
3
Drugs. 
4
‘‘(E) The Director of the National Insti-
5
tutes of Health. 
6
‘‘(F) The Administrator of the Centers for 
7
Medicare & Medicaid Services. 
8
‘‘(G) The Administrator of the Administra-
9
tion for Community Living. 
10
‘‘(H) The Administrator of the Federal 
11
Emergency Management Agency. 
12
‘‘(I) The Under Secretary for Health of 
13
the Department of Veterans Affairs. 
14
‘‘(J) At least 2 non-Federal health care 
15
professionals with expertise in geriatric medical 
16
disaster planning, preparedness, response, or 
17
recovery. 
18
‘‘(K) At least 2 representatives of State, 
19
local, Tribal, or territorial agencies with exper-
20
tise in geriatric disaster planning, preparedness, 
21
response, or recovery. 
22
‘‘(L) Representatives of such other Federal 
23
agencies (such as the Department of Energy 
24
and the Department of Homeland Security) as 
25
95 
•HR 269 EH
the Secretary determines necessary to fulfill the 
1
duties of the Advisory Committee. 
2
‘‘(e) MEETINGS.—The Advisory Committee shall 
3
meet not less frequently than biannually. At least one 
4
meeting per year shall be an in-person meeting. 
5
‘‘(f) COORDINATION.—The Secretary shall coordinate 
6
duties and activities authorized under this section in ac-
7
cordance with section 2811D. 
8
‘‘(g) SUNSET.— 
9
‘‘(1) IN
GENERAL.—The Advisory Committee 
10
shall terminate on September 30, 2023. 
11
‘‘(2) EXTENSION
OF
COMMITTEE.—Not later 
12
than October 1, 2022, the Secretary shall submit to 
13
Congress a recommendation on whether the Advisory 
14
Committee should be extended.’’. 
15
(c) NATIONAL ADVISORY COMMITTEE ON INDIVID-
16
UALS WITH DISABILITIES AND DISASTERS.—Subtitle B 
17
of title XXVIII (42 U.S.C. 300hh et seq.), as amended 
18
by subsection (b), is further amended by inserting after 
19
section 2811B the following: 
20
‘‘SEC. 2811C. NATIONAL ADVISORY COMMITTEE ON INDIVID-
21
UALS WITH DISABILITIES AND DISASTERS. 
22
‘‘(a) ESTABLISHMENT.—The Secretary, in consulta-
23
tion with the Secretary of Homeland Security, shall estab-
24
lish a national advisory committee to be known as the Na-
25
96 
•HR 269 EH
tional Advisory Committee on Individuals with Disabilities 
1
and Disasters (referred to in this section as the ‘Advisory 
2
Committee’). 
3
‘‘(b) DUTIES.—The Advisory Committee shall— 
4
‘‘(1) provide advice and consultation with re-
5
spect to activities carried out pursuant to section 
6
2814, as applicable and appropriate; 
7
‘‘(2) evaluate and provide input with respect to 
8
the medical, public health, and accessibility needs of 
9
individuals with disabilities related to preparation 
10
for, response to, and recovery from all-hazards emer-
11
gencies; and 
12
‘‘(3) provide advice and consultation with re-
13
spect to State emergency preparedness and response 
14
activities, including related drills and exercises pur-
15
suant to the preparedness goals under section 
16
2802(b). 
17
‘‘(c) MEMBERSHIP.— 
18
‘‘(1) IN GENERAL.—The Secretary, in consulta-
19
tion with such other heads of agencies and depart-
20
ments as appropriate, shall appoint not more than 
21
17 members to the Advisory Committee. In appoint-
22
ing such members, the Secretary shall ensure that 
23
the total membership of the Advisory Committee is 
24
an odd number. 
25
97 
•HR 269 EH
‘‘(2) 
REQUIRED
MEMBERS.—The 
Advisory 
1
Committee shall include Federal members or their 
2
designees (who may be nonvoting members, as deter-
3
mined by the Secretary) and non-Federal members, 
4
as follows: 
5
‘‘(A) The Assistant Secretary for Pre-
6
paredness and Response. 
7
‘‘(B) The Administrator of the Administra-
8
tion for Community Living. 
9
‘‘(C) The Director of the Biomedical Ad-
10
vanced Research and Development Authority. 
11
‘‘(D) The Director of the Centers for Dis-
12
ease Control and Prevention. 
13
‘‘(E) The Commissioner of Food and 
14
Drugs. 
15
‘‘(F) The Director of the National Insti-
16
tutes of Health. 
17
‘‘(G) The Administrator of the Federal 
18
Emergency Management Agency. 
19
‘‘(H) The Chair of the National Council on 
20
Disability. 
21
‘‘(I) The Chair of the United States Access 
22
Board. 
23
‘‘(J) The Under Secretary for Health of 
24
the Department of Veterans Affairs. 
25
98 
•HR 269 EH
‘‘(K) At least 2 non-Federal health care 
1
professionals with expertise in disability accessi-
2
bility before, during, and after disasters, med-
3
ical and mass care disaster planning, prepared-
4
ness, response, or recovery. 
5
‘‘(L) At least 2 representatives from State, 
6
local, Tribal, or territorial agencies with exper-
7
tise in disaster planning, preparedness, re-
8
sponse, or recovery for individuals with disabil-
9
ities. 
10
‘‘(M) At least 2 individuals with a dis-
11
ability with expertise in disaster planning, pre-
12
paredness, response, or recovery for individuals 
13
with disabilities. 
14
‘‘(d) MEETINGS.—The Advisory Committee shall 
15
meet not less frequently than biannually. At least one 
16
meeting per year shall be an in-person meeting. 
17
‘‘(e) DISABILITY DEFINED.—For purposes of this 
18
section, the term ‘disability’ has the meaning given such 
19
term in section 3 of the Americans with Disabilities Act 
20
of 1990. 
21
‘‘(f) COORDINATION.—The Secretary shall coordinate 
22
duties and activities authorized under this section in ac-
23
cordance with section 2811D. 
24
‘‘(g) SUNSET.— 
25
99 
•HR 269 EH
‘‘(1) IN
GENERAL.—The Advisory Committee 
1
shall terminate on September 30, 2023. 
2
‘‘(2) RECOMMENDATION.—Not later than Octo-
3
ber 1, 2022, the Secretary shall submit to Congress 
4
a recommendation on whether the Advisory Com-
5
mittee should be extended.’’. 
6
(d) ADVISORY COMMITTEE COORDINATION.—Sub-
7
title B of title XXVIII (42 U.S.C. 300hh et seq.), as 
8
amended by subsection (c), is further amended by insert-
9
ing after section 2811C the following: 
10
‘‘SEC. 2811D. ADVISORY COMMITTEE COORDINATION. 
11
‘‘(a) IN GENERAL.—The Secretary shall coordinate 
12
duties and activities authorized under sections 2811A, 
13
2811B, and 2811C, and make efforts to reduce unneces-
14
sary or duplicative reporting, or unnecessary duplicative 
15
meetings and recommendations under such sections, as 
16
practicable. Members of the advisory committees author-
17
ized under such sections, or their designees, shall annually 
18
meet to coordinate any recommendations, as appropriate, 
19
that may be similar, duplicative, or overlapping with re-
20
spect to addressing the needs of children, seniors, and in-
21
dividuals with disabilities during public health emer-
22
gencies. If such coordination occurs through an in-person 
23
meeting, it shall not be considered the required in-person 
24
100 
•HR 269 EH
meetings under any of sections 2811A(e), 2811B(e), or 
1
2811C(d). 
2
‘‘(b) COORDINATION
AND ALIGNMENT.—The Sec-
3
retary, acting through the employee designated pursuant 
4
to section 2814, shall align preparedness and response 
5
programs or activities to address similar, dual, or overlap-
6
ping needs of children, seniors, and individuals with dis-
7
abilities, and any challenges in preparing for and respond-
8
ing to such needs. 
9
‘‘(c) NOTIFICATION.—The Secretary shall annually 
10
notify the congressional committees of jurisdiction regard-
11
ing the steps taken to coordinate, as appropriate, the rec-
12
ommendations under this section, and provide a summary 
13
description of such coordination.’’. 
14
SEC. 306. GUIDANCE FOR PARTICIPATION IN EXERCISES 
15
AND DRILLS. 
16
Not later than 2 years after the date of enactment 
17
of this Act, the Secretary of Health and Human Services 
18
shall issue final guidance regarding the ability of per-
19
sonnel funded by programs authorized under this Act (in-
20
cluding the amendments made by this Act) to participate 
21
in drills and operational exercises related to all-hazards 
22
medical and public health preparedness and response. 
23
Such drills and operational exercises may include activities 
24
that incorporate medical surge capacity planning, medical 
25
101 
•HR 269 EH
countermeasure distribution and administration, and pre-
1
paring for and responding to identified threats for that 
2
region. Such personnel may include State, local, Tribal, 
3
and territorial public health department or agency per-
4
sonnel funded under this Act (including the amendments 
5
made by this Act). The Secretary shall consult with the 
6
Department of Homeland Security, the Department of 
7
Defense, the Department of Veterans Affairs, and other 
8
applicable Federal departments and agencies as necessary 
9
and appropriate in the development of such guidance. The 
10
Secretary shall make the guidance available on the inter-
11
net website of the Department of Health and Human 
12
Services. 
13
TITLE IV—PRIORITIZING A 
14
THREAT-BASED APPROACH 
15
SEC. 401. ASSISTANT SECRETARY FOR PREPAREDNESS AND 
16
RESPONSE. 
17
Section 2811(b) (42 U.S.C. 300hh–10(b)) is amend-
18
ed— 
19
(1) in the matter preceding paragraph (1), by 
20
inserting ‘‘utilize experience related to public health 
21
emergency preparedness and response, biodefense, 
22
medical countermeasures, and other relevant topics 
23
to’’ after ‘‘shall’’; and 
24
102 
•HR 269 EH
(2) in paragraph (4), by adding at the end the 
1
following: 
2
‘‘(I) 
THREAT
AWARENESS.—Coordinate 
3
with the Director of the Centers for Disease 
4
Control and Prevention, the Director of Na-
5
tional Intelligence, the Secretary of Homeland 
6
Security, the Assistant to the President for Na-
7
tional Security Affairs, the Secretary of De-
8
fense, and other relevant Federal officials, such 
9
as the Secretary of Agriculture, to maintain a 
10
current assessment of national security threats 
11
and inform preparedness and response capabili-
12
ties based on the range of the threats that have 
13
the potential to result in a public health emer-
14
gency.’’. 
15
SEC. 402. PUBLIC HEALTH EMERGENCY MEDICAL COUN-
16
TERMEASURES ENTERPRISE. 
17
(a) IN GENERAL.—Title XXVIII is amended by in-
18
serting after section 2811 (42 U.S.C. 300hh–10) the fol-
19
lowing: 
20
‘‘SEC. 
2811–1. 
PUBLIC 
HEALTH 
EMERGENCY 
MEDICAL 
21
COUNTERMEASURES ENTERPRISE. 
22
‘‘(a) IN GENERAL.—The Secretary shall establish the 
23
Public Health Emergency Medical Countermeasures En-
24
terprise (referred to in this section as the ‘PHEMCE’). 
25
103 
•HR 269 EH
The Assistant Secretary for Preparedness and Response 
1
shall serve as chair of the PHEMCE. 
2
‘‘(b) MEMBERS.—The PHEMCE shall include each 
3
of the following members, or the designee of such mem-
4
bers: 
5
‘‘(1) The Assistant Secretary for Preparedness 
6
and Response. 
7
‘‘(2) The Director of the Centers for Disease 
8
Control and Prevention. 
9
‘‘(3) The Director of the National Institutes of 
10
Health. 
11
‘‘(4) The Commissioner of Food and Drugs. 
12
‘‘(5) The Secretary of Defense. 
13
‘‘(6) The Secretary of Homeland Security. 
14
‘‘(7) The Secretary of Agriculture. 
15
‘‘(8) The Secretary of Veterans Affairs. 
16
‘‘(9) The Director of National Intelligence. 
17
‘‘(10) Representatives of any other Federal 
18
agency, which may include the Director of the Bio-
19
medical Advanced Research and Development Au-
20
thority, the Director of the Strategic National Stock-
21
pile, the Director of the National Institute of Allergy 
22
and Infectious Diseases, and the Director of the Of-
23
fice of Public Health Preparedness and Response, as 
24
the Secretary determines appropriate. 
25
104 
•HR 269 EH
‘‘(c) FUNCTIONS.— 
1
‘‘(1) IN
GENERAL.—The functions of the 
2
PHEMCE shall include the following: 
3
‘‘(A) Utilize a process to make rec-
4
ommendations to the Secretary regarding re-
5
search, advanced research, development, pro-
6
curement, stockpiling, deployment, distribution, 
7
and utilization with respect to countermeasures, 
8
as defined in section 319F–2(c), including 
9
prioritization based on the health security needs 
10
of the United States. Such recommendations 
11
shall be informed by, when available and prac-
12
ticable, the National Health Security Strategy 
13
pursuant to section 2802, the Strategic Na-
14
tional Stockpile needs pursuant to section 
15
319F–2, and assessments of current national 
16
security threats, including chemical, biological, 
17
radiological, and nuclear threats, including 
18
emerging infectious diseases. In the event that 
19
members of the PHEMCE do not agree upon a 
20
recommendation, the Secretary shall provide a 
21
determination regarding such recommendation. 
22
‘‘(B) Identify national health security 
23
needs, including gaps in public health prepared-
24
ness and response related to countermeasures 
25
105 
•HR 269 EH
and challenges to addressing such needs (in-
1
cluding any regulatory challenges), and support 
2
alignment of countermeasure procurement with 
3
recommendations to address such needs under 
4
subparagraph (A). 
5
‘‘(C) Assist the Secretary in developing 
6
strategies related to logistics, deployment, dis-
7
tribution, dispensing, and use of counter-
8
measures that may be applicable to the activi-
9
ties of the strategic national stockpile under 
10
section 319F–2(a). 
11
‘‘(D) Provide consultation for the develop-
12
ment of the strategy and implementation plan 
13
under section 2811(d). 
14
‘‘(2) INPUT.—In carrying out subparagraphs 
15
(B) and (C) of paragraph (1), the PHEMCE shall 
16
solicit and consider input from State, local, Tribal, 
17
and territorial public health departments or officials, 
18
as appropriate.’’. 
19
(b) PUBLIC HEALTH EMERGENCY MEDICAL COUN-
20
TERMEASURES ENTERPRISE STRATEGY AND IMPLEMEN-
21
TATION PLAN.—Section 2811(d) (42 U.S.C. 300hh– 
22
10(d)) is amended— 
23
(1) in paragraph (1)— 
24
106 
•HR 269 EH
(A) by striking ‘‘Not later than 180 days 
1
after the date of enactment of this subsection, 
2
and every year thereafter’’ and inserting ‘‘Not 
3
later than March 15, 2020, and biennially 
4
thereafter’’; and 
5
(B) by striking ‘‘Director of the Bio-
6
medical’’ and all that follows through ‘‘Food 
7
and Drugs’’ and inserting ‘‘Public Health 
8
Emergency Medical Countermeasures Enter-
9
prise established under section 2811–1’’; and 
10
(2) in paragraph (2)(J)(v), by striking ‘‘one- 
11
year period’’ and inserting ‘‘2-year period’’. 
12
SEC. 403. STRATEGIC NATIONAL STOCKPILE. 
13
(a) IN GENERAL.—Section 319F–2(a) (42 U.S.C. 
14
247d–6b(a)) is amended— 
15
(1) by redesignating paragraphs (2) and (3) as 
16
paragraphs (3) and (4), respectively; and 
17
(2) in paragraph (1)— 
18
(A) by inserting ‘‘the Assistant Secretary 
19
for Preparedness and Response and’’ after ‘‘col-
20
laboration with’’; 
21
(B) by inserting ‘‘and optimize’’ after 
22
‘‘provide for’’; 
23
(C) by inserting ‘‘and, as informed by ex-
24
isting recommendations of, or consultations 
25
107 
•HR 269 EH
with, the Public Health Emergency Medical 
1
Countermeasure Enterprise established under 
2
section 2811–1, make necessary additions or 
3
modifications to the contents of such stockpile 
4
or stockpiles based on the review conducted 
5
under paragraph (2)’’ before the period of the 
6
first sentence; and 
7
(D) by striking the second sentence; 
8
(3) by inserting after paragraph (1) the fol-
9
lowing: 
10
‘‘(2) THREAT-BASED REVIEW.— 
11
‘‘(A) IN
GENERAL.—The Secretary shall 
12
conduct an annual threat-based review (taking 
13
into account at-risk individuals) of the contents 
14
of the stockpile under paragraph (1), including 
15
non-pharmaceutical supplies, and, in consulta-
16
tion with the Public Health Emergency Medical 
17
Countermeasures Enterprise established under 
18
section 2811–1, review contents within the 
19
stockpile and assess whether such contents are 
20
consistent with the recommendations made pur-
21
suant to section 2811–1(c)(1)(A). Such review 
22
shall be submitted on June 15, 2019, and on 
23
March 15 of each year thereafter, to the Com-
24
mittee on Health, Education, Labor, and Pen-
25
108 
•HR 269 EH
sions and the Committee on Appropriations of 
1
the Senate and the Committee on Energy and 
2
Commerce and the Committee on Appropria-
3
tions of the House of Representatives, in a 
4
manner that does not compromise national se-
5
curity. 
6
‘‘(B) ADDITIONS, 
MODIFICATIONS, 
AND 
7
REPLENISHMENTS.—Each annual threat-based 
8
review under subparagraph (A) shall, for each 
9
new or modified countermeasure procurement 
10
or replenishment, provide— 
11
‘‘(i) information regarding— 
12
‘‘(I) the quantities of the addi-
13
tional or modified countermeasure 
14
procured for, or contracted to be pro-
15
cured for, the stockpile; 
16
‘‘(II) planning considerations for 
17
appropriate manufacturing capacity 
18
and capability to meet the goals of 
19
such additions or modifications (with-
20
out disclosing proprietary informa-
21
tion), including consideration of the 
22
effect such additions or modifications 
23
may have on the availability of such 
24
109 
•HR 269 EH
products and ancillary medical sup-
1
plies in the health care system; 
2
‘‘(III) the presence or lack of a 
3
commercial market for the counter-
4
measure at the time of procurement; 
5
‘‘(IV) the emergency health secu-
6
rity threat or threats such counter-
7
measure procurement is intended to 
8
address, including whether such pro-
9
curement is consistent with meeting 
10
emergency health security needs asso-
11
ciated with such threat or threats; 
12
‘‘(V) an assessment of whether 
13
the emergency health security threat 
14
or threats described in subclause (IV) 
15
could be addressed in a manner that 
16
better utilizes the resources of the 
17
stockpile and permits the greatest 
18
possible increase in the level of emer-
19
gency preparedness to address such 
20
threats; 
21
‘‘(VI) 
whether 
such 
counter-
22
measure is replenishing an expiring or 
23
expired countermeasure, is a different 
24
countermeasure with the same indica-
25
110 
•HR 269 EH
tion that is replacing an expiring or 
1
expired countermeasure, or is a new 
2
addition to the stockpile; 
3
‘‘(VII) a description of how such 
4
additions or modifications align with 
5
projected investments under previous 
6
countermeasures budget plans under 
7
section 2811(b)(7), including expected 
8
life-cycle costs, expenditures related to 
9
countermeasure procurement to ad-
10
dress the threat or threats described 
11
in subclause (IV), replenishment dates 
12
(including the ability to extend the 
13
maximum shelf life of a counter-
14
measure), and the manufacturing ca-
15
pacity required to replenish such 
16
countermeasure; and 
17
‘‘(VIII) appropriate protocols and 
18
processes for the deployment, distribu-
19
tion, or dispensing of the counter-
20
measure at the State and local level, 
21
including plans for relevant capabili-
22
ties of State and local entities to dis-
23
pense, distribute, and administer the 
24
countermeasure; and 
25
111 
•HR 269 EH
‘‘(ii) an assurance, which need not be 
1
provided in advance of procurement, that 
2
for each countermeasure procured or re-
3
plenished under this subsection, the Sec-
4
retary completed a review addressing each 
5
item listed under this subsection in ad-
6
vance of such procurement or replenish-
7
ment.’’; 
8
(4) in paragraph (3), as so redesignated— 
9
(A) in subparagraph (A), by inserting 
10
‘‘and the Public Health Emergency Medical 
11
Countermeasures Enterprise established under 
12
section 2811–1’’ before the semicolon; 
13
(B) in subparagraph (C), by inserting ‘‘, 
14
and the availability, deployment, dispensing, 
15
and administration of countermeasures’’ before 
16
the semicolon; 
17
(C) by amending subparagraph (E) to read 
18
as follows: 
19
‘‘(E) devise plans for effective and timely 
20
supply-chain management of the stockpile, in 
21
consultation with the Director of the Centers 
22
for Disease Control and Prevention, the Assist-
23
ant Secretary for Preparedness and Response, 
24
the Secretary of Transportation, the Secretary 
25
112 
•HR 269 EH
of Homeland Security, the Secretary of Vet-
1
erans Affairs, and the heads of other appro-
2
priate Federal agencies; State, local, Tribal, 
3
and territorial agencies; and the public and pri-
4
vate health care infrastructure, as applicable, 
5
taking into account the manufacturing capacity 
6
and other available sources of products and ap-
7
propriate alternatives to supplies in the stock-
8
pile;’’; 
9
(D) in subparagraph (G), by striking ‘‘; 
10
and’’ and inserting a semicolon; 
11
(E) in subparagraph (H), by striking the 
12
period and inserting a semicolon; and 
13
(F) by adding at the end the following: 
14
‘‘(I) ensure that each countermeasure or 
15
product under consideration for procurement 
16
pursuant to this subsection receives the same 
17
consideration regardless of whether such coun-
18
termeasure or product receives or had received 
19
funding under section 319L, including with re-
20
spect to whether the countermeasure or product 
21
is most appropriate to meet the emergency 
22
health security needs of the United States; and 
23
‘‘(J) provide assistance, including technical 
24
assistance, to maintain and improve State and 
25
113 
•HR 269 EH
local public health preparedness capabilities to 
1
distribute 
and 
dispense 
medical 
counter-
2
measures and products from the stockpile, as 
3
appropriate.’’; and 
4
(5) by adding at the end the following: 
5
‘‘(5) GAO REPORT.— 
6
‘‘(A) IN GENERAL.—Not later than 3 years 
7
after the date of enactment of the Pandemic 
8
and All-Hazards Preparedness and Advancing 
9
Innovation Act of 2019, and every 5 years 
10
thereafter, the Comptroller General of the 
11
United States shall conduct a review of any 
12
changes to the contents or management of the 
13
stockpile since January 1, 2015. Such review 
14
shall include— 
15
‘‘(i) an assessment of the comprehen-
16
siveness and completeness of each annual 
17
threat-based review under paragraph (2), 
18
including whether all newly procured or re-
19
plenished 
countermeasures 
within 
the 
20
stockpile were described in each annual re-
21
view, and whether, consistent with para-
22
graph (2)(B), the Secretary conducted the 
23
necessary internal review in advance of 
24
such procurement or replenishment; 
25
114 
•HR 269 EH
‘‘(ii) an assessment of whether the 
1
Secretary established health security and 
2
science-based justifications, and a descrip-
3
tion of such justifications for procurement 
4
decisions related to health security needs 
5
with respect to the identified threat, for 
6
additions or modifications to the stockpile 
7
based on the information provided in such 
8
reviews under paragraph (2)(B), including 
9
whether such review was conducted prior 
10
to procurement, modification, or replenish-
11
ment; 
12
‘‘(iii) an assessment of the plans de-
13
veloped by the Secretary for the deploy-
14
ment, distribution, and dispensing of coun-
15
termeasures procured, modified, or replen-
16
ished under paragraph (1), including 
17
whether such plans were developed prior to 
18
procurement, modification, or replenish-
19
ment; 
20
‘‘(iv) 
an 
accounting 
of 
counter-
21
measures procured, modified, or replen-
22
ished under paragraph (1) that received 
23
advanced research and development fund-
24
115 
•HR 269 EH
ing from the Biomedical Advanced Re-
1
search and Development Authority; 
2
‘‘(v) an analysis of how such procure-
3
ment decisions made progress toward 
4
meeting emergency health security needs 
5
related to the identified threats for coun-
6
termeasures added, modified, or replen-
7
ished under paragraph (1); 
8
‘‘(vi) a description of the resources ex-
9
pended related to the procurement of coun-
10
termeasures (including additions, modifica-
11
tions, and replenishments) in the stockpile, 
12
and how such expenditures relate to the 
13
ability of the stockpile to meet emergency 
14
health security needs; 
15
‘‘(vii) an assessment of the extent to 
16
which additions, modifications, and replen-
17
ishments reviewed under paragraph (2) 
18
align with previous relevant reports or re-
19
views by the Secretary or the Comptroller 
20
General; 
21
‘‘(viii) with respect to any change in 
22
the Federal organizational management of 
23
the stockpile, an assessment and compari-
24
son of the processes affected by such 
25
116 
•HR 269 EH
change, including planning for potential 
1
countermeasure deployment, distribution, 
2
or dispensing capabilities and processes re-
3
lated to procurement decisions, use of 
4
stockpiled countermeasures, and use of re-
5
sources for such activities; and 
6
‘‘(ix) an assessment of whether the 
7
processes and procedures described by the 
8
Secretary pursuant to section 403(b) of 
9
the Pandemic and All-Hazards Prepared-
10
ness and Advancing Innovation Act of 
11
2019 are sufficient to ensure counter-
12
measures and products under consideration 
13
for procurement pursuant to subsection (a) 
14
receive the same consideration regardless 
15
of whether such countermeasures and 
16
products receive or had received funding 
17
under section 319L, including with respect 
18
to whether such countermeasures and 
19
products are most appropriate to meet the 
20
emergency health security needs of the 
21
United States. 
22
‘‘(B) SUBMISSION.—Not later than 6 
23
months after completing a classified version of 
24
the review under subparagraph (A), the Comp-
25
117 
•HR 269 EH
troller General shall submit an unclassified 
1
version of the review to the congressional com-
2
mittees of jurisdiction.’’. 
3
(b) ADDITIONAL REPORTING.—In the first threat- 
4
based review submitted after the date of enactment of this 
5
Act pursuant to paragraph (2) of section 319F–2(a) of 
6
the Public Health Service Act (42 U.S.C. 247d–6b(a)), as 
7
amended by subsection (a), the Secretary shall include a 
8
description of the processes and procedures through which 
9
the Director of the Strategic National Stockpile and the 
10
Director of the Biomedical Advanced Research and Devel-
11
opment Authority coordinate with respect to counter-
12
measures and products procured under such section 
13
319F–2(a), including such processes and procedures in 
14
place to ensure countermeasures and products under con-
15
sideration for procurement pursuant to such section 
16
319F–2(a) receive the same consideration regardless of 
17
whether such countermeasures or products receive or had 
18
received funding under section 319L of the Public Health 
19
Service Act (42 U.S.C. 247d–7e), and whether such coun-
20
termeasures and products are the most appropriate to 
21
meet the emergency health security needs of the United 
22
States. 
23
(c) AUTHORIZATION
OF APPROPRIATIONS, STRA-
24
TEGIC NATIONAL STOCKPILE.—Section 319F–2(f)(1) (42 
25
118 
•HR 269 EH
U.S.C. 
247d–6b(f)(1)) 
is 
amended 
by 
striking 
1
‘‘$533,800,000 for each of fiscal years 2014 through 
2
2018’’ and inserting ‘‘$610,000,000 for each of fiscal 
3
years 2019 through 2023, to remain available until ex-
4
pended’’. 
5
SEC. 404. PREPARING FOR PANDEMIC INFLUENZA, ANTI-
6
MICROBIAL RESISTANCE, AND OTHER SIG-
7
NIFICANT THREATS. 
8
(a) STRATEGIC INITIATIVES.—Section 319L(c)(4) 
9
(247d–7e(c)(4)) is amended by adding at the end the fol-
10
lowing: 
11
‘‘(F) STRATEGIC
INITIATIVES.—The Sec-
12
retary, acting through the Director of BARDA, 
13
may implement strategic initiatives, including 
14
by building on existing programs and by award-
15
ing contracts, grants, and cooperative agree-
16
ments, or entering into other transactions, to 
17
support innovative candidate products in pre-
18
clinical and clinical development that address 
19
priority, naturally occurring and man-made 
20
threats that, as determined by the Secretary, 
21
pose a significant level of risk to national secu-
22
rity based on the characteristics of a chemical, 
23
biological, radiological or nuclear threat, or ex-
24
isting capabilities to respond to such a threat 
25
119 
•HR 269 EH
(including medical response and treatment ca-
1
pabilities and manufacturing infrastructure). 
2
Such initiatives shall accelerate and support the 
3
advanced research, development, and procure-
4
ment of countermeasures and products, as ap-
5
plicable, to address areas including— 
6
‘‘(i) chemical, biological, radiological, 
7
or nuclear threats, including emerging in-
8
fectious diseases, for which insufficient ap-
9
proved, licensed, or authorized counter-
10
measures exist, or for which such threat, 
11
or the result of an exposure to such threat, 
12
may become resistant to countermeasures 
13
or existing countermeasures may be ren-
14
dered ineffective; 
15
‘‘(ii) threats that consistently exist or 
16
continually circulate and have a significant 
17
potential to become a pandemic, such as 
18
pandemic influenza, which may include the 
19
advanced research and development, manu-
20
facturing, and appropriate stockpiling of 
21
qualified pandemic or epidemic products, 
22
and products, technologies, or processes to 
23
support the advanced research and devel-
24
opment of such countermeasures (including 
25
120 
•HR 269 EH
multiuse 
platform 
technologies 
for 
1
diagnostics, vaccines, and therapeutics; 
2
virus seeds; clinical trial lots; novel virus 
3
strains; and antigen and adjuvant mate-
4
rial); and 
5
‘‘(iii) threats that may result pri-
6
marily or secondarily from a chemical, bio-
7
logical, radiological, or nuclear agent, or 
8
emerging infectious diseases, and which 
9
may present increased treatment complica-
10
tions such as the occurrence of resistance 
11
to available countermeasures or potential 
12
countermeasures, including antimicrobial 
13
resistant pathogens.’’. 
14
(b) PROTECTION
OF NATIONAL SECURITY FROM 
15
THREATS.—Section 2811 (42 U.S.C. 300hh–10) is 
16
amended by adding at the end the following: 
17
‘‘(f) PROTECTION OF NATIONAL SECURITY FROM 
18
THREATS.— 
19
‘‘(1) IN GENERAL.—In carrying out subsection 
20
(b)(3), the Assistant Secretary for Preparedness and 
21
Response shall implement strategic initiatives or ac-
22
tivities to address threats, including pandemic influ-
23
enza and which may include a chemical, biological, 
24
radiological, or nuclear agent (including any such 
25
121 
•HR 269 EH
agent with a significant potential to become a pan-
1
demic), that pose a significant level of risk to public 
2
health and national security based on the character-
3
istics of such threat. Such initiatives shall include 
4
activities to— 
5
‘‘(A) accelerate and support the advanced 
6
research, development, manufacturing capacity, 
7
procurement, 
and 
stockpiling 
of 
counter-
8
measures, including initiatives under section 
9
319L(c)(4)(F); 
10
‘‘(B) support the development and manu-
11
facturing of virus seeds, clinical trial lots, and 
12
stockpiles of novel virus strains; and 
13
‘‘(C) maintain or improve preparedness ac-
14
tivities, including for pandemic influenza. 
15
‘‘(2) AUTHORIZATION OF APPROPRIATIONS.— 
16
‘‘(A) IN GENERAL.—To carry out this sub-
17
section, there is authorized to be appropriated 
18
$250,000,000 for each of fiscal years 2019 
19
through 2023. 
20
‘‘(B) SUPPLEMENT, 
NOT
SUPPLANT.— 
21
Amounts appropriated under this paragraph 
22
shall be used to supplement and not supplant 
23
funds provided under sections 319L(d) and 
24
319F–2(g). 
25
122 
•HR 269 EH
‘‘(C) DOCUMENTATION
REQUIRED.—The 
1
Assistant Secretary for Preparedness and Re-
2
sponse, in accordance with subsection (b)(7), 
3
shall document amounts expended for purposes 
4
of carrying out this subsection, including 
5
amounts appropriated under the heading ‘Pub-
6
lic Health and Social Services Emergency 
7
Fund’ under the heading ‘Office of the Sec-
8
retary’ under title II of division H of the Con-
9
solidated Appropriations Act, 2018 (Public Law 
10
115–141) and allocated to carrying out section 
11
319L(c)(4)(F).’’. 
12
SEC. 405. REPORTING ON THE FEDERAL SELECT AGENT 
13
PROGRAM. 
14
Section 351A(k) (42 U.S.C. 262a(k)) is amended— 
15
(1) by striking ‘‘The Secretary’’ and inserting 
16
the following: 
17
‘‘(1) IN GENERAL.—The Secretary’’; and 
18
(2) by adding at the end the following: 
19
‘‘(2) IMPLEMENTATION OF RECOMMENDATIONS 
20
OF
THE
FEDERAL
EXPERTS
SECURITY
ADVISORY 
21
PANEL AND THE FAST TRACK ACTION COMMITTEE 
22
ON SELECT AGENT REGULATIONS.— 
23
‘‘(A) IN GENERAL.—Not later than 1 year 
24
after the date of the enactment of the Pan-
25
123 
•HR 269 EH
demic and All-Hazards Preparedness and Ad-
1
vancing Innovation Act of 2019, the Secretary 
2
shall report to the congressional committees of 
3
jurisdiction on the implementation of rec-
4
ommendations of the Federal Experts Security 
5
Advisory Panel concerning the select agent pro-
6
gram. 
7
‘‘(B) CONTINUED
UPDATES.—The Sec-
8
retary shall report to the congressional commit-
9
tees of jurisdiction annually following the sub-
10
mission of the report under subparagraph (A) 
11
until the recommendations described in such 
12
subparagraph are fully implemented, or a jus-
13
tification is provided for the delay in, or lack of, 
14
implementation.’’. 
15
TITLE V—INCREASING COMMU-
16
NICATION IN MEDICAL COUN-
17
TERMEASURE ADVANCED RE-
18
SEARCH AND DEVELOPMENT 
19
SEC. 501. MEDICAL COUNTERMEASURE BUDGET PLAN. 
20
Section 2811(b)(7) (42 U.S.C. 300hh–10(b)(7)) is 
21
amended— 
22
(1) in the matter preceding subparagraph (A), 
23
by striking ‘‘March 1’’ and inserting ‘‘March 15’’; 
24
(2) in subparagraph (A)— 
25
124 
•HR 269 EH
(A) in clause (ii), by striking ‘‘; and’’ and 
1
inserting ‘‘;’’; and 
2
(B) by striking clause (iii) and inserting 
3
the following: 
4
‘‘(iii) procurement, stockpiling, main-
5
tenance, and potential replenishment (in-
6
cluding manufacturing capabilities) of all 
7
products in the Strategic National Stock-
8
pile; 
9
‘‘(iv) the availability of technologies 
10
that may assist in the advanced research 
11
and development of countermeasures and 
12
opportunities to use such technologies to 
13
accelerate and navigate challenges unique 
14
to countermeasure research and develop-
15
ment; and 
16
‘‘(v) potential deployment, distribu-
17
tion, and utilization of medical counter-
18
measures; development of clinical guidance 
19
and emergency use instructions for the use 
20
of medical countermeasures; and, as appli-
21
cable, potential postdeployment activities 
22
related to medical countermeasures;’’; 
23
(3) by redesignating subparagraphs (D) and 
24
(E) as subparagraphs (E) and (F), respectively; and 
25
125 
•HR 269 EH
(4) by inserting after subparagraph (C), the fol-
1
lowing: 
2
‘‘(D) identify the full range of anticipated 
3
medical countermeasure needs related to re-
4
search and development, procurement, and 
5
stockpiling, including the potential need for in-
6
dications, dosing, and administration tech-
7
nologies, and other countermeasure needs as 
8
applicable and appropriate;’’. 
9
SEC. 502. MATERIAL THREAT AND MEDICAL COUNTER-
10
MEASURE NOTIFICATIONS. 
11
(a) CONGRESSIONAL NOTIFICATION OF MATERIAL 
12
THREAT DETERMINATION.—Section 319F–2(c)(2)(C) (42 
13
U.S.C. 247d–6b(c)(2)(C)) is amended by striking ‘‘The 
14
Secretary and the Homeland Security Secretary shall 
15
promptly notify the appropriate committees of Congress’’ 
16
and inserting ‘‘The Secretary and the Secretary of Home-
17
land Security shall send to Congress, on an annual basis, 
18
all current material threat determinations and shall 
19
promptly notify the Committee on Health, Education, 
20
Labor, and Pensions and the Committee on Homeland Se-
21
curity and Governmental Affairs of the Senate and the 
22
Committee on Energy and Commerce and the Committee 
23
on Homeland Security of the House of Representatives’’. 
24
126 
•HR 269 EH
(b) CONTRACTING COMMUNICATION.—Section 319F– 
1
2(c)(7)(B)(ii)(III) (42 U.S.C. 247d–6b(c)(7)(B)(ii)(III)) 
2
is amended by adding at the end the following: ‘‘The Sec-
3
retary shall notify the vendor within 90 days of a deter-
4
mination by the Secretary to renew, extend, or terminate 
5
such contract.’’. 
6
SEC. 503. AVAILABILITY OF REGULATORY MANAGEMENT 
7
PLANS. 
8
Section 565(f) of the Federal Food, Drug, and Cos-
9
metic Act (21 U.S.C. 360bbb–4(f)) is amended— 
10
(1) by redesignating paragraphs (3) through 
11
(6) as paragraphs (4) through (7), respectively; 
12
(2) by inserting after paragraph (2) the fol-
13
lowing: 
14
‘‘(3) PUBLICATION.—The Secretary shall make 
15
available on the internet website of the Food and 
16
Drug Administration information regarding regu-
17
latory management plans, including— 
18
‘‘(A) the process by which an applicant 
19
may submit a request for a regulatory manage-
20
ment plan; 
21
‘‘(B) the timeframe by which the Secretary 
22
is required to respond to such request; 
23
‘‘(C) the information required for the sub-
24
mission of such request; 
25
127 
•HR 269 EH
‘‘(D) a description of the types of develop-
1
ment milestones and performance targets that 
2
could be discussed and included in such plans; 
3
and 
4
‘‘(E) contact information for beginning the 
5
regulatory management plan process.’’; 
6
(3) in paragraph (6), as so redesignated, in the 
7
matter preceding subparagraph (A)— 
8
(A) by striking ‘‘paragraph (4)(A)’’ and in-
9
serting ‘‘paragraph (5)(A)’’; and 
10
(B) by striking ‘‘paragraph (4)(B)’’ and 
11
inserting ‘‘paragraph (5)(B)’’; and 
12
(4) in paragraph (7)(A), as so redesignated, by 
13
striking ‘‘paragraph (3)(A)’’ and inserting ‘‘para-
14
graph (4)(A)’’. 
15
SEC. 504. THE BIOMEDICAL ADVANCED RESEARCH AND DE-
16
VELOPMENT 
AUTHORITY 
AND 
THE 
BIO-
17
SHIELD SPECIAL RESERVE FUND. 
18
(a) BIOSHIELD SPECIAL RESERVE FUND.—Section 
19
319F–2(g)(1) (42 U.S.C. 247d–6b(g)(1)) is amended— 
20
(1) by striking ‘‘$2,800,000,000 for the period 
21
of fiscal years 2014 through 2018’’ and inserting 
22
‘‘$7,100,000,000 for the period of fiscal years 2019 
23
through 2028, to remain available until expended’’; 
24
and 
25
128 
•HR 269 EH
(2) by striking the second sentence. 
1
(b) THE BIOMEDICAL ADVANCED RESEARCH AND 
2
DEVELOPMENT
AUTHORITY.—Section 319L(d)(2) (42 
3
U.S.C. 
247d–7e(d)(2)) 
is 
amended 
by 
striking 
4
‘‘$415,000,000 for each of fiscal years 2014 through 
5
2018’’ and inserting ‘‘$611,700,000 for each of fiscal 
6
years 2019 through 2023’’. 
7
SEC. 505. ADDITIONAL STRATEGIES FOR COMBATING ANTI-
8
BIOTIC RESISTANCE. 
9
(a) ADVISORY COUNCIL.—The Secretary of Health 
10
and Human Services (referred to in this section as the 
11
‘‘Secretary’’) may continue the Presidential Advisory 
12
Council on Combating Antibiotic-Resistant Bacteria, re-
13
ferred to in this section as the ‘‘Advisory Council’’. 
14
(b) DUTIES.—The Advisory Council shall advise and 
15
provide information and recommendations to the Sec-
16
retary regarding programs and policies intended to reduce 
17
or combat antibiotic-resistant bacteria that may present 
18
a public health threat and improve capabilities to prevent, 
19
diagnose, mitigate, or treat such resistance. Such advice, 
20
information, and recommendations may be related to im-
21
proving— 
22
(1) the effectiveness of antibiotics; 
23
(2) research and advanced research on, and the 
24
development of, improved and innovative methods 
25
129 
•HR 269 EH
for combating or reducing antibiotic resistance, in-
1
cluding 
new 
treatments, 
rapid 
point-of-care 
2
diagnostics, alternatives to antibiotics, including al-
3
ternatives to animal antibiotics, and antimicrobial 
4
stewardship activities; 
5
(3) surveillance of antibiotic-resistant bacterial 
6
infections, including publicly available and up-to- 
7
date information on resistance to antibiotics; 
8
(4) education for health care providers and the 
9
public with respect to up-to-date information on an-
10
tibiotic resistance and ways to reduce or combat 
11
such resistance to antibiotics related to humans and 
12
animals; 
13
(5) methods to prevent or reduce the trans-
14
mission of antibiotic-resistant bacterial infections, 
15
including stewardship programs; and 
16
(6) coordination with respect to international 
17
efforts in order to inform and advance United States 
18
capabilities to combat antibiotic resistance. 
19
(c) MEETINGS AND COORDINATION.— 
20
(1) MEETINGS.—The Advisory Council shall 
21
meet not less than biannually and, to the extent 
22
practicable, in coordination with meetings of the 
23
Antimicrobial Resistance Task Force established in 
24
section 319E(a) of the Public Health Service Act. 
25
130 
•HR 269 EH
(2) COORDINATION.—The Advisory Council 
1
shall, to the greatest extent practicable, coordinate 
2
activities carried out by the Council with the Anti-
3
microbial Resistance Task Force established under 
4
section 319E(a) of the Public Health Service Act 
5
(42 U.S.C. 247d–5(a)). 
6
(d) FACA.—The Federal Advisory Committee Act (5 
7
U.S.C. App.) shall apply to the activities and duties of 
8
the Advisory Council. 
9
(e) EXTENSION OF ADVISORY COUNCIL.—Not later 
10
than October 1, 2022, the Secretary shall submit to the 
11
Committee on Health, Education, Labor, and Pensions of 
12
the Senate and the Committee on Energy and Commerce 
13
of the House of Representatives a recommendation on 
14
whether the Advisory Council should be extended, and in 
15
addition, identify whether there are other committees, 
16
councils, or task forces that have overlapping or similar 
17
duties to that of the Advisory Council, and whether such 
18
committees, councils, or task forces should be combined, 
19
including with respect to section 319E(a) of the Public 
20
Health Service Act (42 U.S.C. 247d–5(a)). 
21
131 
•HR 269 EH
TITLE 
VI—ADVANCING 
TECH-
1
NOLOGIES 
FOR 
MEDICAL 
2
COUNTERMEASURES 
3
SEC. 601. ADMINISTRATION OF COUNTERMEASURES. 
4
Section 
319L(c)(4)(D)(iii) 
(42 
U.S.C. 
247d– 
5
7e(c)(4)(D)(iii)) is amended by striking ‘‘and platform 
6
technologies’’ and inserting ‘‘platform technologies, tech-
7
nologies to administer countermeasures, and technologies 
8
to improve storage and transportation of counter-
9
measures’’. 
10
SEC. 602. UPDATING DEFINITIONS OF OTHER TRANS-
11
ACTIONS. 
12
Section 319L (42 U.S.C. 247d–7e) is amended— 
13
(1) in subsection (a)(3), by striking ‘‘, such as’’ 
14
and all that follows through ‘‘Code’’; and 
15
(2) in subsection (c)(5)(A)— 
16
(A) in clause (i), by striking ‘‘under this 
17
subsection’’ and all that follows through ‘‘Code’’ 
18
and inserting ‘‘(as defined in subsection (a)(3)) 
19
under this subsection’’; and 
20
(B) in clause (ii)— 
21
(i) by amending subclause (I) to read 
22
as follows: 
23
‘‘(I) IN GENERAL.—To the max-
24
imum extent practicable, competitive 
25
132 
•HR 269 EH
procedures shall be used when enter-
1
ing into transactions to carry out 
2
projects under this subsection.’’; and 
3
(ii) in subclause (II)— 
4
(I) by striking ‘‘$20,000,000’’ 
5
and inserting ‘‘$100,000,000’’; 
6
(II) by striking ‘‘senior procure-
7
ment executive for the Department 
8
(as designated for purpose of section 
9
16(c) of the Office of Federal Pro-
10
curement Policy Act (41 U.S.C. 
11
414(c)))’’ and inserting ‘‘Assistant 
12
Secretary for Financial Resources’’; 
13
and 
14
(III) by striking ‘‘senior procure-
15
ment executive under’’ and inserting 
16
‘‘Assistant Secretary for Financial Re-
17
sources under’’. 
18
SEC. 603. MEDICAL COUNTERMEASURE MASTER FILES. 
19
(a) IN GENERAL.—The purpose of this section (in-
20
cluding section 565B of the Federal Food, Drug, and Cos-
21
metic Act, as added by subsection (b)) is to support and 
22
advance the development or manufacture of security coun-
23
termeasures, qualified countermeasures, and qualified 
24
pandemic or epidemic products by facilitating and encour-
25
133 
•HR 269 EH
aging submission of data and information to support the 
1
development of such products, and through clarifying the 
2
authority to cross-reference to data and information pre-
3
viously submitted to the Secretary of Health and Human 
4
Services (referred to in this section as the ‘‘Secretary’’), 
5
including data and information submitted to medical coun-
6
termeasure master files or other master files. 
7
(b) MEDICAL COUNTERMEASURE MASTER FILES.— 
8
Chapter V of the Federal Food, Drug, and Cosmetic Act 
9
(21 U.S.C. 351 et seq.) is amended by inserting after sec-
10
tion 565A the following: 
11
‘‘SEC. 565B. MEDICAL COUNTERMEASURE MASTER FILES. 
12
‘‘(a) APPLICABILITY OF REFERENCE.— 
13
‘‘(1) IN GENERAL.—A person may submit data 
14
and information in a master file to the Secretary 
15
with the intent to reference, or to authorize, in writ-
16
ing, another person to reference, such data or infor-
17
mation to support a medical countermeasure submis-
18
sion (including a supplement or amendment to any 
19
such submission), without requiring the master file 
20
holder to disclose the data and information to any 
21
such persons authorized to reference the master file. 
22
Such data and information shall be available for ref-
23
erence by the master file holder or by a person au-
24
thorized by the master file holder, in accordance 
25
134 
•HR 269 EH
with applicable privacy and confidentiality protocols 
1
and regulations. 
2
‘‘(2) 
REFERENCE
OF
CERTAIN
MASTER 
3
FILES.—In the case that data or information within 
4
a medical countermeasure master file is used only to 
5
support the conditional approval of an application 
6
filed under section 571, such master file may be re-
7
lied upon to support the effectiveness of a product 
8
that is the subject of a subsequent medical counter-
9
measure submission only if such application is sup-
10
plemented by additional data or information to sup-
11
port review and approval in a manner consistent 
12
with the standards applicable to such review and ap-
13
proval for such countermeasure, qualified counter-
14
measure, or qualified pandemic or epidemic product. 
15
‘‘(b) MEDICAL COUNTERMEASURE MASTER FILE 
16
CONTENT.— 
17
‘‘(1) IN GENERAL.—A master file under this 
18
section may include data or information to sup-
19
port— 
20
‘‘(A) the development of medical counter-
21
measure submissions to support the approval, 
22
licensure, classification, clearance, conditional 
23
approval, or authorization of one or more secu-
24
rity 
countermeasures, 
qualified 
counter-
25
135 
•HR 269 EH
measures, or qualified pandemic or epidemic 
1
products; and 
2
‘‘(B) the manufacture of security counter-
3
measures, qualified countermeasures, or quali-
4
fied pandemic or epidemic products. 
5
‘‘(2) REQUIRED UPDATES.—The Secretary may 
6
require, as appropriate, that the master file holder 
7
ensure that the contents of such master file are up-
8
dated during the time such master file is referenced 
9
for a medical countermeasure submission. 
10
‘‘(c) SPONSOR REFERENCE.— 
11
‘‘(1) IN GENERAL.—Each incorporation of data 
12
or information within a medical countermeasure 
13
master file shall describe the incorporated material 
14
in a manner in which the Secretary determines ap-
15
propriate and that permits the review of such infor-
16
mation within such master file without necessitating 
17
resubmission of such data or information. Master 
18
files shall be submitted in an electronic format in ac-
19
cordance with sections 512(b)(4), 571(a)(4), and 
20
745A, as applicable, and as specified in applicable 
21
guidance. 
22
‘‘(2) REFERENCE BY A MASTER FILE HOLD-
23
ER.—A master file holder that is the sponsor of a 
24
medical countermeasure submission shall notify the 
25
136 
•HR 269 EH
Secretary in writing of the intent to reference the 
1
medical countermeasure master file as a part of the 
2
submission. 
3
‘‘(3) REFERENCE
BY
AN
AUTHORIZED
PER-
4
SON.—A person submitting an application for review 
5
may, where the Secretary determines appropriate, 
6
incorporate by reference all or part of the contents 
7
of a medical countermeasure master file, if the mas-
8
ter file holder authorizes the incorporation in writ-
9
ing. 
10
‘‘(d) ACKNOWLEDGMENT OF AND RELIANCE UPON A 
11
MASTER FILE BY THE SECRETARY.— 
12
‘‘(1) IN GENERAL.—The Secretary shall provide 
13
the master file holder with a written notification in-
14
dicating that the Secretary has reviewed and relied 
15
upon specified data or information within a master 
16
file and the purposes for which such data or infor-
17
mation was incorporated by reference if the Sec-
18
retary has reviewed and relied upon such specified 
19
data or information to support the approval, classi-
20
fication, conditional approval, clearance, licensure, or 
21
authorization of a security countermeasure, qualified 
22
countermeasure, or qualified pandemic or epidemic 
23
product. The Secretary may rely upon the data and 
24
information within the medical countermeasure mas-
25
137 
•HR 269 EH
ter file for which such written notification was pro-
1
vided in additional applications, as applicable and 
2
appropriate and upon the request of the master file 
3
holder so notified in writing or by an authorized per-
4
son of such holder. 
5
‘‘(2) CERTAIN APPLICATIONS.—If the Secretary 
6
has reviewed and relied upon specified data or infor-
7
mation within a medical countermeasure master file 
8
to support the conditional approval of an application 
9
under section 571 to subsequently support the ap-
10
proval, clearance, licensure, or authorization of a se-
11
curity countermeasure, qualified countermeasure, or 
12
qualified pandemic or epidemic product, the Sec-
13
retary shall provide a brief written description to the 
14
master file holder regarding the elements of the ap-
15
plication fulfilled by the data or information within 
16
the master file and how such data or information 
17
contained in such application meets the standards of 
18
evidence under subsection (c) or (d) of section 505, 
19
subsection (d) of section 512, or section 351 of the 
20
Public Health Service Act (as applicable), which 
21
shall not include any trade secret or confidential 
22
commercial information. 
23
‘‘(e) RULES OF CONSTRUCTION.—Nothing in this 
24
section shall be construed to— 
25
138 
•HR 269 EH
‘‘(1) limit the authority of the Secretary to ap-
1
prove, license, clear, conditionally approve, or au-
2
thorize drugs, biological products, or devices pursu-
3
ant to, as applicable, this Act or section 351 of the 
4
Public Health Service Act (as such applicable Act is 
5
in effect on the day before the date of enactment of 
6
the Pandemic and All-Hazards Preparedness and 
7
Advancing Innovation Act of 2019), including the 
8
standards of evidence, and applicable conditions, for 
9
approval under the applicable Act; 
10
‘‘(2) alter the standards of evidence with re-
11
spect to approval, licensure, or clearance, as applica-
12
ble, of drugs, biological products, or devices under 
13
this Act or section 351 of the Public Health Service 
14
Act, including, as applicable, the substantial evi-
15
dence standards under sections 505(d) and 512(d) 
16
or this Act and section 351(a) of the Public Health 
17
Service Act; or 
18
‘‘(3) alter the authority of the Secretary under 
19
this Act or the Public Health Service Act to deter-
20
mine the types of data or information previously 
21
submitted by a sponsor or any other person that 
22
may be incorporated by reference in an application, 
23
request, or notification for a drug, biological prod-
24
uct, or device submitted under sections 505(i), 
25
139 
•HR 269 EH
505(b), 505(j), 512(b)(1), 512(b)(2), 512(j), 564, 
1
571, 520(g), 515(c), 513(f)(2), or 510(k) of this 
2
Act, or subsection (a) or (k) of section 351 of the 
3
Public Health Service Act, including a supplement 
4
or amendment to any such submission, and the re-
5
quirements associated with such reference. 
6
‘‘(f) DEFINITIONS.—In this section: 
7
‘‘(1) The term ‘master file holder’ means a per-
8
son who submits data and information to the Sec-
9
retary with the intent to reference or authorize an-
10
other person to reference such data or information 
11
to support a medical countermeasure submission, as 
12
described in subsection (a). 
13
‘‘(2) The term ‘medical countermeasure submis-
14
sion’ means an investigational new drug application 
15
under section 505(i), a new drug application under 
16
section 505(b), or an abbreviated new drug applica-
17
tion under section 505(j) of this Act, a biological 
18
product license application under section 351(a) of 
19
the Public Health Service Act or a biosimilar biologi-
20
cal product license application under section 351(k) 
21
of the Public Health Service Act, a new animal drug 
22
application under section 512(b)(1) or abbreviated 
23
new 
animal 
drug 
application 
under 
section 
24
512(b)(2), an application for conditional approval of 
25
140 
•HR 269 EH
a new animal drug under section 571, an investiga-
1
tional device application under section 520(g), an 
2
application with respect to a device under section 
3
515(c), a request for classification of a device under 
4
section 513(f)(2), a notification with respect to a de-
5
vice under section 510(k), or a request for an emer-
6
gency use authorization under section 564 to sup-
7
port— 
8
‘‘(A) the approval, licensure, classification, 
9
clearance, conditional approval, or authorization 
10
of a security countermeasure, qualified counter-
11
measure, or qualified pandemic or epidemic 
12
product; or 
13
‘‘(B) a new indication to an approved secu-
14
rity countermeasure, qualified countermeasure, 
15
or qualified pandemic or epidemic product. 
16
‘‘(3) The terms ‘qualified countermeasure’, ‘se-
17
curity countermeasure’, and ‘qualified pandemic or 
18
epidemic product’ have the meanings given such 
19
terms in sections 319F–1, 319F–2, and 319F–3, re-
20
spectively, of the Public Health Service Act.’’. 
21
(c) STAKEHOLDER
INPUT.—Not later than 18 
22
months after the date of enactment of this Act, the Sec-
23
retary, acting through the Commissioner of Food and 
24
Drugs and in consultation with the Assistant Secretary 
25
141 
•HR 269 EH
for Preparedness and Response, shall solicit input from 
1
stakeholders, including stakeholders developing security 
2
countermeasures, qualified countermeasures, or qualified 
3
pandemic or epidemic products, and stakeholders devel-
4
oping technologies to assist in the development of such 
5
countermeasures with respect to how the Food and Drug 
6
Administration can advance the use of tools and tech-
7
nologies to support and advance the development or manu-
8
facture of security countermeasures, qualified counter-
9
measures, and qualified pandemic or epidemic products, 
10
including through reliance on cross-referenced data and 
11
information contained within master files and submissions 
12
previously submitted to the Secretary as set forth in sec-
13
tion 565B of the Federal Food, Drug, and Cosmetic Act, 
14
as added by subsection (b). 
15
(d) GUIDANCE.—Not later than 2 years after the 
16
date of enactment of this Act, the Secretary, acting 
17
through the Commissioner of Food and Drugs, shall pub-
18
lish draft guidance about how reliance on cross-referenced 
19
data and information contained within master files under 
20
section 565B of the Federal Food, Drug, and Cosmetic 
21
Act, as added by subsection (b) or submissions otherwise 
22
submitted to the Secretary may be used for specific tools 
23
or technologies (including platform technologies) that have 
24
the potential to support and advance the development or 
25
142 
•HR 269 EH
manufacture of security countermeasures, qualified coun-
1
termeasures, and qualified pandemic or epidemic products. 
2
The Secretary, acting through the Commissioner of Food 
3
and Drugs, shall publish the final guidance not later than 
4
3 years after the enactment of this Act. 
5
SEC. 604. ANIMAL RULE REPORT. 
6
(a) STUDY.—The Comptroller General of the United 
7
States shall conduct a study on the application of the re-
8
quirements under subsections (c) and (d) of section 565 
9
of the of the Federal Food, Drug, and Cosmetic Act (21 
10
U.S.C. 360bbb–4) (referred to in this section as the ‘‘ani-
11
mal rule’’) as a component of medical countermeasure ad-
12
vanced development under the Biomedical Advanced Re-
13
search and Development Authority and regulatory review 
14
by the Food and Drug Administration. In conducting such 
15
study, the Comptroller General shall examine the fol-
16
lowing: 
17
(1) The extent to which advanced development 
18
and review of a medical countermeasure are coordi-
19
nated between the Biomedical Advanced Research 
20
and Development Authority and the Food and Drug 
21
Administration, including activities that facilitate 
22
appropriate and efficient design of studies to sup-
23
port approval, licensure, and authorization under the 
24
animal rule, consistent with the recommendations in 
25
143 
•HR 269 EH
the animal rule guidance, issued pursuant to section 
1
565(c) of the Federal Food, Drug, and Cosmetic Act 
2
(21 U.S.C. 360bbb–4(c)) and entitled ‘‘Product De-
3
velopment Under the Animal Rule: Guidance for In-
4
dustry’’ (issued in October 2015), to resolve discrep-
5
ancies in the design of adequate and well-controlled 
6
efficacy studies conducted in animal models related 
7
to the provision of substantial evidence of effective-
8
ness for the product approved, licensed, or author-
9
ized under the animal rule. 
10
(2) The consistency of the application of the 
11
animal rule among and between review divisions 
12
within the Food and Drug Administration. 
13
(3) The flexibility pursuant to the animal rule 
14
to address variations in countermeasure development 
15
and review processes, including the extent to which 
16
qualified animal models are adopted and used within 
17
the Food and Drug Administration in regulatory de-
18
cisionmaking with respect to medical counter-
19
measures. 
20
(4) The extent to which the guidance issued 
21
under section 565(c) of the Federal Food, Drug, and 
22
Cosmetic Act (21 U.S.C. 360bbb–4(c)), entitled, 
23
‘‘Product Development Under the Animal Rule: 
24
Guidance for Industry’’ (issued in October 2015), 
25
144 
•HR 269 EH
has assisted in achieving the purposes described in 
1
paragraphs (1), (2), and (3). 
2
(b) CONSULTATIONS.—In conducting the study under 
3
subsection (a), the Comptroller General of the United 
4
States shall consult with— 
5
(1) the Federal agencies responsible for advanc-
6
ing, reviewing, and procuring medical counter-
7
measures, including the Office of the Assistant Sec-
8
retary for Preparedness and Response, the Bio-
9
medical Advanced Research and Development Au-
10
thority, the Food and Drug Administration, and the 
11
Department of Defense; 
12
(2) manufacturers involved in the research and 
13
development of medical countermeasures to address 
14
biological, chemical, radiological, or nuclear threats; 
15
and 
16
(3) other biodefense stakeholders, as applicable. 
17
(c) REPORT.—Not later than 3 years after the date 
18
of enactment of this Act, the Comptroller General of the 
19
United States shall submit to the Committee on Health, 
20
Education, Labor, and Pensions of the Senate and the 
21
Committee on Energy and Commerce of the House of 
22
Representatives a report containing the results of the 
23
study conducted under subsection (a) and recommenda-
24
tions to improve the application and consistency of the re-
25
145 
•HR 269 EH
quirements under subsections (c) and (d) of section 565 
1
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
2
360bbb–4) to support and expedite the research and devel-
3
opment of medical countermeasures, as applicable. 
4
(d) PROTECTION
OF NATIONAL SECURITY.—The 
5
Comptroller General of the United States shall conduct 
6
the study and issue the assessment and report under this 
7
section in a manner that does not compromise national 
8
security. 
9
SEC. 605. REVIEW OF THE BENEFITS OF GENOMIC ENGI-
10
NEERING TECHNOLOGIES AND THEIR POTEN-
11
TIAL ROLE IN NATIONAL SECURITY. 
12
(a) MEETING.— 
13
(1) IN GENERAL.—Not later than 1 year after 
14
the date of enactment of this Act, the Secretary of 
15
Health and Human Services (referred to in this sec-
16
tion as the ‘‘Secretary’’) shall convene a meeting to 
17
discuss the potential role advancements in genomic 
18
engineering technologies (including genome editing 
19
technologies) may have in advancing national health 
20
security. Such meeting shall be held in a manner 
21
that does not compromise national security. 
22
(2) ATTENDEES.—The attendees of the meeting 
23
under paragraph (1)— 
24
(A) shall include— 
25
146 
•HR 269 EH
(i) representatives from the Office of 
1
the Assistant Secretary for Preparedness 
2
and Response, the National Institutes of 
3
Health, the Centers for Disease Control 
4
and Prevention, and the Food and Drug 
5
Administration; and 
6
(ii) representatives from academic, 
7
private, and nonprofit entities with exper-
8
tise in genome engineering technologies, 
9
biopharmaceuticals, 
medicine, 
or 
bio-
10
defense, and other relevant stakeholders; 
11
and 
12
(B) may include— 
13
(i) other representatives from the De-
14
partment of Health and Human Services, 
15
as the Secretary determines appropriate; 
16
and 
17
(ii) representatives from the Depart-
18
ment of Homeland Security, the Depart-
19
ment of Defense, the Department of Agri-
20
culture, and other departments, as the Sec-
21
retary may request for the meeting. 
22
(3) TOPICS.—The meeting under paragraph (1) 
23
shall include a discussion of— 
24
147 
•HR 269 EH
(A) the current state of the science of 
1
genomic engineering technologies related to na-
2
tional health security, including— 
3
(i) medical countermeasure develop-
4
ment, including potential efficiencies in the 
5
development pathway and detection tech-
6
nologies; and 
7
(ii) the international and domestic 
8
regulation of products utilizing genome ed-
9
iting technologies; and 
10
(B) national security implications, includ-
11
ing— 
12
(i) capabilities of the United States to 
13
leverage genomic engineering technologies 
14
as a part of the medical countermeasure 
15
enterprise, including current applicable re-
16
search, development, and application ef-
17
forts underway within the Department of 
18
Defense; 
19
(ii) the potential for state and non- 
20
state actors to utilize genomic engineering 
21
technologies as a national health security 
22
threat; and 
23
(iii) security measures to monitor and 
24
assess the potential threat that may result 
25
148 
•HR 269 EH
from utilization of genomic engineering 
1
technologies and related technologies for 
2
the purpose of compromising national 
3
health security. 
4
(b) REPORT.—Not later than 270 days after the 
5
meeting described in subsection (a) is held, the Assistant 
6
Secretary for Preparedness and Response shall issue a re-
7
port to the congressional committees of jurisdiction on the 
8
topics discussed at such meeting, and provide rec-
9
ommendations, as applicable, to utilize innovations in 
10
genomic engineering (including genome editing) and re-
11
lated technologies as a part of preparedness and response 
12
activities to advance national health security. Such report 
13
shall be issued in a manner that does not compromise na-
14
tional security. 
15
SEC. 606. REPORT ON VACCINES DEVELOPMENT. 
16
Not later than one year after the date of the enact-
17
ment of this Act, the Secretary of Health and Human 
18
Services shall submit to the Committee on Health, Edu-
19
cation, Labor, and Pensions of the Senate and the Com-
20
mittee on Energy and Commerce of the House of Rep-
21
resentatives a report describing efforts and activities to 
22
coordinate with other countries and international partners 
23
during recent public health emergencies with respect to 
24
the research and advanced research on, and development 
25
149 
•HR 269 EH
of, qualified pandemic or epidemic products (as defined 
1
in section 319F–3 of the Public Health Service Act (42 
2
U.S.C. 247d–6d)). Such report may include information 
3
regarding relevant work carried out under section 
4
319L(c)(5)(E) of the Public Health Service Act (42 
5
U.S.C. 247d–7e(c)(5)(E)), through public-private partner-
6
ships, and through collaborations with other countries to 
7
assist with or expedite the research and development of 
8
qualified pandemic or epidemic products. Such report shall 
9
not include information that may compromise national se-
10
curity. 
11
SEC. 607. STRENGTHENING MOSQUITO ABATEMENT FOR 
12
SAFETY AND HEALTH. 
13
(a) REAUTHORIZATION OF MOSQUITO ABATEMENT 
14
FOR SAFETY AND HEALTH PROGRAM.—Section 317S (42 
15
U.S.C. 247b–21) is amended— 
16
(1) in subsection (a)(1)(B)— 
17
(A) by inserting ‘‘including programs to 
18
address emerging infectious mosquito-borne dis-
19
eases,’’ after ‘‘subdivisions for control pro-
20
grams,’’; and 
21
(B) by inserting ‘‘or improving existing 
22
control programs’’ before the period at the end; 
23
(2) in subsection (b)— 
24
150 
•HR 269 EH
(A) in paragraph (1), by inserting ‘‘, in-
1
cluding improvement,’’ after ‘‘operation’’; 
2
(B) in paragraph (2)— 
3
(i) in subparagraph (A)— 
4
(I) in clause (ii), by striking ‘‘or’’ 
5
at the end; 
6
(II) in clause (iii), by striking the 
7
semicolon at the end and inserting ‘‘, 
8
including an emerging infectious mos-
9
quito-borne disease that presents a se-
10
rious public health threat; or’’; and 
11
(III) by adding at the end the 
12
following: 
13
‘‘(iv) a public health emergency due to 
14
the incidence or prevalence of a mosquito- 
15
borne disease that presents a serious pub-
16
lic health threat;’’; and 
17
(ii) by amending subparagraph (D) to 
18
read as follows: 
19
‘‘(D)(i) is located in a State that has re-
20
ceived a grant under subsection (a); or 
21
‘‘(ii) that demonstrates to the Secretary 
22
that the control program is consistent with ex-
23
isting State mosquito control plans or policies, 
24
or other applicable State preparedness plans.’’; 
25
151 
•HR 269 EH
(C) in paragraph (4)(C), by striking ‘‘that 
1
extraordinary’’ and all that follows through the 
2
period at the end and inserting the following: 
3
‘‘that— 
4
‘‘(i) extraordinary economic conditions 
5
in the political subdivision or consortium of 
6
political subdivisions involved justify the 
7
waiver; or 
8
‘‘(ii) the geographical area covered by 
9
a political subdivision or consortium for a 
10
grant under paragraph (1) has an extreme 
11
mosquito control need due to— 
12
‘‘(I) the size or density of the po-
13
tentially impacted human population; 
14
‘‘(II) the size or density of a 
15
mosquito population that requires 
16
heightened control; or 
17
‘‘(III) the severity of the mos-
18
quito-borne disease, such that ex-
19
pected serious adverse health out-
20
comes for the human population jus-
21
tify the waiver.’’; and 
22
(D) by amending paragraph (6) to read as 
23
follows: 
24
152 
•HR 269 EH
‘‘(6) NUMBER OF GRANTS.—A political subdivi-
1
sion or a consortium of political subdivisions may 
2
not receive more than one grant under paragraph 
3
(1).’’; and 
4
(3) in subsection (f)— 
5
(A) in paragraph (1) by striking ‘‘for fiscal 
6
year 2003, and such sums as may be necessary 
7
for each of fiscal years 2004 through 2007’’ 
8
and inserting ‘‘for each of fiscal years 2019 
9
through 2023’’; 
10
(B) in paragraph (2), by striking ‘‘the 
11
Public Health Security and Bioterrorism Pre-
12
paredness and Response Act of 2002’’ and in-
13
serting ‘‘this Act and other medical and public 
14
health preparedness and response laws’’; and 
15
(C) in paragraph (3)— 
16
(i) in the paragraph heading, by strik-
17
ing ‘‘2004’’ and inserting ‘‘2019’’; and 
18
(ii) by striking ‘‘2004,’’ and inserting 
19
‘‘2019,’’. 
20
(b) 
EPIDEMIOLOGY-LABORATORY
CAPACITY 
21
GRANTS.—Section 2821 (42 U.S.C. 300hh–31) is amend-
22
ed— 
23
153 
•HR 269 EH
(1) in subsection (a)(1), by inserting ‘‘, includ-
1
ing mosquito and other vector-borne diseases,’’ after 
2
‘‘infectious diseases’’; and 
3
(2) in subsection (b), by striking ‘‘2010 through 
4
2013’’ and inserting ‘‘2019 through 2023’’. 
5
TITLE VII—MISCELLANEOUS 
6
PROVISIONS 
7
SEC. 701. REAUTHORIZATIONS AND EXTENSIONS. 
8
(a) VETERANS AFFAIRS.—Section 8117(g) of title 
9
38, United States Code, is amended by striking ‘‘2014 
10
through 2018’’ and inserting ‘‘2019 through 2023’’. 
11
(b) VACCINE TRACKING AND DISTRIBUTION.—Sec-
12
tion 319A(e) (42 U.S.C. 247d–1(e)) is amended by strik-
13
ing ‘‘2014 through 2018’’ and inserting ‘‘2019 through 
14
2023’’. 
15
(c) TEMPORARY REASSIGNMENT.—Section 319(e)(8) 
16
(42 U.S.C. 247d(e)(8)) is amended by striking ‘‘2018’’ 
17
and inserting ‘‘2023’’. 
18
(d) STRATEGIC
INNOVATION
PARTNER.—Section 
19
319L(c)(4)(E)(ix) (42 U.S.C. 247d–7e(c)(4)(E)(ix)) is 
20
amended by striking ‘‘2022’’ and inserting ‘‘2023’’. 
21
(e) LIMITED ANTITRUST EXEMPTION.— 
22
(1) IN GENERAL.—Section 405 of the Pandemic 
23
and All-Hazards Preparedness Act (Public Law 
24
109–417; 42 U.S.C. 247d–6a note) is amended— 
25
154 
•HR 269 EH
(A) in subsection (a)(1)(A)— 
1
(i) by striking ‘‘Secretary of Health 
2
and Human Services (referred to in this 
3
subsection as the ‘Secretary’)’’ and insert-
4
ing ‘‘Secretary’’; 
5
(ii) by striking ‘‘of the Public Health 
6
Service Act (42 U.S.C. 247d–6b)) (as 
7
amended by this Act’’; 
8
(iii) by striking ‘‘of the Public Health 
9
Service Act (42 U.S.C. 247d–6a)) (as 
10
amended by this Act’’; and 
11
(iv) by striking ‘‘of the Public Health 
12
Service Act (42 U.S.C. 247d–6d)’’; 
13
(B) in subsection (b), by striking ‘‘12- 
14
year’’ and inserting ‘‘17-year’’; 
15
(C) by redesignating such section 405 as 
16
section 319L–1; and 
17
(D) by transferring such section 319L–1, 
18
as redesignated, to the Public Health Service 
19
Act (42 U.S.C. 201 et seq.), to appear after 
20
section 319L of such Act (42 U.S.C. 247d–7e). 
21
(2) CONFORMING AMENDMENT.—The table of 
22
contents in section 1(b) of the Pandemic and All- 
23
Hazards Preparedness Act (Public Law 109–417) is 
24
amended by striking the item related to section 405. 
25
155 
•HR 269 EH
(f) INAPPLICABILITY
OF CERTAIN PROVISIONS.— 
1
Subsection (e)(1) of section 319L (42 U.S.C. 247d– 
2
7e(e)(1)) is amended— 
3
(1) by amending subparagraph (A) to read as 
4
follows: 
5
‘‘(A) 
NONDISCLOSURE
OF
INFORMA-
6
TION.— 
7
‘‘(i) IN
GENERAL.—Information de-
8
scribed in clause (ii) shall be deemed to be 
9
information described in section 552(b)(3) 
10
of title 5, United States Code. 
11
‘‘(ii) INFORMATION DESCRIBED.—The 
12
information described in this clause is in-
13
formation relevant to programs of the De-
14
partment of Health and Human Services 
15
that could compromise national security 
16
and reveal significant and not otherwise 
17
publicly known vulnerabilities of existing 
18
medical or public health defenses against 
19
chemical, biological, radiological, or nuclear 
20
threats, and is comprised of— 
21
‘‘(I) specific technical data or sci-
22
entific information that is created or 
23
obtained during the countermeasure 
24
and product advanced research and 
25
156 
•HR 269 EH
development carried out under sub-
1
section (c); 
2
‘‘(II) information pertaining to 
3
the location security, personnel, and 
4
research materials and methods of 
5
high-containment 
laboratories 
con-
6
ducting research with select agents, 
7
toxins, or other agents with a material 
8
threat determination under section 
9
319F–2(c)(2); or 
10
‘‘(III) security and vulnerability 
11
assessments.’’; 
12
(2) by redesignating subparagraph (C) as sub-
13
paragraph (D); 
14
(3) by inserting after subparagraph (B) the fol-
15
lowing: 
16
‘‘(C) REPORTING.—One year after the 
17
date of enactment of the Pandemic and All- 
18
Hazards Preparedness and Advancing Innova-
19
tion Act of 2019, and annually thereafter, the 
20
Secretary shall report to the Committee on 
21
Health, Education, Labor, and Pensions of the 
22
Senate and the Committee on Energy and Com-
23
merce of the House of Representatives on the 
24
number of instances in which the Secretary has 
25
157 
•HR 269 EH
used the authority under this subsection to 
1
withhold information from disclosure, as well as 
2
the nature of any request under section 552 of 
3
title 5, United States Code that was denied 
4
using such authority.’’; and 
5
(4) in subparagraph (D), as so redesignated, by 
6
striking ‘‘12’’ and inserting ‘‘17’’. 
7
SEC. 702. LOCATION OF MATERIALS IN THE STOCKPILE. 
8
Subsection (d) of section 319F–2 (42 U.S.C. 247d– 
9
6b) is amended to read as follows: 
10
‘‘(d) DISCLOSURES.—No Federal agency may dis-
11
close under section 552 of title 5, United States Code any 
12
information identifying the location at which materials in 
13
the stockpile described in subsection (a) are stored, or 
14
other information regarding the contents or deployment 
15
capability of the stockpile that could compromise national 
16
security.’’. 
17
SEC. 703. CYBERSECURITY. 
18
(a) STRATEGY FOR PUBLIC HEALTH PREPAREDNESS 
19
AND RESPONSE TO CYBERSECURITY THREATS.— 
20
(1) STRATEGY.—Not later than 18 months 
21
after the date of enactment of this Act, the Sec-
22
retary of Health and Human Services (referred to in 
23
this section as the ‘‘Secretary’’) shall prepare and 
24
submit to the relevant committees of Congress a 
25
158 
•HR 269 EH
strategy for public health preparedness and response 
1
to address cybersecurity threats (as defined in sec-
2
tion 102 of Cybersecurity Information Sharing Act 
3
of 2015 (6 U.S.C. 1501)) that present a threat to 
4
national health security. Such strategy shall in-
5
clude— 
6
(A) identifying the duties, functions, and 
7
preparedness goals for which the Secretary is 
8
responsible in order to prepare for and respond 
9
to such cybersecurity threats, including metrics 
10
by which to measure success in meeting pre-
11
paredness goals; 
12
(B) identifying gaps in public health capa-
13
bilities to achieve such preparedness goals; and 
14
(C) strategies to address identified gaps 
15
and strengthen public health emergency pre-
16
paredness and response capabilities to address 
17
such cybersecurity threats. 
18
(2) PROTECTION
OF
NATIONAL
SECURITY.— 
19
The Secretary shall make such strategy available to 
20
the Committee on Health, Education, Labor, and 
21
Pensions of the Senate, the Committee on Energy 
22
and Commerce of the House of Representatives, and 
23
other congressional committees of jurisdiction, in a 
24
manner that does not compromise national security. 
25
159 
•HR 269 EH
(b) COORDINATION OF PREPAREDNESS FOR AND RE-
1
SPONSE
TO
ALL-HAZARDS
PUBLIC
HEALTH
EMER-
2
GENCIES.—Subparagraph (D) of section 2811(b)(4) (42 
3
U.S.C. 300hh–10(b)(4)) is amended to read as follows: 
4
‘‘(D) POLICY
COORDINATION
AND
STRA-
5
TEGIC
DIRECTION.—Provide integrated policy 
6
coordination and strategic direction, before, 
7
during, and following public health emergencies, 
8
with respect to all matters related to Federal 
9
public health and medical preparedness and 
10
execution and deployment of the Federal re-
11
sponse for public health emergencies and inci-
12
dents covered by the National Response Plan 
13
described in section 504(a)(6) of the Homeland 
14
Security Act of 2002 (6 U.S.C. 314(a)(6)), or 
15
any successor plan; and such Federal responses 
16
covered by the National Cybersecurity Incident 
17
Response Plan developed under section 228(c) 
18
of the Homeland Security Act of 2002 (6 
19
U.S.C. 149(c)), including public health emer-
20
gencies or incidents related to cybersecurity 
21
threats that present a threat to national health 
22
security.’’. 
23
160 
•HR 269 EH
SEC. 704. STRATEGY AND REPORT. 
1
Not later than 14 days after the date of the enact-
2
ment of this Act, the Secretary of Health and Human 
3
Services, in coordination with the Assistant Secretary for 
4
Preparedness and Response and the Assistant Secretary 
5
for the Administration on Children and Families or other 
6
appropriate office, and in collaboration with other depart-
7
ments, as appropriate, shall submit to the Committee on 
8
Energy and Commerce of the House of Representatives, 
9
the Committee on Health, Education, Labor, and Pen-
10
sions of the Senate, and other relevant congressional com-
11
mittees— 
12
(1) a formal strategy, including interdepart-
13
mental actions and efforts to reunify children with 
14
their parents or guardians, in all cases in which such 
15
children have been separated from their parents or 
16
guardians as a result of the initiative announced on 
17
April 6, 2018, and due to prosecution under section 
18
275(a) of the Immigration and Nationality Act (8 
19
U.S.C. 1325(a)), if the parent or guardian chooses 
20
such reunification and the child— 
21
(A) was separated from a parent or guard-
22
ian and placed into a facility funded by the De-
23
partment of Health and Human Services; 
24
161 
•HR 269 EH
(B) as of the date of the enactment of this 
1
Act, remains in the care of the Department of 
2
Health and Human Services; and 
3
(C) can be safely reunited with such parent 
4
or guardian; and 
5
(2) a report on challenges and deficiencies re-
6
lated to the oversight of, and care for, unaccom-
7
panied alien children and appropriately reuniting 
8
such children with their parents or guardians, and 
9
the actions taken to address any challenges and defi-
10
ciencies related to unaccompanied alien children in 
11
the custody of the Department of Health and 
12
Human Services, including deficiencies identified 
13
and publicly reported by Congress, the Government 
14
Accountability Office, or the inspectors general of 
15
the Department of Health and Human Services or 
16
other Federal departments. 
17
SEC. 705. TECHNICAL AMENDMENTS. 
18
(a) PUBLIC HEALTH SERVICE ACT.—Title III (42 
19
U.S.C. 241 et seq.) is amended— 
20
(1) in paragraphs (1) and (5) of section 319F– 
21
1(a) (42 U.S.C. 247d–6a(a)), by striking ‘‘section 
22
319F(h)’’ each place such term appears and insert-
23
ing ‘‘section 319F(e)’’; and 
24
162 
•HR 269 EH
(2) in section 319K(a) (42 U.S.C. 247d–7d(a)), 
1
by striking ‘‘section 319F(h)(4)’’ and inserting ‘‘sec-
2
tion 319F(e)(4)’’. 
3
(b) PUBLIC HEALTH SECURITY GRANTS.—Section 
4
319C–1(b)(2) (42 U.S.C. 247d–3a(b)(2)) is amended— 
5
(1) in subparagraph (C), by striking ‘‘individ-
6
uals,,’’ and inserting ‘‘individuals,’’; and 
7
(2) in subparagraph (F), by striking ‘‘make sat-
8
isfactory annual improvement and describe’’ and in-
9
serting ‘‘makes satisfactory annual improvement and 
10
describes’’. 
11
(c) EMERGENCY
USE
INSTRUCTIONS.—Subpara-
12
graph (A) of section 564A(e)(2) of the Federal Food, 
13
Drug, and Cosmetic Act (21 U.S.C. 360bbb–3a(e)(2)) is 
14
amended by striking ‘‘subsection (a)(1)(C)(i)’’ and insert-
15
ing ‘‘subsection (a)(1)(C)’’. 
16
(d) PRODUCTS HELD FOR EMERGENCY USE.—Sec-
17
tion 564B(2) of the Federal Food, Drug, and Cosmetic 
18
Act (21 U.S.C. 360bbb–3b) is amended— 
19
(1) in subparagraph (B), by inserting a comma 
20
after ‘‘505’’; and 
21
(2) in subparagraph (C), by inserting ‘‘or sec-
22
tion 564A’’ before the period at the end. 
23
163 
•HR 269 EH
(e) TRANSPARENCY.—Section 507(c)(3) of the Fed-
1
eral Food, Drug, and Cosmetic Act (21 U.S.C. 357(c)(3)) 
2
is amended— 
3
(1) by striking ‘‘Nothing in’’ and inserting the 
4
following: 
5
‘‘(A) IN GENERAL.—Nothing in’’; 
6
(2) by inserting ‘‘or directing’’ after ‘‘author-
7
izing’’; 
8
(3) by striking ‘‘disclose any’’ and inserting 
9
‘‘disclose— 
10
‘‘(i) any’’; 
11
(4) by striking the period and inserting ‘‘; or’’; 
12
and 
13
(5) by adding at the end the following: 
14
‘‘(ii) in the case of a drug develop-
15
ment tool that may be used to support the 
16
development of a qualified countermeasure, 
17
security countermeasure, or qualified pan-
18
demic or epidemic product, as defined in 
19
sections 319F–1, 319F–2, and 319F–3, 
20
respectively, of the Public Health Service 
21
Act, any information that the Secretary 
22
determines has a significant potential to 
23
affect national security. 
24
164 
•HR 269 EH
‘‘(B) PUBLIC ACKNOWLEDGMENT.—In the 
1
case that the Secretary, pursuant to subpara-
2
graph (A)(ii), does not make information pub-
3
licly available, the Secretary shall provide on 
4
the internet website of the Food and Drug Ad-
5
ministration an acknowledgment of the informa-
6
tion that has not been disclosed, pursuant to 
7
subparagraph (A)(ii).’’. 
8
DIVISION 
B—OVER-THE- 
9
COUNTER MONOGRAPH SAFE-
10
TY, 
INNOVATION, 
AND 
RE-
11
FORM 
12
SEC. 1000. SHORT TITLE; REFERENCES IN DIVISION. 
13
(a) SHORT TITLE.—This division may be cited as the 
14
‘‘Over-the-Counter Monograph Safety, Innovation, and 
15
Reform Act of 2019’’. 
16
(b) REFERENCES.—Except as otherwise specified, 
17
any reference to ‘‘this Act’’ contained in this division shall 
18
be treated as referring only to the provisions of this divi-
19
sion. 
20
165 
•HR 269 EH
TITLE I—OTC DRUG REVIEW 
1
SEC. 1001. REGULATION OF CERTAIN NONPRESCRIPTION 
2
DRUGS THAT ARE MARKETED WITHOUT AN 
3
APPROVED DRUG APPLICATION. 
4
(a) IN GENERAL.—Chapter V of the Federal Food, 
5
Drug, and Cosmetic Act is amended by inserting after sec-
6
tion 505F of such Act (21 U.S.C. 355g) the following: 
7
‘‘SEC. 505G. REGULATION OF CERTAIN NONPRESCRIPTION 
8
DRUGS THAT ARE MARKETED WITHOUT AN 
9
APPROVED DRUG APPLICATION. 
10
‘‘(a) NONPRESCRIPTION DRUGS MARKETED WITH-
11
OUT
AN
APPROVED
APPLICATION.—Nonprescription 
12
drugs marketed without an approved drug application 
13
under section 505, as of the date of the enactment of this 
14
section, shall be treated in accordance with this sub-
15
section. 
16
‘‘(1) DRUGS SUBJECT TO A FINAL MONOGRAPH; 
17
CATEGORY
I
DRUGS
SUBJECT
TO
A
TENTATIVE 
18
FINAL MONOGRAPH.—A drug is deemed to be gen-
19
erally recognized as safe and effective under section 
20
201(p)(1), not a new drug under section 201(p), and 
21
not subject to section 503(b)(1), if— 
22
‘‘(A) the drug is— 
23
‘‘(i) in conformity with the require-
24
ments for nonprescription use of a final 
25
166 
•HR 269 EH
monograph issued under part 330 of title 
1
21, Code of Federal Regulations (except as 
2
provided in paragraph (2)), the general re-
3
quirements for nonprescription drugs, and 
4
conditions or requirements under sub-
5
sections (b), (c), and (k); and 
6
‘‘(ii) except as permitted by an order 
7
issued under subsection (b) or, in the case 
8
of a minor change in the drug, in con-
9
formity with an order issued under sub-
10
section (c), in a dosage form that, imme-
11
diately prior to the date of the enactment 
12
of this section, has been used to a material 
13
extent and for a material time under sec-
14
tion 201(p)(2); or 
15
‘‘(B) the drug is— 
16
‘‘(i) classified in category I for safety 
17
and effectiveness under a tentative final 
18
monograph that is the most recently appli-
19
cable proposal or determination issued 
20
under part 330 of title 21, Code of Federal 
21
Regulations; 
22
‘‘(ii) in conformity with the proposed 
23
requirements for nonprescription use of 
24
such tentative final monograph, any appli-
25
167 
•HR 269 EH
cable subsequent determination by the Sec-
1
retary, the general requirements for non-
2
prescription drugs, and conditions or re-
3
quirements under subsections (b), (c), and 
4
(k); and 
5
‘‘(iii) except as permitted by an order 
6
issued under subsection (b) or, in the case 
7
of a minor change in the drug, in con-
8
formity with an order issued under sub-
9
section (c), in a dosage form that, imme-
10
diately prior to the date of the enactment 
11
of this section, has been used to a material 
12
extent and for a material time under sec-
13
tion 201(p)(2). 
14
‘‘(2) TREATMENT
OF
SUNSCREEN
DRUGS.— 
15
With respect to sunscreen drugs subject to this sec-
16
tion, the applicable requirements in terms of con-
17
formity with a final monograph, for purposes of 
18
paragraph (1)(A)(i), shall be the requirements speci-
19
fied in part 352 of title 21, Code of Federal Regula-
20
tions, as published on May 21, 1999, beginning on 
21
page 27687 of volume 64 of the Federal Register, 
22
except that the applicable requirements governing ef-
23
fectiveness and labeling shall be those specified in 
24
168 
•HR 269 EH
section 201.327 of title 21, Code of Federal Regula-
1
tions. 
2
‘‘(3) CATEGORY III DRUGS SUBJECT TO A TEN-
3
TATIVE
FINAL
MONOGRAPH; CATEGORY
I
DRUGS 
4
SUBJECT TO PROPOSED MONOGRAPH OR ADVANCE 
5
NOTICE OF PROPOSED RULEMAKING.—A drug that 
6
is not described in paragraph (1), (2), or (4) is not 
7
required to be the subject of an application approved 
8
under section 505, and is not subject to section 
9
503(b)(1), if— 
10
‘‘(A) the drug is— 
11
‘‘(i) classified in category III for safe-
12
ty or effectiveness in the preamble of a 
13
proposed rule establishing a tentative final 
14
monograph that is the most recently appli-
15
cable proposal or determination for such 
16
drug issued under part 330 of title 21, 
17
Code of Federal Regulations; 
18
‘‘(ii) in conformity with— 
19
‘‘(I) the conditions of use, includ-
20
ing indication and dosage strength, if 
21
any, described for such category III 
22
drug in such preamble or in an appli-
23
cable subsequent proposed rule; 
24
169 
•HR 269 EH
‘‘(II) the proposed requirements 
1
for drugs classified in such tentative 
2
final monograph in category I in the 
3
most recently proposed rule estab-
4
lishing requirements related to such 
5
tentative final monograph and in any 
6
final rule establishing requirements 
7
that are applicable to the drug; and 
8
‘‘(III) the general requirements 
9
for nonprescription drugs and condi-
10
tions or requirements under sub-
11
section (b) or (k); and 
12
‘‘(iii) in a dosage form that, imme-
13
diately prior to the date of the enactment 
14
of this section, had been used to a material 
15
extent and for a material time under sec-
16
tion 201(p)(2); or 
17
‘‘(B) the drug is— 
18
‘‘(i) classified in category I for safety 
19
and effectiveness under a proposed mono-
20
graph or advance notice of proposed rule-
21
making that is the most recently applicable 
22
proposal or determination for such drug 
23
issued under part 330 of title 21, Code of 
24
Federal Regulations; 
25
170 
•HR 269 EH
‘‘(ii) in conformity with the require-
1
ments for nonprescription use of such pro-
2
posed monograph or advance notice of pro-
3
posed rulemaking, any applicable subse-
4
quent determination by the Secretary, the 
5
general requirements for nonprescription 
6
drugs, and conditions or requirements 
7
under subsection (b) or (k); and 
8
‘‘(iii) in a dosage form that, imme-
9
diately prior to the date of the enactment 
10
of this section, has been used to a material 
11
extent and for a material time under sec-
12
tion 201(p)(2). 
13
‘‘(4) CATEGORY
II
DRUGS
DEEMED
NEW 
14
DRUGS.—A drug that is classified in category II for 
15
safety or effectiveness under a tentative final mono-
16
graph or that is subject to a determination to be not 
17
generally recognized as safe and effective in a pro-
18
posed rule that is the most recently applicable pro-
19
posal issued under part 330 of title 21, Code of Fed-
20
eral Regulations, shall be deemed to be a new drug 
21
under section 201(p), misbranded under section 
22
502(ee), and subject to the requirement for an ap-
23
proved new drug application under section 505 be-
24
ginning on the day that is 180 calendar days after 
25
171 
•HR 269 EH
the date of the enactment of this section, unless, be-
1
fore such day, the Secretary determines that it is in 
2
the interest of public health to extend the period 
3
during which the drug may be marketed without 
4
such an approved new drug application. 
5
‘‘(5) 
DRUGS
NOT
GRASE
DEEMED
NEW 
6
DRUGS.—A drug that the Secretary has determined 
7
not to be generally recognized as safe and effective 
8
under section 201(p)(1) under a final determination 
9
issued under part 330 of title 21, Code of Federal 
10
Regulations, shall be deemed to be a new drug under 
11
section 201(p), misbranded under section 502(ee), 
12
and subject to the requirement for an approved new 
13
drug application under section 505. 
14
‘‘(6) OTHER DRUGS DEEMED NEW DRUGS.— 
15
Except as provided in subsection (m), a drug is 
16
deemed to be a new drug under section 201(p) and 
17
misbranded under section 502(ee) if the drug— 
18
‘‘(A) is not subject to section 503(b)(1); 
19
and 
20
‘‘(B) is not described in paragraph (1), 
21
(2), (3), (4), or (5), or subsection (b)(1)(B). 
22
‘‘(b) ADMINISTRATIVE ORDERS.— 
23
‘‘(1) IN GENERAL.— 
24
172 
•HR 269 EH
‘‘(A) 
DETERMINATION.—The 
Secretary 
1
may, on the initiative of the Secretary or at the 
2
request of one or more requestors, issue an ad-
3
ministrative order determining whether there 
4
are conditions under which a specific drug, a 
5
class of drugs, or a combination of drugs, is de-
6
termined to be— 
7
‘‘(i) not subject to section 503(b)(1); 
8
and 
9
‘‘(ii) generally recognized as safe and 
10
effective under section 201(p)(1). 
11
‘‘(B) EFFECT.—A drug or combination of 
12
drugs shall be deemed to not require approval 
13
under section 505 if such drug or combination 
14
of drugs— 
15
‘‘(i) is determined by the Secretary to 
16
meet the conditions specified in clauses (i) 
17
and (ii) of subparagraph (A); 
18
‘‘(ii) is marketed in conformity with 
19
an administrative order under this sub-
20
section; 
21
‘‘(iii) meets the general requirements 
22
for nonprescription drugs; and 
23
‘‘(iv) meets the requirements under 
24
subsections (c) and (k). 
25
173 
•HR 269 EH
‘‘(C) STANDARD.—The Secretary shall find 
1
that a drug is not generally recognized as safe 
2
and effective under section 201(p)(1) if— 
3
‘‘(i) the evidence shows that the drug 
4
is not generally recognized as safe and ef-
5
fective under section 201(p)(1); or 
6
‘‘(ii) the evidence is inadequate to 
7
show that the drug is generally recognized 
8
as 
safe 
and 
effective 
under 
section 
9
201(p)(1). 
10
‘‘(2) ADMINISTRATIVE
ORDERS
INITIATED
BY 
11
THE SECRETARY.— 
12
‘‘(A) IN GENERAL.—In issuing an adminis-
13
trative order under paragraph (1) upon the 
14
Secretary’s initiative, the Secretary shall— 
15
‘‘(i) make reasonable efforts to notify 
16
informally, not later than 2 business days 
17
before the issuance of the proposed order, 
18
the sponsors of drugs who have a listing in 
19
effect under section 510(j) for the drugs or 
20
combination of drugs that will be subject 
21
to the administrative order; 
22
‘‘(ii) after any such reasonable efforts 
23
of notification— 
24
174 
•HR 269 EH
‘‘(I) issue a proposed administra-
1
tive order by publishing it on the 
2
website of the Food and Drug Admin-
3
istration and include in such order the 
4
reasons for the issuance of such order; 
5
and 
6
‘‘(II) publish a notice of avail-
7
ability of such proposed order in the 
8
Federal Register; 
9
‘‘(iii) except as provided in subpara-
10
graph (B), provide for a public comment 
11
period with respect to such proposed order 
12
of not less than 45 calendar days; and 
13
‘‘(iv) if, after completion of the pro-
14
ceedings specified in clauses (i) through 
15
(iii), the Secretary determines that it is ap-
16
propriate to issue a final administrative 
17
order— 
18
‘‘(I) issue the final administrative 
19
order, together with a detailed state-
20
ment of reasons, which order shall not 
21
take effect until the time for request-
22
ing judicial review under paragraph 
23
(3)(D)(ii) has expired; 
24
175 
•HR 269 EH
‘‘(II) publish a notice of such 
1
final administrative order in the Fed-
2
eral Register; 
3
‘‘(III) afford requestors of drugs 
4
that will be subject to such order the 
5
opportunity for formal dispute resolu-
6
tion up to the level of the Director of 
7
the Center for Drug Evaluation and 
8
Research, which initially must be re-
9
quested within 45 calendar days of 
10
the issuance of the order, and, for 
11
subsequent levels of appeal, within 30 
12
calendar days of the prior decision; 
13
and 
14
‘‘(IV) except with respect to 
15
drugs described in paragraph (3)(B), 
16
upon completion of the formal dispute 
17
resolution procedure, inform the per-
18
sons which sought such dispute reso-
19
lution of their right to request a hear-
20
ing. 
21
‘‘(B) EXCEPTIONS.—When issuing an ad-
22
ministrative order under paragraph (1) on the 
23
Secretary’s initiative proposing to determine 
24
that a drug described in subsection (a)(3) is not 
25
176 
•HR 269 EH
generally recognized as safe and effective under 
1
section 201(p)(1), the Secretary shall follow the 
2
procedures in subparagraph (A), except that— 
3
‘‘(i) the proposed order shall include 
4
notice of— 
5
‘‘(I) the general categories of 
6
data the Secretary has determined 
7
necessary to establish that the drug is 
8
generally recognized as safe and effec-
9
tive under section 201(p)(1); and 
10
‘‘(II) the format for submissions 
11
by interested persons; 
12
‘‘(ii) the Secretary shall provide for a 
13
public comment period of no less than 180 
14
calendar days with respect to such pro-
15
posed order, except when the Secretary de-
16
termines, for good cause, that a shorter pe-
17
riod is in the interest of public health; and 
18
‘‘(iii) any person who submits data in 
19
such comment period shall include a cer-
20
tification that the person has submitted all 
21
evidence created, obtained, or received by 
22
that person that is both within the cat-
23
egories of data identified in the proposed 
24
order and relevant to a determination as to 
25
177 
•HR 269 EH
whether the drug is generally recognized as 
1
safe and effective under section 201(p)(1). 
2
‘‘(3) HEARINGS; JUDICIAL REVIEW.— 
3
‘‘(A) IN
GENERAL.—Only a person who 
4
participated in each stage of formal dispute res-
5
olution under subclause (III) of paragraph 
6
(2)(A)(iv) of an administrative order with re-
7
spect to a drug may request a hearing con-
8
cerning a final administrative order issued 
9
under such paragraph with respect to such 
10
drug. If a hearing is sought, such person must 
11
submit a request for a hearing, which shall be 
12
based solely on information in the administra-
13
tive record, to the Secretary not later than 30 
14
calendar days after receiving notice of the final 
15
decision of the formal dispute resolution proce-
16
dure. 
17
‘‘(B) NO
HEARING
REQUIRED
WITH
RE-
18
SPECT
TO
ORDERS
RELATING
TO
CERTAIN 
19
DRUGS.— 
20
‘‘(i) IN
GENERAL.—The Secretary 
21
shall not be required to provide notice and 
22
an opportunity for a hearing pursuant to 
23
paragraph (2)(A)(iv) if the final adminis-
24
trative order involved relates to a drug— 
25
178 
•HR 269 EH
‘‘(I) that is described in sub-
1
section (a)(3)(A); and 
2
‘‘(II) with respect to which no 
3
human or non-human data studies rel-
4
evant to the safety or effectiveness of 
5
such drug have been submitted to the 
6
administrative 
record 
since 
the 
7
issuance of the most recent tentative 
8
final monograph relating to such 
9
drug. 
10
‘‘(ii) HUMAN
DATA
STUDIES
AND 
11
NON-HUMAN DATA DEFINED.—In this sub-
12
paragraph: 
13
‘‘(I) The term ‘human data stud-
14
ies’ means clinical trials of safety or 
15
effectiveness (including actual use 
16
studies), pharmacokinetics studies, or 
17
bioavailability studies. 
18
‘‘(II) The term ‘non-human data’ 
19
means data from testing other than 
20
with human subjects which provides 
21
information concerning safety or ef-
22
fectiveness. 
23
‘‘(C) HEARING PROCEDURES.— 
24
179 
•HR 269 EH
‘‘(i) DENIAL OF REQUEST FOR HEAR-
1
ING.—If the Secretary determines that in-
2
formation submitted in a request for a 
3
hearing under subparagraph (A) with re-
4
spect to a final administrative order issued 
5
under paragraph (2)(A)(iv) does not iden-
6
tify the existence of a genuine and sub-
7
stantial question of material fact, the Sec-
8
retary may deny such request. In making 
9
such a determination, the Secretary may 
10
consider only information and data that 
11
are based on relevant and reliable scientific 
12
principles and methodologies. 
13
‘‘(ii) SINGLE HEARING FOR MULTIPLE 
14
RELATED
REQUESTS.—If more than one 
15
request for a hearing is submitted with re-
16
spect to the same administrative order 
17
under subparagraph (A), the Secretary 
18
may direct that a single hearing be con-
19
ducted in which all persons whose hearing 
20
requests were granted may participate. 
21
‘‘(iii) PRESIDING OFFICER.—The pre-
22
siding officer of a hearing requested under 
23
subparagraph (A) shall— 
24
180 
•HR 269 EH
‘‘(I) be designated by the Sec-
1
retary; 
2
‘‘(II) not be an employee of the 
3
Center for Drug Evaluation and Re-
4
search; and 
5
‘‘(III) not have been previously 
6
involved in the development of the ad-
7
ministrative order involved or pro-
8
ceedings relating to that administra-
9
tive order. 
10
‘‘(iv) RIGHTS OF PARTIES TO HEAR-
11
ING.—The parties to a hearing requested 
12
under subparagraph (A) shall have the 
13
right to present testimony, including testi-
14
mony of expert witnesses, and to cross-ex-
15
amine witnesses presented by other parties. 
16
Where appropriate, the presiding officer 
17
may require that cross-examination by par-
18
ties representing substantially the same in-
19
terests be consolidated to promote effi-
20
ciency and avoid duplication. 
21
‘‘(v) FINAL DECISION.— 
22
‘‘(I) At the conclusion of a hear-
23
ing requested under subparagraph 
24
(A), the presiding officer of the hear-
25
181 
•HR 269 EH
ing shall issue a decision containing 
1
findings of fact and conclusions of 
2
law. The decision of the presiding offi-
3
cer shall be final. 
4
‘‘(II) The final decision may not 
5
take effect until the period under sub-
6
paragraph (D)(ii) for submitting a re-
7
quest for judicial review of such deci-
8
sion expires. 
9
‘‘(D) JUDICIAL REVIEW OF FINAL ADMIN-
10
ISTRATIVE ORDER.— 
11
‘‘(i) IN
GENERAL.—The procedures 
12
described in section 505(h) shall apply 
13
with respect to judicial review of final ad-
14
ministrative orders issued under this sub-
15
section in the same manner and to the 
16
same extent as such section applies to an 
17
order described in such section except that 
18
the judicial review shall be taken by filing 
19
in an appropriate district court of the 
20
United States in lieu of the appellate 
21
courts specified in such section. 
22
‘‘(ii) PERIOD TO SUBMIT A REQUEST 
23
FOR JUDICIAL REVIEW.—A person eligible 
24
to request a hearing under this paragraph 
25
182 
•HR 269 EH
and seeking judicial review of a final ad-
1
ministrative order issued under this sub-
2
section shall file such request for judicial 
3
review not later than 60 calendar days 
4
after the latest of— 
5
‘‘(I) the date on which notice of 
6
such order is published; 
7
‘‘(II) the date on which a hearing 
8
with respect to such order is denied 
9
under subparagraph (B) or (C)(i); 
10
‘‘(III) the date on which a final 
11
decision is made following a hearing 
12
under subparagraph (C)(v); or 
13
‘‘(IV) if no hearing is requested, 
14
the date on which the time for re-
15
questing a hearing expires. 
16
‘‘(4) EXPEDITED PROCEDURE WITH RESPECT 
17
TO
ADMINISTRATIVE
ORDERS
INITIATED
BY
THE 
18
SECRETARY.— 
19
‘‘(A) IMMINENT HAZARD TO THE PUBLIC 
20
HEALTH.— 
21
‘‘(i) IN GENERAL.—In the case of a 
22
determination by the Secretary that a 
23
drug, class of drugs, or combination of 
24
drugs subject to this section poses an im-
25
183 
•HR 269 EH
minent hazard to the public health, the 
1
Secretary, after first making reasonable ef-
2
forts to notify, not later than 48 hours be-
3
fore issuance of such order under this sub-
4
paragraph, sponsors who have a listing in 
5
effect under section 510(j) for such drug 
6
or combination of drugs— 
7
‘‘(I) may issue an interim final 
8
administrative order for such drug, 
9
class of drugs, or combination of 
10
drugs under paragraph (1), together 
11
with a detailed statement of the rea-
12
sons for such order; 
13
‘‘(II) shall publish in the Federal 
14
Register a notice of availability of any 
15
such order; and 
16
‘‘(III) shall provide for a public 
17
comment period of at least 45 cal-
18
endar days with respect to such in-
19
terim final order. 
20
‘‘(ii) 
NONDELEGATION.—The 
Sec-
21
retary may not delegate the authority to 
22
issue an interim final administrative order 
23
under this subparagraph. 
24
‘‘(B) SAFETY LABELING CHANGES.— 
25
184 
•HR 269 EH
‘‘(i) IN GENERAL.—In the case of a 
1
determination by the Secretary that a 
2
change in the labeling of a drug, class of 
3
drugs, or combination of drugs subject to 
4
this section is reasonably expected to miti-
5
gate a significant or unreasonable risk of 
6
a serious adverse event associated with use 
7
of the drug, the Secretary may— 
8
‘‘(I) make reasonable efforts to 
9
notify informally, not later than 48 
10
hours before the issuance of the in-
11
terim final order, the sponsors of 
12
drugs who have a listing in effect 
13
under section 510(j) for such drug or 
14
combination of drugs; 
15
‘‘(II) after reasonable efforts of 
16
notification, issue an interim final ad-
17
ministrative order in accordance with 
18
paragraph (1) to require such change, 
19
together with a detailed statement of 
20
the reasons for such order; 
21
‘‘(III) publish in the Federal 
22
Register a notice of availability of 
23
such order; and 
24
185 
•HR 269 EH
‘‘(IV) provide for a public com-
1
ment period of at least 45 calendar 
2
days with respect to such interim final 
3
order. 
4
‘‘(ii) CONTENT
OF
ORDER.—An in-
5
terim final order issued under this sub-
6
paragraph with respect to the labeling of a 
7
drug may provide for new warnings and 
8
other information required for safe use of 
9
the drug. 
10
‘‘(C) EFFECTIVE DATE.—An order under 
11
subparagraph (A) or (B) shall take effect on a 
12
date specified by the Secretary. 
13
‘‘(D) FINAL ORDER.—After the completion 
14
of the proceedings in subparagraph (A) or (B), 
15
the Secretary shall— 
16
‘‘(i) issue a final order in accordance 
17
with paragraph (1); 
18
‘‘(ii) publish a notice of availability of 
19
such final administrative order in the Fed-
20
eral Register; and 
21
‘‘(iii) afford sponsors of such drugs 
22
that will be subject to such an order the 
23
opportunity for formal dispute resolution 
24
up to the level of the Director of the Cen-
25
186 
•HR 269 EH
ter for Drug Evaluation and Research, 
1
which must initially be within 45 calendar 
2
days of the issuance of the order, and for 
3
subsequent levels of appeal, within 30 cal-
4
endar days of the prior decision. 
5
‘‘(E) HEARINGS.—A sponsor of a drug 
6
subject to a final order issued under subpara-
7
graph (D) and that participated in each stage 
8
of formal dispute resolution under clause (iii) of 
9
such subparagraph may request a hearing on 
10
such order. The provisions of subparagraphs 
11
(A), (B), and (C) of paragraph (3), other than 
12
paragraph (3)(C)(v)(II), shall apply with re-
13
spect to a hearing on such order in the same 
14
manner and to the same extent as such provi-
15
sions apply with respect to a hearing on an ad-
16
ministrative order issued under paragraph 
17
(2)(A)(iv). 
18
‘‘(F) TIMING.— 
19
‘‘(i) FINAL ORDER AND HEARING.— 
20
The Secretary shall— 
21
‘‘(I) not later than 6 months 
22
after the date on which the comment 
23
period closes under subparagraph (A) 
24
187 
•HR 269 EH
or (B), issue a final order in accord-
1
ance with paragraph (1); and 
2
‘‘(II) not later than 12 months 
3
after the date on which such final 
4
order is issued, complete any hearing 
5
under subparagraph (E). 
6
‘‘(ii) 
DISPUTE
RESOLUTION
RE-
7
QUEST.—The Secretary shall specify in an 
8
interim final order issued under subpara-
9
graph (A) or (B) such shorter periods for 
10
requesting dispute resolution under sub-
11
paragraph (D)(iii) as are necessary to 
12
meet the requirements of this subpara-
13
graph. 
14
‘‘(G) JUDICIAL
REVIEW.—A final order 
15
issued pursuant to subparagraph (F) shall be 
16
subject to judicial review in accordance with 
17
paragraph (3)(D). 
18
‘‘(5) ADMINISTRATIVE
ORDER
INITIATED
AT 
19
THE REQUEST OF A REQUESTOR.— 
20
‘‘(A) IN GENERAL.—In issuing an adminis-
21
trative order under paragraph (1) at the re-
22
quest of a requestor with respect to certain 
23
drugs, classes of drugs, or combinations of 
24
drugs— 
25
188 
•HR 269 EH
‘‘(i) the Secretary shall, after receiv-
1
ing a request under this subparagraph, de-
2
termine whether the request is sufficiently 
3
complete and formatted to permit a sub-
4
stantive review; 
5
‘‘(ii) if the Secretary determines that 
6
the request is sufficiently complete and for-
7
matted to permit a substantive review, the 
8
Secretary shall— 
9
‘‘(I) file the request; and 
10
‘‘(II) initiate proceedings with re-
11
spect to issuing an administrative 
12
order in accordance with paragraphs 
13
(2) and (3); and 
14
‘‘(iii) except as provided in paragraph 
15
(6), if the Secretary determines that a re-
16
quest does not meet the requirements for 
17
filing or is not sufficiently complete and 
18
formatted to permit a substantive review, 
19
the requestor may demand that the request 
20
be filed over protest, and the Secretary 
21
shall initiate proceedings to review the re-
22
quest in accordance with paragraph (2)(A). 
23
‘‘(B) 
REQUEST
TO
INITIATE
PRO-
24
CEEDINGS.— 
25
189 
•HR 269 EH
‘‘(i) IN GENERAL.—A requestor seek-
1
ing an administrative order under para-
2
graph (1) with respect to certain drugs, 
3
classes of drugs, or combinations of drugs, 
4
shall submit to the Secretary a request to 
5
initiate proceedings for such order in the 
6
form and manner as specified by the Sec-
7
retary. Such requestor may submit a re-
8
quest under this subparagraph for the 
9
issuance of an administrative order— 
10
‘‘(I) determining whether a drug 
11
is generally recognized as safe and ef-
12
fective under section 201(p)(1), ex-
13
empt from section 503(b)(1), and not 
14
required to be the subject of an ap-
15
proved application under section 505; 
16
or 
17
‘‘(II) 
determining 
whether 
a 
18
change to a condition of use of a drug 
19
is generally recognized as safe and ef-
20
fective under section 201(p)(1), ex-
21
empt from section 503(b)(1), and not 
22
required to be the subject of an ap-
23
proved application under section 505, 
24
190 
•HR 269 EH
if, absent such a changed condition of 
1
use, such drug is— 
2
‘‘(aa) generally recognized 
3
as safe and effective under sec-
4
tion 201(p)(1) in accordance with 
5
subsection (a)(1), (a)(2), or an 
6
order under this subsection; or 
7
‘‘(bb) subject to subsection 
8
(a)(3), but only if such requestor 
9
initiates such request in conjunc-
10
tion with a request for the Sec-
11
retary to determine whether such 
12
drug is generally recognized as 
13
safe and effective under section 
14
201(p)(1), which is filed by the 
15
Secretary under subparagraph 
16
(A)(ii). 
17
‘‘(ii) EXCEPTION.—The Secretary is 
18
not required to complete review of a re-
19
quest for a change described in clause 
20
(i)(II) if the Secretary determines that 
21
there is an inadequate basis to find the 
22
drug is generally recognized as safe and ef-
23
fective under section 201(p)(1) under para-
24
191 
•HR 269 EH
graph (1) and issues a final order an-
1
nouncing that determination. 
2
‘‘(iii) WITHDRAWAL.—The requestor 
3
may withdraw a request under this para-
4
graph, according to the procedures set 
5
forth pursuant to subsection (d)(2)(B). 
6
Notwithstanding any other provision of 
7
this section, if such request is withdrawn, 
8
the Secretary may cease proceedings under 
9
this subparagraph. 
10
‘‘(C) EXCLUSIVITY.— 
11
‘‘(i) IN GENERAL.—A final adminis-
12
trative order issued in response to a re-
13
quest under this section shall have the ef-
14
fect of authorizing solely the order re-
15
questor (or the licensees, assignees, or suc-
16
cessors in interest of such requestor with 
17
respect to the subject of such order), for a 
18
period of 18 months following the effective 
19
date of such final order and beginning on 
20
the date the requestor may lawfully market 
21
such drugs pursuant to the order, to mar-
22
ket drugs— 
23
‘‘(I) incorporating changes de-
24
scribed in clause (ii); and 
25
192 
•HR 269 EH
‘‘(II) subject to the limitations 
1
under clause (iv). 
2
‘‘(ii) 
CHANGES
DESCRIBED.—A 
3
change described in this clause is a change 
4
subject to an order specified in clause (i), 
5
which— 
6
‘‘(I) provides for a drug to con-
7
tain an active ingredient (including 
8
any ester or salt of the active ingre-
9
dient) not previously incorporated in a 
10
drug described in clause (iii); or 
11
‘‘(II) provides for a change in the 
12
conditions of use of a drug, for which 
13
new human data studies conducted or 
14
sponsored by the requestor (or for 
15
which the requestor has an exclusive 
16
right of reference) were essential to 
17
the issuance of such order. 
18
‘‘(iii) DRUGS DESCRIBED.—The drugs 
19
described in this clause are drugs— 
20
‘‘(I) 
specified 
in 
subsection 
21
(a)(1), (a)(2), or (a)(3); 
22
‘‘(II) subject to a final order 
23
issued under this section; 
24
193 
•HR 269 EH
‘‘(III) subject to a final sun-
1
screen order (as defined in section 
2
586(2)(A)); or 
3
‘‘(IV) described in subsection 
4
(m)(1), other than drugs subject to an 
5
active enforcement action under chap-
6
ter III of this Act. 
7
‘‘(iv) 
LIMITATIONS
ON
EXCLU-
8
SIVITY.— 
9
‘‘(I) IN GENERAL.—Only one 18- 
10
month period under this subpara-
11
graph shall be granted, under each 
12
order described in clause (i), with re-
13
spect to changes (to the drug subject 
14
to such order) which are either— 
15
‘‘(aa) changes described in 
16
clause (ii)(I), relating to active 
17
ingredients; or 
18
‘‘(bb) changes described in 
19
clause (ii)(II), relating to condi-
20
tions of use. 
21
‘‘(II) 
NO
EXCLUSIVITY
AL-
22
LOWED.—No exclusivity shall apply to 
23
changes to a drug which are— 
24
194 
•HR 269 EH
‘‘(aa) the subject of a Tier 2 
1
OTC monograph order request 
2
(as defined in section 744L); 
3
‘‘(bb) safety-related changes, 
4
as defined by the Secretary, or 
5
any other changes the Secretary 
6
considers necessary to assure 
7
safe use; or 
8
‘‘(cc) changes related to 
9
methods of testing safety or effi-
10
cacy. 
11
‘‘(v) NEW HUMAN DATA STUDIES DE-
12
FINED.—In this subparagraph, the term 
13
‘new human data studies’ means clinical 
14
trials of safety or effectiveness (including 
15
actual use studies), pharmacokinetics stud-
16
ies, or bioavailability studies, the results of 
17
which— 
18
‘‘(I) have not been relied on by 
19
the Secretary to support— 
20
‘‘(aa) a proposed or final de-
21
termination that a drug described 
22
in subclause (I), (II), or (III) of 
23
clause (iii) is generally recognized 
24
195 
•HR 269 EH
as safe and effective under sec-
1
tion 201(p)(1); or 
2
‘‘(bb) approval of a drug 
3
that was approved under section 
4
505; and 
5
‘‘(II) do not duplicate the results 
6
of another study that was relied on by 
7
the Secretary to support— 
8
‘‘(aa) a proposed or final de-
9
termination that a drug described 
10
in subclause (I), (II), or (III) of 
11
clause (iii) is generally recognized 
12
as safe and effective under sec-
13
tion 201(p)(1); or 
14
‘‘(bb) approval of a drug 
15
that was approved under section 
16
505. 
17
‘‘(6) INFORMATION
REGARDING
SAFE
NON-
18
PRESCRIPTION MARKETING AND USE AS CONDITION 
19
FOR FILING A GENERALLY RECOGNIZED AS SAFE 
20
AND EFFECTIVE REQUEST.— 
21
‘‘(A) IN GENERAL.—In response to a re-
22
quest under this section that a drug described 
23
in subparagraph (B) be generally recognized as 
24
safe and effective, the Secretary— 
25
196 
•HR 269 EH
‘‘(i) may file such request, if the re-
1
quest includes information specified under 
2
subparagraph (C) with respect to safe non-
3
prescription marketing and use of such 
4
drug; or 
5
‘‘(ii) if the request fails to include in-
6
formation specified under subparagraph 
7
(C), shall refuse to file such request and 
8
require that nonprescription marketing of 
9
the drug be pursuant to a new drug appli-
10
cation as described in subparagraph (D). 
11
‘‘(B) DRUG
DESCRIBED.—A drug de-
12
scribed in this subparagraph is a nonprescrip-
13
tion drug which contains an active ingredient 
14
not previously incorporated in a drug— 
15
‘‘(i) specified in subsection (a)(1), 
16
(a)(2), or (a)(3); 
17
‘‘(ii) subject to a final order under 
18
this section; or 
19
‘‘(iii) subject to a final sunscreen 
20
order (as defined in section 586(2)(A)). 
21
‘‘(C) 
INFORMATION
DEMONSTRATING 
22
PRIMA
FACIE
SAFE
NONPRESCRIPTION
MAR-
23
KETING
AND
USE.—Information specified in 
24
197 
•HR 269 EH
this subparagraph, with respect to a request de-
1
scribed in subparagraph (A)(i), is— 
2
‘‘(i) information sufficient for a prima 
3
facie demonstration that the drug subject 
4
to such request has a verifiable history of 
5
being marketed and safely used by con-
6
sumers in the United States as a non-
7
prescription drug under comparable condi-
8
tions of use; 
9
‘‘(ii) if the drug has not been pre-
10
viously marketed in the United States as a 
11
nonprescription drug, information suffi-
12
cient for a prima facie demonstration that 
13
the drug was marketed and safely used 
14
under comparable conditions of marketing 
15
and use in a country listed in section 
16
802(b)(1)(A) or designated by the Sec-
17
retary 
in 
accordance 
with 
section 
18
802(b)(1)(B)— 
19
‘‘(I) for such period as needed to 
20
provide reasonable assurances con-
21
cerning the safe nonprescription use 
22
of the drug; and 
23
‘‘(II) during such time was sub-
24
ject to sufficient monitoring by a reg-
25
198 
•HR 269 EH
ulatory body considered acceptable by 
1
the Secretary for such monitoring 
2
purposes, including for adverse events 
3
associated with nonprescription use of 
4
the drug; or 
5
‘‘(iii) if the Secretary determines that 
6
information described in clause (i) or (ii) is 
7
not needed to provide a prima facie dem-
8
onstration that the drug can be safely mar-
9
keted and used as a nonprescription drug, 
10
such other information the Secretary deter-
11
mines is sufficient for such purposes. 
12
‘‘(D) MARKETING
PURSUANT
TO
NEW 
13
DRUG APPLICATION.—In the case of a request 
14
described in subparagraph (A)(ii), the drug 
15
subject to such request may be resubmitted for 
16
filing only if— 
17
‘‘(i) the drug is marketed as a non-
18
prescription drug, under conditions of use 
19
comparable to the conditions specified in 
20
the request, for such period as the Sec-
21
retary determines appropriate (not to ex-
22
ceed 5 consecutive years) pursuant to an 
23
application approved under section 505; 
24
and 
25
199 
•HR 269 EH
‘‘(ii) during such period, 1,000,000 
1
retail packages of the drug, or an equiva-
2
lent quantity as determined by the Sec-
3
retary, were distributed for retail sale, as 
4
determined in such manner as the Sec-
5
retary finds appropriate. 
6
‘‘(E) RULE OF APPLICATION.—Except in 
7
the case of a request involving a drug described 
8
in section 586(9), as in effect on January 1, 
9
2017, if the Secretary refuses to file a request 
10
under this paragraph, the requestor may not 
11
file such request over protest under paragraph 
12
(5)(A)(iii). 
13
‘‘(7) PACKAGING.—An administrative order 
14
issued under paragraph (2), (4)(A), or (5) may in-
15
clude requirements for the packaging of a drug to 
16
encourage use in accordance with labeling. Such re-
17
quirements may include unit dose packaging, re-
18
quirements for products intended for use by pedi-
19
atric populations, requirements to reduce risk of 
20
harm from unsupervised ingestion, and other appro-
21
priate requirements. This paragraph does not au-
22
thorize the Food and Drug Administration to re-
23
quire standards or testing procedures as described in 
24
part 1700 of title 16, Code of Federal Regulations. 
25
200 
•HR 269 EH
‘‘(8) FINAL
AND
TENTATIVE
FINAL
MONO-
1
GRAPHS FOR CATEGORY I DRUGS DEEMED FINAL 
2
ADMINISTRATIVE ORDERS.— 
3
‘‘(A) IN GENERAL.—A final monograph or 
4
tentative final monograph described in subpara-
5
graph (B) shall be deemed to be a final admin-
6
istrative order under this subsection and may 
7
be amended, revoked, or otherwise modified in 
8
accordance with the procedures of this sub-
9
section. 
10
‘‘(B) MONOGRAPHS DESCRIBED.—For pur-
11
poses of subparagraph (A), a final monograph 
12
or tentative final monograph is described in this 
13
subparagraph if it— 
14
‘‘(i) establishes conditions of use for a 
15
drug described in paragraph (1) or (2) of 
16
subsection (a); and 
17
‘‘(ii) represents the most recently pro-
18
mulgated version of such conditions, in-
19
cluding as modified, in whole or in part, by 
20
any proposed or final rule. 
21
‘‘(C) DEEMED ORDERS INCLUDE HARMO-
22
NIZING
TECHNICAL
AMENDMENTS.—The 
23
deemed establishment of a final administrative 
24
order under subparagraph (A) shall be con-
25
201 
•HR 269 EH
strued to include any technical amendments to 
1
such order as the Secretary determines nec-
2
essary to ensure that such order is appro-
3
priately harmonized, in terms of terminology or 
4
cross-references, with the applicable provisions 
5
of this Act (and regulations thereunder) and 
6
any other orders issued under this section. 
7
‘‘(c) PROCEDURE FOR MINOR CHANGES.— 
8
‘‘(1) IN GENERAL.—Minor changes in the dos-
9
age form of a drug that is described in paragraph 
10
(1) or (2) of subsection (a) or the subject of an 
11
order issued under subsection (b) may be made by 
12
a requestor without the issuance of an order under 
13
subsection (b) if— 
14
‘‘(A) the requestor maintains such infor-
15
mation as is necessary to demonstrate that the 
16
change— 
17
‘‘(i) will not affect the safety or effec-
18
tiveness of the drug; and 
19
‘‘(ii) will not materially affect the ex-
20
tent of absorption or other exposure to the 
21
active ingredient in comparison to a suit-
22
able reference product; and 
23
‘‘(B) the change is in conformity with the 
24
requirements of an applicable administrative 
25
202 
•HR 269 EH
order issued by the Secretary under paragraph 
1
(3). 
2
‘‘(2) ADDITIONAL INFORMATION.— 
3
‘‘(A) ACCESS
TO
RECORDS.—A sponsor 
4
shall submit records requested by the Secretary 
5
relating to such a minor change under section 
6
704(a)(4), within 15 business days of receiving 
7
such a request, or such longer period as the 
8
Secretary may provide. 
9
‘‘(B) INSUFFICIENT INFORMATION.—If the 
10
Secretary determines that the information con-
11
tained in such records is not sufficient to dem-
12
onstrate that the change does not affect the 
13
safety or effectiveness of the drug or materially 
14
affect the extent of absorption or other expo-
15
sure to the active ingredient, the Secretary— 
16
‘‘(i) may so inform the sponsor of the 
17
drug in writing; and 
18
‘‘(ii) if the Secretary so informs the 
19
sponsor, shall provide the sponsor of the 
20
drug with a reasonable opportunity to pro-
21
vide additional information. 
22
‘‘(C) FAILURE TO SUBMIT SUFFICIENT IN-
23
FORMATION.—If the sponsor fails to provide 
24
such additional information within a time pre-
25
203 
•HR 269 EH
scribed by the Secretary, or if the Secretary de-
1
termines that such additional information does 
2
not demonstrate that the change does not— 
3
‘‘(i) affect the safety or effectiveness 
4
of the drug; or 
5
‘‘(ii) materially affect the extent of 
6
absorption or other exposure to the active 
7
ingredient in comparison to a suitable ref-
8
erence product, 
9
the drug as modified is a new drug under sec-
10
tion 201(p) and shall be deemed to be mis-
11
branded under section 502(ee). 
12
‘‘(3) DETERMINING WHETHER A CHANGE WILL 
13
AFFECT SAFETY OR EFFECTIVENESS.— 
14
‘‘(A) IN
GENERAL.—The Secretary shall 
15
issue one or more administrative orders speci-
16
fying requirements for determining whether a 
17
minor change made by a sponsor pursuant to 
18
this subsection will affect the safety or effective-
19
ness of a drug or materially affect the extent of 
20
absorption or other exposure to an active ingre-
21
dient in the drug in comparison to a suitable 
22
reference product, together with guidance for 
23
applying those orders to specific dosage forms. 
24
204 
•HR 269 EH
‘‘(B) STANDARD PRACTICES.—The orders 
1
and guidance issued by the Secretary under 
2
subparagraph (A) shall take into account rel-
3
evant public standards and standard practices 
4
for evaluating the quality of drugs, and may 
5
take into account the special needs of popu-
6
lations, including children. 
7
‘‘(d) CONFIDENTIALITY
OF
INFORMATION
SUB-
8
MITTED TO THE SECRETARY.— 
9
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
10
any information, including reports of testing con-
11
ducted on the drug or drugs involved, that is sub-
12
mitted by a requestor in connection with proceedings 
13
on an order under this section (including any minor 
14
change under subsection (c)) and is a trade secret 
15
or confidential information subject to section 
16
552(b)(4) of title 5, United States Code, or section 
17
1905 of title 18, United States Code, shall not be 
18
disclosed to the public unless the requestor consents 
19
to that disclosure. 
20
‘‘(2) PUBLIC AVAILABILITY.— 
21
‘‘(A) IN GENERAL.—Except as provided in 
22
subparagraph (B), the Secretary shall— 
23
‘‘(i) make any information submitted 
24
by a requestor in support of a request 
25
205 
•HR 269 EH
under subsection (b)(5)(A) available to the 
1
public not later than the date on which the 
2
proposed order is issued; and 
3
‘‘(ii) make any information submitted 
4
by any other person with respect to an 
5
order requested (or initiated by the Sec-
6
retary) under subsection (b), available to 
7
the public upon such submission. 
8
‘‘(B) LIMITATIONS
ON
PUBLIC
AVAIL-
9
ABILITY.—Information described in subpara-
10
graph (A) shall not be made public if— 
11
‘‘(i) the information pertains to phar-
12
maceutical quality information, unless such 
13
information is necessary to establish stand-
14
ards under which a drug is generally rec-
15
ognized as safe and effective under section 
16
201(p)(1); 
17
‘‘(ii) the information is submitted in a 
18
requestor-initiated request, but the re-
19
questor withdraws such request, in accord-
20
ance with withdrawal procedures estab-
21
lished by the Secretary, before the Sec-
22
retary issues the proposed order; 
23
‘‘(iii) the Secretary requests and ob-
24
tains the information under subsection (c) 
25
206 
•HR 269 EH
and such information is not submitted in 
1
relation to an order under subsection (b); 
2
or 
3
‘‘(iv) the information is of the type 
4
contained in raw datasets. 
5
‘‘(e) UPDATES TO DRUG LISTING INFORMATION.— 
6
A sponsor who makes a change to a drug subject to this 
7
section shall submit updated drug listing information for 
8
the drug in accordance with section 510(j) within 30 cal-
9
endar days of the date when the drug is first commercially 
10
marketed, except that a sponsor who was the order re-
11
questor with respect to an order subject to subsection 
12
(b)(5)(C) (or a licensee, assignee, or successor in interest 
13
of such requestor) shall submit updated drug listing infor-
14
mation on or before the date when the drug is first com-
15
mercially marketed. 
16
‘‘(f) APPROVALS UNDER SECTION 505.—The provi-
17
sions of this section shall not be construed to preclude a 
18
person from seeking or maintaining the approval of an ap-
19
plication for a drug under sections 505(b)(1), 505(b)(2), 
20
and 505(j). A determination under this section that a drug 
21
is not subject to section 503(b)(1), is generally recognized 
22
as safe and effective under section 201(p)(1), and is not 
23
a new drug under section 201(p) shall constitute a finding 
24
that the drug is safe and effective that may be relied upon 
25
207 
•HR 269 EH
for purposes of an application under section 505(b)(2), so 
1
that the applicant shall be required to submit for purposes 
2
of such application only information needed to support any 
3
modification of the drug that is not covered by such deter-
4
mination under this section. 
5
‘‘(g) PUBLIC AVAILABILITY OF ADMINISTRATIVE OR-
6
DERS.—The Secretary shall establish, maintain, update 
7
(as determined necessary by the Secretary but no less fre-
8
quently than annually), and make publicly available, with 
9
respect to orders issued under this section— 
10
‘‘(1) a repository of each final order and in-
11
terim final order in effect, including the complete 
12
text of the order; and 
13
‘‘(2) a listing of all orders proposed and under 
14
development under subsection (b)(2), including— 
15
‘‘(A) a brief description of each such order; 
16
and 
17
‘‘(B) the Secretary’s expectations, if re-
18
sources permit, for issuance of proposed orders 
19
over a 3-year period. 
20
‘‘(h) DEVELOPMENT ADVICE TO SPONSORS OR RE-
21
QUESTORS.—The Secretary shall establish procedures 
22
under which sponsors or requestors may meet with appro-
23
priate officials of the Food and Drug Administration to 
24
obtain advice on the studies and other information nec-
25
208 
•HR 269 EH
essary to support submissions under this section and other 
1
matters relevant to the regulation of nonprescription 
2
drugs and the development of new nonprescription drugs 
3
under this section. 
4
‘‘(i) PARTICIPATION OF MULTIPLE SPONSORS OR RE-
5
QUESTORS.—The Secretary shall establish procedures to 
6
facilitate efficient participation by multiple sponsors or re-
7
questors in proceedings under this section, including provi-
8
sion for joint meetings with multiple sponsors or reques-
9
tors or with organizations nominated by sponsors or re-
10
questors to represent their interests in a proceeding. 
11
‘‘(j) ELECTRONIC FORMAT.—All submissions under 
12
this section shall be in electronic format. 
13
‘‘(k) EFFECT
ON EXISTING REGULATIONS GOV-
14
ERNING NONPRESCRIPTION DRUGS.— 
15
‘‘(1) REGULATIONS
OF
GENERAL
APPLICA-
16
BILITY
TO
NONPRESCRIPTION
DRUGS.—Except as 
17
provided in this subsection, nothing in this section 
18
supersedes regulations establishing general require-
19
ments for nonprescription drugs, including regula-
20
tions of general applicability contained in parts 201, 
21
250, and 330 of title 21, Code of Federal Regula-
22
tions, or any successor regulations. The Secretary 
23
shall establish or modify such regulations by means 
24
209 
•HR 269 EH
of rulemaking in accordance with section 553 of title 
1
5, United States Code. 
2
‘‘(2) REGULATIONS
ESTABLISHING
REQUIRE-
3
MENTS FOR SPECIFIC NONPRESCRIPTION DRUGS.— 
4
‘‘(A) The provisions of section 310.545 of 
5
title 21, Code of Federal Regulations, as in ef-
6
fect on the day before the date of the enact-
7
ment of this section, shall be deemed to be a 
8
final order under subsection (b). 
9
‘‘(B) Regulations in effect on the day be-
10
fore the date of the enactment of this section, 
11
establishing requirements for specific non-
12
prescription drugs marketed pursuant to this 
13
section (including such requirements in parts 
14
201 and 250 of title 21, Code of Federal Regu-
15
lations), shall be deemed to be final orders 
16
under subsection (b), only as they apply to 
17
drugs— 
18
‘‘(i) subject to paragraph (1), (2), (3), 
19
or (4) of subsection (a); or 
20
‘‘(ii) otherwise subject to an order 
21
under this section. 
22
‘‘(3) WITHDRAWAL
OF
REGULATIONS.—The 
23
Secretary shall withdraw regulations establishing 
24
final monographs and the procedures governing the 
25
210 
•HR 269 EH
over-the-counter drug review under part 330 and 
1
other relevant parts of title 21, Code of Federal 
2
Regulations (as in effect on the day before the date 
3
of the enactment of this section), or make technical 
4
changes to such regulations to ensure conformity 
5
with appropriate terminology and cross references. 
6
Notwithstanding subchapter II of chapter 5 of title 
7
5, United States Code, any such withdrawal or tech-
8
nical changes shall be made without public notice 
9
and comment and shall be effective upon publication 
10
through notice in the Federal Register (or upon such 
11
date as specified in such notice). 
12
‘‘(l) GUIDANCE.—The Secretary shall issue guidance 
13
that specifies— 
14
‘‘(1) the procedures and principles for formal 
15
meetings between the Secretary and sponsors or re-
16
questors for drugs subject to this section; 
17
‘‘(2) the format and content of data submis-
18
sions to the Secretary under this section; 
19
‘‘(3) the format of electronic submissions to the 
20
Secretary under this section; 
21
‘‘(4) consolidated proceedings for appeal and 
22
the procedures for such proceedings where appro-
23
priate; and 
24
211 
•HR 269 EH
‘‘(5) for minor changes in drugs, recommenda-
1
tions on how to comply with the requirements in or-
2
ders issued under subsection (c)(3). 
3
‘‘(m) RULE OF CONSTRUCTION.— 
4
‘‘(1) IN GENERAL.—This section shall not af-
5
fect the treatment or status of a nonprescription 
6
drug— 
7
‘‘(A) that is marketed without an applica-
8
tion approved under section 505 as of the date 
9
of the enactment of this section; 
10
‘‘(B) that is not subject to an order issued 
11
under this section; and 
12
‘‘(C) to which paragraphs (1), (2), (3), (4), 
13
or (5) of subsection (a) do not apply. 
14
‘‘(2) TREATMENT
OF
PRODUCTS
PREVIOUSLY 
15
FOUND TO BE SUBJECT TO TIME AND EXTENT RE-
16
QUIREMENTS.— 
17
‘‘(A) Notwithstanding subsection (a), a 
18
drug described in subparagraph (B) may only 
19
be lawfully marketed, without an application 
20
approved under section 505, pursuant to an 
21
order issued under this section. 
22
‘‘(B) A drug described in this subpara-
23
graph is a drug which, prior to the date of the 
24
enactment of this section, the Secretary deter-
25
212 
•HR 269 EH
mined in a proposed or final rule to be ineligible 
1
for review under the OTC drug review (as such 
2
phrase ‘OTC drug review’ was used in section 
3
330.14 of title 21, Code of Federal Regulations, 
4
as in effect on the day before the date of the 
5
enactment of this section). 
6
‘‘(3) PRESERVATION OF AUTHORITY.— 
7
‘‘(A) Nothing in paragraph (1) shall be 
8
construed to preclude or limit the applicability 
9
of any provision of this Act other than this sec-
10
tion. 
11
‘‘(B) Nothing in subsection (a) shall be 
12
construed to prohibit the Secretary from issuing 
13
an order under this section finding a drug to be 
14
not generally recognized as safe and effective 
15
under section 201(p)(1), as the Secretary deter-
16
mines appropriate. 
17
‘‘(n) INVESTIGATIONAL NEW DRUGS.—A drug is not 
18
subject to this section if an exemption for investigational 
19
use under section 505(i) is in effect for such drug. 
20
‘‘(o) INAPPLICABILITY OF PAPERWORK REDUCTION 
21
ACT.—Chapter 35 of title 44, United States Code, shall 
22
not apply to collections of information made under this 
23
section. 
24
213 
•HR 269 EH
‘‘(p) INAPPLICABILITY OF NOTICE AND COMMENT 
1
RULEMAKING
AND OTHER REQUIREMENTS.—The re-
2
quirements of subsection (b) shall apply with respect to 
3
orders issued under this section instead of the require-
4
ments of subchapter II of chapter 5 of title 5, United 
5
States Code. 
6
‘‘(q) DEFINITIONS.—In this section: 
7
‘‘(1) The term ‘nonprescription drug’ refers to 
8
a drug not subject to the requirements of section 
9
503(b)(1). 
10
‘‘(2) The term ‘sponsor’ refers to any person 
11
marketing, manufacturing, or processing a drug 
12
that— 
13
‘‘(A) is listed pursuant to section 510(j); 
14
and 
15
‘‘(B) is or will be subject to an administra-
16
tive order under this section of the Food and 
17
Drug Administration. 
18
‘‘(3) The term ‘requestor’ refers to any person 
19
or group of persons marketing, manufacturing, proc-
20
essing, or developing a drug.’’. 
21
(b) GAO STUDY.—Not later than 4 years after the 
22
date of enactment of this Act, the Comptroller General 
23
of the United States shall submit a study to the Com-
24
mittee on Energy and Commerce of the House of Rep-
25
214 
•HR 269 EH
resentatives and the Committee on Health, Education, 
1
Labor, and Pensions of the Senate addressing the effec-
2
tiveness and overall impact of exclusivity under section 
3
505G of the Federal Food, Drug, and Cosmetic Act, as 
4
added by subsection (a), and section 586C of such Act 
5
(21 U.S.C. 360fff–3), including the impact of such exclu-
6
sivity on consumer access. Such study shall include— 
7
(1) an analysis of the impact of exclusivity 
8
under such section 505G for nonprescription drug 
9
products, including— 
10
(A) the number of nonprescription drug 
11
products that were granted exclusivity and the 
12
indication for which the nonprescription drug 
13
products were determined to be generally recog-
14
nized as safe and effective; 
15
(B) whether the exclusivity for such drug 
16
products was granted for— 
17
(i) a new active ingredient (including 
18
any ester or salt of the active ingredient); 
19
or 
20
(ii) changes in the conditions of use of 
21
a drug, for which new human data studies 
22
conducted or sponsored by the requestor 
23
were essential; 
24
215 
•HR 269 EH
(C) whether, and to what extent, the exclu-
1
sivity impacted the requestor’s or sponsor’s de-
2
cision to develop the drug product; 
3
(D) an analysis of the implementation of 
4
the exclusivity provision in such section 505G, 
5
including— 
6
(i) the resources used by the Food 
7
and Drug Administration; 
8
(ii) the impact of such provision on 
9
innovation, as well as research and devel-
10
opment in the nonprescription drug mar-
11
ket; 
12
(iii) the impact of such provision on 
13
competition in the nonprescription drug 
14
market; 
15
(iv) the impact of such provision on 
16
consumer access to nonprescription drug 
17
products; 
18
(v) the impact of such provision on 
19
the prices of nonprescription drug prod-
20
ucts; and 
21
(vi) whether the administrative orders 
22
initiated by requestors under such section 
23
505G have been sufficient to encourage the 
24
development of nonprescription drug prod-
25
216 
•HR 269 EH
ucts that would likely not be otherwise de-
1
veloped, or developed in as timely a man-
2
ner; and 
3
(E) whether the administrative orders ini-
4
tiated by requestors under such section 505G 
5
have been sufficient incentive to encourage in-
6
novation in the nonprescription drug market; 
7
and 
8
(2) an analysis of the impact of exclusivity 
9
under such section 586C for sunscreen ingredients, 
10
including— 
11
(A) the number of sunscreen ingredients 
12
that were granted exclusivity and the specific 
13
ingredient that was determined to be generally 
14
recognized as safe and effective; 
15
(B) whether, and to what extent, the exclu-
16
sivity impacted the requestor’s or sponsor’s de-
17
cision to develop the sunscreen ingredient; 
18
(C) whether, and to what extent, the sun-
19
screen ingredient granted exclusivity had pre-
20
viously been available outside of the United 
21
States; 
22
(D) an analysis of the implementation of 
23
the exclusivity provision in such section 586C, 
24
including— 
25
217 
•HR 269 EH
(i) the resources used by the Food 
1
and Drug Administration; 
2
(ii) the impact of such provision on 
3
innovation, as well as research and devel-
4
opment in the sunscreen market; 
5
(iii) the impact of such provision on 
6
competition in the sunscreen market; 
7
(iv) the impact of such provision on 
8
consumer access to sunscreen products; 
9
(v) the impact of such provision on 
10
the prices of sunscreen products; and 
11
(vi) whether the administrative orders 
12
initiated by requestors under such section 
13
505G have been utilized by sunscreen in-
14
gredient sponsors and whether such proc-
15
ess has been sufficient to encourage the 
16
development of sunscreen ingredients that 
17
would likely not be otherwise developed, or 
18
developed in as timely a manner; and 
19
(E) whether the administrative orders ini-
20
tiated by requestors under such section 586C 
21
have been sufficient incentive to encourage in-
22
novation in the sunscreen market. 
23
218 
•HR 269 EH
(c) CONFORMING AMENDMENT.—Section 751(d)(1) 
1
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
2
379r(d)(1)) is amended— 
3
(1) in the matter preceding subparagraph (A)— 
4
(A) by striking ‘‘final regulation promul-
5
gated’’ and inserting ‘‘final order under section 
6
505G’’; and 
7
(B) by striking ‘‘and not misbranded’’; and 
8
(2) in subparagraph (A), by striking ‘‘regula-
9
tion in effect’’ and inserting ‘‘regulation or order in 
10
effect’’. 
11
SEC. 1002. MISBRANDING. 
12
Section 502 of the Federal Food, Drug, and Cosmetic 
13
Act (21 U.S.C. 352) is amended by adding at the end the 
14
following: 
15
‘‘(ee) If it is a nonprescription drug that is subject 
16
to section 505G, is not the subject of an application ap-
17
proved under section 505, and does not comply with the 
18
requirements under section 505G. 
19
‘‘(ff) If it is a drug and it was manufactured, pre-
20
pared, propagated, compounded, or processed in a facility 
21
for which fees have not been paid as required by section 
22
744M.’’. 
23
219 
•HR 269 EH
SEC. 1003. DRUGS EXCLUDED FROM THE OVER-THE- 
1
COUNTER DRUG REVIEW. 
2
(a) IN GENERAL.—Nothing in this Act (or the 
3
amendments made by this Act) shall apply to any non-
4
prescription drug (as defined in section 505G(q) of the 
5
Federal Food, Drug, and Cosmetic Act, as added by sec-
6
tion 1001 of this Act) which was excluded by the Food 
7
and Drug Administration from the Over-the-Counter 
8
Drug Review in accordance with the paragraph numbered 
9
25 on page 9466 of volume 37 of the Federal Register, 
10
published on May 11, 1972. 
11
(b) RULE OF CONSTRUCTION.—Nothing in this sec-
12
tion shall be construed to preclude or limit the applica-
13
bility of any other provision of the Federal Food, Drug, 
14
and Cosmetic Act (21 U.S.C. 301 et seq.). 
15
SEC. 1004. TREATMENT OF SUNSCREEN INNOVATION ACT. 
16
(a) REVIEW OF NONPRESCRIPTION SUNSCREEN AC-
17
TIVE INGREDIENTS.— 
18
(1) APPLICABILITY
OF
SECTION
505G
FOR 
19
PENDING SUBMISSIONS.— 
20
(A) IN GENERAL.—A sponsor of a non-
21
prescription sunscreen active ingredient or com-
22
bination of nonprescription sunscreen active in-
23
gredients that, as of the date of enactment of 
24
this Act, is subject to a proposed sunscreen 
25
order under section 586C of the Federal Food, 
26
220 
•HR 269 EH
Drug, and Cosmetic Act (21 U.S.C. 360fff–3) 
1
may elect, by means of giving written notifica-
2
tion to the Secretary of Health and Human 
3
Services within 180 calendar days of the enact-
4
ment of this Act, to transition into the review 
5
of such ingredient or combination of ingredients 
6
pursuant to the process set out in section 505G 
7
of the Federal Food, Drug, and Cosmetic Act, 
8
as added by section 1001 of this Act. 
9
(B) ELECTION EXERCISED.—Upon receipt 
10
by the Secretary of Health and Human Services 
11
of a timely notification under subparagraph 
12
(A)— 
13
(i) the proposed sunscreen order in-
14
volved is deemed to be a request for an 
15
order under subsection (b) of section 505G 
16
of the Federal Food, Drug, and Cosmetic 
17
Act, as added by section 1001 of this Act; 
18
and 
19
(ii) such order is deemed to have been 
20
accepted 
for 
filing 
under 
subsection 
21
(b)(6)(A)(i) of such section 505G. 
22
(C) ELECTION NOT EXERCISED.—If a noti-
23
fication under subparagraph (A) is not received 
24
by the Secretary of Health and Human Services 
25
221 
•HR 269 EH
within 180 calendar days of the date of enact-
1
ment of this Act, the review of the proposed 
2
sunscreen order described in subparagraph 
3
(A)— 
4
(i) shall continue under section 586C 
5
of the Federal Food, Drug, and Cosmetic 
6
Act (21 U.S.C. 360fff–3); and 
7
(ii) shall not be eligible for review 
8
under section 505G, added by section 1001 
9
of this Act. 
10
(2) DEFINITIONS.—In this subsection, the 
11
terms ‘‘sponsor’’, ‘‘nonprescription’’, ‘‘sunscreen ac-
12
tive ingredient’’, and ‘‘proposed sunscreen order’’ 
13
have the meanings given to those terms in section 
14
586 of the Federal Food, Drug, and Cosmetic Act 
15
(21 U.S.C. 360fff). 
16
(b) AMENDMENTS TO SUNSCREEN PROVISIONS.— 
17
(1) FINAL
SUNSCREEN
ORDERS.—Paragraph 
18
(3) of section 586C(e) of the Federal Food, Drug, 
19
and Cosmetic Act (21 U.S.C. 360fff–3(e)) is amend-
20
ed to read as follows: 
21
‘‘(3) RELATIONSHIP TO ORDERS UNDER SEC-
22
TION 505G.—A final sunscreen order shall be deemed 
23
to be a final order under section 505G.’’. 
24
222 
•HR 269 EH
(2) MEETINGS.—Paragraph (7) of section 
1
586C(b) of the Federal Food, Drug, and Cosmetic 
2
Act (21 U.S.C. 360fff–3(b)) is amended— 
3
(A) by striking ‘‘A sponsor may request’’ 
4
and inserting the following: 
5
‘‘(A) IN
GENERAL.—A sponsor may re-
6
quest’’; and 
7
(B) by adding at the end the following: 
8
‘‘(B) CONFIDENTIAL MEETINGS.—A spon-
9
sor may request one or more confidential meet-
10
ings with respect to a proposed sunscreen order, 
11
including a letter deemed to be a proposed sun-
12
screen order under paragraph (3), to discuss 
13
matters relating to data requirements to sup-
14
port a general recognition of safety and effec-
15
tiveness involving confidential information and 
16
public information related to such proposed 
17
sunscreen order, as appropriate. The Secretary 
18
shall convene a confidential meeting with such 
19
sponsor in a reasonable time period. If a spon-
20
sor requests more than one confidential meeting 
21
for the same proposed sunscreen order, the Sec-
22
retary may refuse to grant an additional con-
23
fidential meeting request if the Secretary deter-
24
mines that such additional confidential meeting 
25
223 
•HR 269 EH
is not reasonably necessary for the sponsor to 
1
advance its proposed sunscreen order, or if the 
2
request for a confidential meeting fails to in-
3
clude sufficient information upon which to base 
4
a substantive discussion. The Secretary shall 
5
publish a post-meeting summary of each con-
6
fidential meeting under this subparagraph that 
7
does not disclose confidential commercial infor-
8
mation or trade secrets. This subparagraph 
9
does not authorize the disclosure of confidential 
10
commercial information or trade secrets subject 
11
to 552(b)(4) of title 5, United States Code, or 
12
section 1905 of title 18, United States Code.’’. 
13
(3) EXCLUSIVITY.—Section 586C of the Fed-
14
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
15
360fff–3) is amended by adding at the end the fol-
16
lowing: 
17
‘‘(f) EXCLUSIVITY.— 
18
‘‘(1) IN
GENERAL.—A final sunscreen order 
19
shall have the effect of authorizing solely the order 
20
requestor (or the licensees, assignees, or successors 
21
in interest of such requestor with respect to the sub-
22
ject of such request and listed under paragraph (5)) 
23
for a period of 18 months, to market a sunscreen in-
24
gredient under this section incorporating changes 
25
224 
•HR 269 EH
described in paragraph (2) subject to the limitations 
1
under paragraph (4), beginning on the date the re-
2
questor (or any licensees, assignees, or successors in 
3
interest of such requestor with respect to the subject 
4
of such request and listed under paragraph (5)) may 
5
lawfully market such sunscreen ingredient pursuant 
6
to the order. 
7
‘‘(2) CHANGES
DESCRIBED.—A change de-
8
scribed in this paragraph is a change subject to an 
9
order specified in paragraph (1) that permits a sun-
10
screen to contain an active sunscreen ingredient not 
11
previously incorporated in a marketed sunscreen list-
12
ed in paragraph (3). 
13
‘‘(3) MARKETED
SUNSCREEN.—The marketed 
14
sunscreen ingredients described in this paragraph 
15
are sunscreen ingredients— 
16
‘‘(A) marketed in accordance with a final 
17
monograph for sunscreen drug products set 
18
forth at part 352 of title 21, Code of Federal 
19
Regulations (as published at 64 Fed. Reg. 
20
27687); or 
21
‘‘(B) marketed in accordance with a final 
22
order issued under this section. 
23
225 
•HR 269 EH
‘‘(4) LIMITATIONS ON EXCLUSIVITY.—Only one 
1
18-month period may be granted per ingredient 
2
under paragraph (1). 
3
‘‘(5) LISTING OF LICENSEES, ASSIGNEES, OR 
4
SUCCESSORS IN INTEREST.—Requestors shall submit 
5
to the Secretary at the time when a drug subject to 
6
such request is introduced or delivered for introduc-
7
tion into interstate commerce, a list of licensees, as-
8
signees, or successors in interest under paragraph 
9
(1).’’. 
10
(4) SUNSET PROVISION.—Subchapter I of chap-
11
ter V of the Federal Food, Drug, and Cosmetic Act 
12
(21 U.S.C. 360fff et seq.) is amended by adding at 
13
the end the following: 
14
‘‘SEC. 586H. SUNSET. 
15
‘‘This subchapter shall cease to be effective at the end 
16
of fiscal year 2022.’’. 
17
(5) 
TREATMENT
OF
FINAL
SUNSCREEN 
18
ORDER.—The Federal Food, Drug, and Cosmetic 
19
Act is amended by striking section 586E of such Act 
20
(21 U.S.C. 360fff–5). 
21
(c) TREATMENT OF AUTHORITY REGARDING FINAL-
22
IZATION OF SUNSCREEN MONOGRAPH.— 
23
(1) IN GENERAL.— 
24
226 
•HR 269 EH
(A) REVISION
OF
FINAL
SUNSCREEN 
1
ORDER.—Not later than November 26, 2019, 
2
the Secretary of Health and Human Services 
3
(referred to in this subsection as the ‘‘Sec-
4
retary’’) shall amend and revise the final ad-
5
ministrative order concerning nonprescription 
6
sunscreen (referred to in this subsection as the 
7
‘‘sunscreen order’’) for which the content, prior 
8
to the date of enactment of this Act, was rep-
9
resented by the final monograph for sunscreen 
10
drug products set forth in part 352 of title 21, 
11
Code of Federal Regulations (as in effect on 
12
May 21, 1999). 
13
(B) ISSUANCE
OF
REVISED
SUNSCREEN 
14
ORDER; EFFECTIVE DATE.—A revised sunscreen 
15
order described in subparagraph (A) shall be— 
16
(i) issued in accordance with the pro-
17
cedures described in section 505G(c)(2) of 
18
the Federal Food, Drug, and Cosmetic 
19
Act; 
20
(ii) issued in proposed form not later 
21
than May 28, 2019; 
22
(iii) effective not later than November 
23
26, 2020; and 
24
227 
•HR 269 EH
(iv) issued by the Secretary at least 1 
1
year prior to the effective date of the re-
2
vised order. 
3
(2) REPORTS.—If a revised sunscreen order 
4
issued under paragraph (1) does not include provi-
5
sions related to the effectiveness of various sun pro-
6
tection factor levels, and does not address all dosage 
7
forms known to the Secretary to be used in sun-
8
screens marketed in the United States without a 
9
new drug application approved under section 505 of 
10
the Federal Food, Drug, and Cosmetic Act (21 
11
U.S.C. 355), the Secretary shall submit a report to 
12
the Committee on Energy and Commerce of the 
13
House of Representatives and the Committee on 
14
Health, Education, Labor, and Pensions of the Sen-
15
ate on the rationale for omission of such provisions 
16
from such order, and a plan and timeline to compile 
17
any information necessary to address such provisions 
18
through such order. 
19
(d) TREATMENT OF NON-SUNSCREEN TIME AND EX-
20
TENT APPLICATIONS.— 
21
(1) IN GENERAL.—Any application described in 
22
section 586F of the Federal Food, Drug, and Cos-
23
metic Act (21 U.S.C. 360fff–6) that was submitted 
24
to the Secretary pursuant to section 330.14 of title 
25
228 
•HR 269 EH
21, Code of Federal Regulations, as such provisions 
1
were in effect immediately prior to the date of enact-
2
ment date of this Act, shall be extinguished as of 
3
such date of enactment, subject to paragraph (2). 
4
(2) ORDER REQUEST.—Nothing in paragraph 
5
(1) precludes the submission of an order request 
6
under section 505G(b) of the Federal Food, Drug, 
7
and Cosmetic Act, as added by section 1001 of this 
8
Act, with respect to a drug that was the subject of 
9
an application extinguished under paragraph (1). 
10
SEC. 1005. ANNUAL UPDATE TO CONGRESS ON APPRO-
11
PRIATE PEDIATRIC INDICATION FOR CER-
12
TAIN OTC COUGH AND COLD DRUGS. 
13
(a) IN GENERAL.—Subject to subsection (c), the Sec-
14
retary of Health and Human Services shall, beginning not 
15
later than 1 year after the date of enactment of this Act, 
16
annually submit to the Committee on Energy and Com-
17
merce of the House of Representatives and the Committee 
18
on Health, Education, Labor, and Pensions of the Senate 
19
a letter describing the progress of the Food and Drug Ad-
20
ministration— 
21
(1) in evaluating the cough and cold monograph 
22
described in subsection (b) with respect to children 
23
under age 6; and 
24
229 
•HR 269 EH
(2) as appropriate, revising such cough and cold 
1
monograph to address such children through the 
2
order process under section 505G(b) of the Federal 
3
Food, Drug, and Cosmetic Act, as added by section 
4
1001 of this Act. 
5
(b) COUGH AND COLD MONOGRAPH DESCRIBED.— 
6
The cough and cold monograph described in this sub-
7
section consists of the conditions under which nonprescrip-
8
tion drugs containing antitussive, expectorant, nasal de-
9
congestant, or antihistamine active ingredients (or com-
10
binations thereof) are generally recognized as safe and ef-
11
fective, as specified in part 341 of title 21, Code of Federal 
12
Regulations (as in effect immediately prior to the date of 
13
enactment of this Act), and included in an order deemed 
14
to be established under section 505G(b) of the Federal 
15
Food, Drug, and Cosmetic Act, as added by section 1001 
16
of this Act. 
17
(c) DURATION
OF AUTHORITY.—The requirement 
18
under subsection (a) shall terminate as of the date of a 
19
letter submitted by the Secretary of Health and Human 
20
Services pursuant to such subsection in which the Sec-
21
retary indicates that the Food and Drug Administration 
22
has completed its evaluation and revised, in a final order, 
23
as applicable, the cough and cold monograph as described 
24
in subsection (a)(2). 
25
230 
•HR 269 EH
SEC. 1006. TECHNICAL CORRECTIONS. 
1
(a) 
IMPORTS
AND
EXPORTS.—Section 
2
801(e)(4)(E)(iii) of the Federal Food, Drug, and Cosmetic 
3
Act (21 U.S.C. 381(e)(4)(E)(iii)) is amended by striking 
4
‘‘subparagraph’’ each place such term appears and insert-
5
ing ‘‘paragraph’’. 
6
(b) FDA REAUTHORIZATION ACT OF 2017.— 
7
(1) IN
GENERAL.—Section 905(b)(4) of the 
8
FDA Reauthorization Act of 2017 (Public Law115– 
9
52) is amended by striking ‘‘Section 744H(e)(2)(B)’’ 
10
and inserting ‘‘Section 744H(f)(2)(B)’’. 
11
(2) EFFECTIVE DATE.—The amendment made 
12
by paragraph (1) shall take effect as of the enact-
13
ment of the FDA Reauthorization Act of 2017 
14
(Public Law 115–52). 
15
TITLE II—USER FEES 
16
SEC. 2001. SHORT TITLE; FINDING. 
17
(a) SHORT TITLE.—This title may be cited as the 
18
‘‘Over-the-Counter Monograph User Fee Act of 2019’’. 
19
(b) FINDING.—The Congress finds that the fees au-
20
thorized by the amendments made in this title will be dedi-
21
cated to OTC monograph drug activities, as set forth in 
22
the goals identified for purposes of part 10 of subchapter 
23
C of chapter VII of the Federal Food, Drug, and Cosmetic 
24
Act, in the letters from the Secretary of Health and 
25
Human Services to the Chairman of the Committee on 
26
231 
•HR 269 EH
Health, Education, Labor, and Pensions of the Senate and 
1
the Chairman of the Committee on Energy and Commerce 
2
of the House of Representatives, as set forth in the Con-
3
gressional Record. 
4
SEC. 2002. FEES RELATING TO OVER-THE-COUNTER DRUGS. 
5
Subchapter C of chapter VII of the Federal Food, 
6
Drug, and Cosmetic Act (21 U.S.C. 379f et seq.) is 
7
amended by inserting after part 9 the following: 
8
‘‘PART 10—FEES RELATING TO OVER-THE- 
9
COUNTER DRUGS 
10
‘‘SEC. 744L. DEFINITIONS. 
11
‘‘In this part: 
12
‘‘(1) The term ‘affiliate’ means a business enti-
13
ty that has a relationship with a second business en-
14
tity if, directly or indirectly— 
15
‘‘(A) one business entity controls, or has 
16
the power to control, the other business entity; 
17
or 
18
‘‘(B) a third party controls, or has power 
19
to control, both of the business entities. 
20
‘‘(2) The term ‘contract manufacturing organi-
21
zation facility’ means an OTC monograph drug facil-
22
ity where neither the owner of such manufacturing 
23
facility nor any affiliate of such owner or facility 
24
sells the OTC monograph drug produced at such fa-
25
232 
•HR 269 EH
cility directly to wholesalers, retailers, or consumers 
1
in the United States. 
2
‘‘(3) The term ‘costs of resources allocated for 
3
OTC monograph drug activities’ means the expenses 
4
in connection with OTC monograph drug activities 
5
for— 
6
‘‘(A) officers and employees of the Food 
7
and Drug Administration, contractors of the 
8
Food and Drug Administration, advisory com-
9
mittees, and costs related to such officers, em-
10
ployees, and committees and costs related to 
11
contracts with such contractors; 
12
‘‘(B) management of information, and the 
13
acquisition, maintenance, and repair of com-
14
puter resources; 
15
‘‘(C) leasing, maintenance, renovation, and 
16
repair of facilities and acquisition, maintenance, 
17
and repair of fixtures, furniture, scientific 
18
equipment, and other necessary materials and 
19
supplies; and 
20
‘‘(D) collecting fees under section 744M 
21
and accounting for resources allocated for OTC 
22
monograph drug activities. 
23
‘‘(4) The term ‘FDA establishment identifier’ is 
24
the unique number automatically generated by Food 
25
233 
•HR 269 EH
and Drug Administration’s Field Accomplishments 
1
and Compliance Tracking System (FACTS) (or any 
2
successor system). 
3
‘‘(5) The term ‘OTC monograph drug’ means a 
4
nonprescription drug without an approved new drug 
5
application which is governed by the provisions of 
6
section 505G. 
7
‘‘(6) The term ‘OTC monograph drug activities’ 
8
means activities of the Secretary associated with 
9
OTC monograph drugs and inspection of facilities 
10
associated with such products, including the fol-
11
lowing activities: 
12
‘‘(A) The activities necessary for review 
13
and evaluation of OTC monographs and OTC 
14
monograph order requests, including— 
15
‘‘(i) orders proposing or finalizing ap-
16
plicable conditions of use for OTC mono-
17
graph drugs; 
18
‘‘(ii) orders affecting status regarding 
19
general recognition of safety and effective-
20
ness of an OTC monograph ingredient or 
21
combination of ingredients under specified 
22
conditions of use; 
23
234 
•HR 269 EH
‘‘(iii) all OTC monograph drug devel-
1
opment and review activities, including 
2
intra-agency collaboration; 
3
‘‘(iv) regulation and policy develop-
4
ment activities related to OTC monograph 
5
drugs; 
6
‘‘(v) development of product standards 
7
for products subject to review and evalua-
8
tion; 
9
‘‘(vi) meetings referred to in section 
10
505G(i); 
11
‘‘(vii) review of labeling prior to 
12
issuance of orders related to OTC mono-
13
graph drugs or conditions of use; and 
14
‘‘(viii) regulatory science activities re-
15
lated to OTC monograph drugs. 
16
‘‘(B) Inspections related to OTC mono-
17
graph drugs. 
18
‘‘(C) Monitoring of clinical and other re-
19
search conducted in connection with OTC 
20
monograph drugs. 
21
‘‘(D) Safety activities with respect to OTC 
22
monograph drugs, including— 
23
235 
•HR 269 EH
‘‘(i) collecting, developing, and review-
1
ing safety information on OTC monograph 
2
drugs, including adverse event reports; 
3
‘‘(ii) developing and using improved 
4
adverse event data-collection systems, in-
5
cluding information technology systems; 
6
and 
7
‘‘(iii) developing and using improved 
8
analytical tools to assess potential safety 
9
risks, including access to external data-
10
bases. 
11
‘‘(E) Other activities necessary for imple-
12
mentation of section 505G. 
13
‘‘(7) The term ‘OTC monograph order request’ 
14
means a request for an order submitted under sec-
15
tion 505G(b)(5). 
16
‘‘(8) The term ‘Tier 1 OTC monograph order 
17
request’ means any OTC monograph order request 
18
not determined to be a Tier 2 OTC monograph 
19
order request. 
20
‘‘(9)(A) The term ‘Tier 2 OTC monograph 
21
order request’ means, subject to subparagraph (B), 
22
an OTC monograph order request for— 
23
236 
•HR 269 EH
‘‘(i) the reordering of existing information 
1
in the drug facts label of an OTC monograph 
2
drug; 
3
‘‘(ii) the addition of information to the 
4
other information section of the drug facts label 
5
of an OTC monograph drug, as limited by sec-
6
tion 201.66(c)(7) of title 21, Code of Federal 
7
Regulations (or any successor regulations); 
8
‘‘(iii) modification to the directions for use 
9
section of the drug facts label of an OTC mono-
10
graph drug, if such changes conform to changes 
11
made pursuant to section 505G(c)(3)(A); 
12
‘‘(iv) the standardization of the concentra-
13
tion or dose of a specific finalized ingredient 
14
within a particular finalized monograph; 
15
‘‘(v) a change to ingredient nomenclature 
16
to align with nomenclature of a standards-set-
17
ting organization; or 
18
‘‘(vi) addition of an interchangeable term 
19
in accordance with section 330.1 of title 21, 
20
Code of Federal Regulations (or any successor 
21
regulations). 
22
‘‘(B) The Secretary may, based on program im-
23
plementation experience or other factors found ap-
24
propriate by the Secretary, characterize any OTC 
25
237 
•HR 269 EH
monograph order request as a Tier 2 OTC mono-
1
graph order request (including recharacterizing a re-
2
quest from Tier 1 to Tier 2) and publish such deter-
3
mination in a proposed order issued pursuant to sec-
4
tion 505G. 
5
‘‘(10)(A) The term ‘OTC monograph drug facil-
6
ity’ means a foreign or domestic business or other 
7
entity that— 
8
‘‘(i) is— 
9
‘‘(I) under one management, either di-
10
rect or indirect; and 
11
‘‘(II) at one geographic location or ad-
12
dress engaged in manufacturing or proc-
13
essing the finished dosage form of an OTC 
14
monograph drug; 
15
‘‘(ii) includes a finished dosage form man-
16
ufacturer facility in a contractual relationship 
17
with the sponsor of one or more OTC mono-
18
graph drugs to manufacture or process such 
19
drugs; and 
20
‘‘(iii) does not include a business or other 
21
entity whose only manufacturing or processing 
22
activities are one or more of the following: pro-
23
duction of clinical research supplies, testing, or 
24
placement of outer packaging on packages con-
25
238 
•HR 269 EH
taining multiple products, for such purposes as 
1
creating multipacks, when each monograph 
2
drug product contained within the overpack-
3
aging is already in a final packaged form prior 
4
to placement in the outer overpackaging. 
5
‘‘(B) For purposes of subparagraph (A)(i)(II), 
6
separate buildings or locations within close proximity 
7
are considered to be at one geographic location or 
8
address if the activities conducted in such buildings 
9
or locations are— 
10
‘‘(i) closely related to the same business 
11
enterprise; 
12
‘‘(ii) under the supervision of the same 
13
local management; and 
14
‘‘(iii) under a single FDA establishment 
15
identifier and capable of being inspected by the 
16
Food and Drug Administration during a single 
17
inspection. 
18
‘‘(C) If a business or other entity would meet 
19
criteria specified in subparagraph (A), but for being 
20
under multiple management, the business or other 
21
entity is deemed to constitute multiple facilities, one 
22
per management entity, for purposes of this para-
23
graph. 
24
239 
•HR 269 EH
‘‘(11) The term ‘OTC monograph drug meet-
1
ing’ means any meeting regarding the content of a 
2
proposed OTC monograph order request. 
3
‘‘(12) The term ‘person’ includes an affiliate of 
4
a person. 
5
‘‘(13) The terms ‘requestor’ and ‘sponsor’ have 
6
the meanings given such terms in section 505G. 
7
‘‘SEC. 744M. AUTHORITY TO ASSESS AND USE OTC MONO-
8
GRAPH FEES. 
9
‘‘(a) TYPES OF FEES.—Beginning with fiscal year 
10
2019, the Secretary shall assess and collect fees in accord-
11
ance with this section as follows: 
12
‘‘(1) FACILITY FEE.— 
13
‘‘(A) IN
GENERAL.—Each person that 
14
owns a facility identified as an OTC monograph 
15
drug facility on December 31 of the fiscal year 
16
or at any time during the preceding 12-month 
17
period shall be assessed an annual fee for each 
18
such facility as determined under subsection 
19
(c). 
20
‘‘(B) EXCEPTIONS.— 
21
‘‘(i) A fee shall not be assessed under 
22
subparagraph (A) if the identified OTC 
23
monograph drug facility— 
24
240 
•HR 269 EH
‘‘(I) has ceased all activities re-
1
lated to OTC monograph drugs prior 
2
to January 31, 2019, for the first pro-
3
gram year, and December 31 of the 
4
fiscal year for subsequent fiscal years; 
5
and 
6
‘‘(II) has updated its registration 
7
to reflect such change under the re-
8
quirements for drug establishment 
9
registration set forth in section 510. 
10
‘‘(ii) The amount of the fee for a con-
11
tract manufacturing organization facility 
12
shall be equal to two-thirds of the amount 
13
of the fee for an OTC monograph drug fa-
14
cility that is not a contract manufacturing 
15
organization facility. 
16
‘‘(C) AMOUNT.—The amount of fees estab-
17
lished under subparagraph (A) shall be estab-
18
lished under subsection (c). 
19
‘‘(D) DUE DATE.— 
20
‘‘(i) FOR FIRST PROGRAM YEAR.—For 
21
fiscal year 2019, the facility fees required 
22
under subparagraph (A) shall be due 45 
23
calendar days after publication of the Fed-
24
241 
•HR 269 EH
eral Register notice provided for under 
1
subsection (c)(4)(A). 
2
‘‘(ii) SUBSEQUENT
FISCAL
YEARS.— 
3
For each fiscal year after fiscal year 2019, 
4
the facility fees required under subpara-
5
graph (A) shall be due on the later of— 
6
‘‘(I) the first business day of 
7
June of such year; or 
8
‘‘(II) the first business day after 
9
the enactment of an appropriations 
10
Act providing for the collection and 
11
obligation of fees under this section 
12
for such year. 
13
‘‘(2) 
OTC 
MONOGRAPH
ORDER
REQUEST 
14
FEE.— 
15
‘‘(A) IN GENERAL.—Each person that sub-
16
mits an OTC monograph order request shall be 
17
subject to a fee for an OTC monograph order 
18
request. The amount of such fee shall be— 
19
‘‘(i) for a Tier 1 OTC monograph 
20
order request, $500,000, adjusted for in-
21
flation for the fiscal year (as determined 
22
under subsection (c)(1)(B)); and 
23
‘‘(ii) for a Tier 2 OTC monograph 
24
order request, $100,000 adjusted for infla-
25
242 
•HR 269 EH
tion for the fiscal year (as determined 
1
under subsection (c)(1)(B)). 
2
‘‘(B) DUE
DATE.—The OTC monograph 
3
order request fees required under subparagraph 
4
(A) shall be due on the date of submission of 
5
the OTC monograph order request. 
6
‘‘(C) EXCEPTION
FOR
CERTAIN
SAFETY 
7
CHANGES.—A person who is named as the re-
8
questor in an OTC monograph order shall not 
9
be subject to a fee under subparagraph (A) if 
10
the Secretary finds that the OTC monograph 
11
order request seeks to change the drug facts la-
12
beling of an OTC monograph drug in a way 
13
that would add to or strengthen— 
14
‘‘(i) a contraindication, warning, or 
15
precaution; 
16
‘‘(ii) a statement about risk associated 
17
with misuse or abuse; or 
18
‘‘(iii) an instruction about dosage and 
19
administration that is intended to increase 
20
the safe use of the OTC monograph drug. 
21
‘‘(D) REFUND OF FEE IF ORDER REQUEST 
22
IS RECATEGORIZED AS A TIER 2 OTC MONO-
23
GRAPH ORDER REQUEST.—If the Secretary de-
24
termines that an OTC monograph request ini-
25
243 
•HR 269 EH
tially characterized as Tier 1 shall be re-charac-
1
terized as a Tier 2 OTC monograph order re-
2
quest, and the requestor has paid a Tier 1 fee 
3
in accordance with subparagraph (A)(i), the 
4
Secretary shall refund the requestor the dif-
5
ference between the Tier 1 and Tier 2 fees de-
6
termined under subparagraphs (A)(i) and 
7
(A)(ii), respectively. 
8
‘‘(E) REFUND OF FEE IF ORDER REQUEST 
9
REFUSED FOR FILING OR WITHDRAWN BEFORE 
10
FILING.—The Secretary shall refund 75 percent 
11
of the fee paid under subparagraph (B) for any 
12
order request which is refused for filing or was 
13
withdrawn before being accepted or refused for 
14
filing. 
15
‘‘(F) FEES
FOR
ORDER
REQUESTS
PRE-
16
VIOUSLY REFUSED FOR FILING OR WITHDRAWN 
17
BEFORE
FILING.—An OTC monograph order 
18
request that was submitted but was refused for 
19
filing, or was withdrawn before being accepted 
20
or refused for filing, shall be subject to the full 
21
fee under subparagraph (A) upon being resub-
22
mitted or filed over protest. 
23
‘‘(G) REFUND OF FEE IF ORDER REQUEST 
24
WITHDRAWN.—If an order request is withdrawn 
25
244 
•HR 269 EH
after the order request was filed, the Secretary 
1
may refund the fee or a portion of the fee if no 
2
substantial work was performed on the order 
3
request after the application was filed. The Sec-
4
retary shall have the sole discretion to refund a 
5
fee or a portion of the fee under this subpara-
6
graph. A determination by the Secretary con-
7
cerning a refund under this subparagraph shall 
8
not be reviewable. 
9
‘‘(3) REFUNDS.— 
10
‘‘(A) IN
GENERAL.—Other than refunds 
11
provided pursuant to any of subparagraphs (D) 
12
through (G) of paragraph (2), the Secretary 
13
shall not refund any fee paid under paragraph 
14
(1) except as provided in subparagraph (B). 
15
‘‘(B) DISPUTES
CONCERNING
FEES.—To 
16
qualify for the return of a fee claimed to have 
17
been paid in error under paragraph (1) or (2), 
18
a person shall submit to the Secretary a written 
19
request justifying such return within 180 cal-
20
endar days after such fee was paid. 
21
‘‘(4) NOTICE.—Within the timeframe specified 
22
in subsection (c), the Secretary shall publish in the 
23
Federal Register the amount of the fees under para-
24
graph (1) for such fiscal year. 
25
245 
•HR 269 EH
‘‘(b) FEE REVENUE AMOUNTS.— 
1
‘‘(1) FISCAL YEAR 2019.—For fiscal year 2019, 
2
fees under subsection (a)(1) shall be established to 
3
generate a total facility fee revenue amount equal to 
4
the sum of— 
5
‘‘(A) the annual base revenue for fiscal 
6
year 2019 (as determined under paragraph 
7
(3)); 
8
‘‘(B) the dollar amount equal to the oper-
9
ating reserve adjustment for the fiscal year, if 
10
applicable (as determined under subsection 
11
(c)(2)); and 
12
‘‘(C) additional direct cost adjustments (as 
13
determined under subsection (c)(3)). 
14
‘‘(2) SUBSEQUENT FISCAL YEARS.—For each of 
15
the fiscal years 2020 through 2023, fees under sub-
16
section (a)(1) shall be established to generate a total 
17
facility fee revenue amount equal to the sum of— 
18
‘‘(A) the annual base revenue for the fiscal 
19
year (as determined under paragraph (3)); 
20
‘‘(B) the dollar amount equal to the infla-
21
tion adjustment for the fiscal year (as deter-
22
mined under subsection (c)(1)); 
23
‘‘(C) the dollar amount equal to the oper-
24
ating reserve adjustment for the fiscal year, if 
25
246 
•HR 269 EH
applicable (as determined under subsection 
1
(c)(2)); 
2
‘‘(D) additional direct cost adjustments (as 
3
determined under subsection (c)(3)); and 
4
‘‘(E) additional dollar amounts for each 
5
fiscal year as follows: 
6
‘‘(i) $7,000,000 for fiscal year 2020. 
7
‘‘(ii) $6,000,000 for fiscal year 2021. 
8
‘‘(iii) $7,000,000 for fiscal year 2022. 
9
‘‘(iv) $3,000,000 for fiscal year 2023. 
10
‘‘(3) ANNUAL BASE REVENUE.—For purposes 
11
of paragraphs (1)(A) and (2)(A), the dollar amount 
12
of the annual base revenue for a fiscal year shall 
13
be— 
14
‘‘(A) for fiscal year 2019, $8,000,000; and 
15
‘‘(B) for fiscal years 2020 through 2023, 
16
the dollar amount of the total revenue amount 
17
established under this subsection for the pre-
18
vious fiscal year, not including any adjustments 
19
made under subsection (c)(2) or (c)(3). 
20
‘‘(c) ADJUSTMENTS; ANNUAL FEE SETTING.— 
21
‘‘(1) INFLATION ADJUSTMENT.— 
22
‘‘(A) IN GENERAL.—For purposes of sub-
23
section (b)(2)(B), the dollar amount of the in-
24
flation adjustment to the annual base revenue 
25
247 
•HR 269 EH
for fiscal year 2020 and each subsequent fiscal 
1
year shall be equal to the product of— 
2
‘‘(i) such annual base revenue for the 
3
fiscal year under subsection (b)(2); and 
4
‘‘(ii) the inflation adjustment percent-
5
age under subparagraph (C). 
6
‘‘(B) OTC MONOGRAPH ORDER REQUEST 
7
FEES.—For purposes of subsection (a)(2), the 
8
dollar amount of the inflation adjustment to the 
9
fee for OTC monograph order requests for fis-
10
cal year 2020 and each subsequent fiscal year 
11
shall be equal to the product of— 
12
‘‘(i) the applicable fee under sub-
13
section (a)(2) for the preceding fiscal year; 
14
and 
15
‘‘(ii) the inflation adjustment percent-
16
age under subparagraph (C). 
17
‘‘(C) INFLATION
ADJUSTMENT
PERCENT-
18
AGE.—The inflation adjustment percentage 
19
under this subparagraph for a fiscal year is 
20
equal to— 
21
‘‘(i) for each of fiscal years 2020 and 
22
2021, the average annual percent change 
23
that occurred in the Consumer Price Index 
24
for urban consumers (Washington-Balti-
25
248 
•HR 269 EH
more, DC–MD–VA–WV; Not Seasonally 
1
Adjusted; All items; Annual Index) for the 
2
first 3 years of the preceding 4 years of 
3
available data; and 
4
‘‘(ii) for each of fiscal years 2022 and 
5
2023, the sum of— 
6
‘‘(I) the average annual percent 
7
change in the cost, per full-time equiv-
8
alent position of the Food and Drug 
9
Administration, of all personnel com-
10
pensation and benefits paid with re-
11
spect to such positions for the first 3 
12
years of the preceding 4 fiscal years, 
13
multiplied by the proportion of per-
14
sonnel 
compensation 
and 
benefits 
15
costs to total costs of OTC mono-
16
graph drug activities for the first 3 
17
years of the preceding 4 fiscal years; 
18
and 
19
‘‘(II) the average annual percent 
20
change that occurred in the Consumer 
21
Price Index for urban consumers 
22
(Washington-Baltimore, DC–MD–VA– 
23
WV; Not Seasonally Adjusted; All 
24
items; Annual Index) for the first 3 
25
249 
•HR 269 EH
years of the preceding 4 years of 
1
available data multiplied by the pro-
2
portion of all costs other than per-
3
sonnel 
compensation 
and 
benefits 
4
costs to total costs of OTC mono-
5
graph drug activities for the first 3 
6
years of the preceding 4 fiscal years. 
7
‘‘(2) OPERATING RESERVE ADJUSTMENT.— 
8
‘‘(A) IN GENERAL.—For fiscal year 2019 
9
and subsequent fiscal years, for purposes of 
10
subsections (b)(1)(B) and (b)(2)(C), the Sec-
11
retary may, in addition to adjustments under 
12
paragraph (1), further increase the fee revenue 
13
and fees if such an adjustment is necessary to 
14
provide operating reserves of carryover user 
15
fees for OTC monograph drug activities for not 
16
more than the number of weeks specified in 
17
subparagraph (B). 
18
‘‘(B) NUMBER OF WEEKS.—The number of 
19
weeks specified in this subparagraph is— 
20
‘‘(i) 3 weeks for fiscal year 2019; 
21
‘‘(ii) 7 weeks for fiscal year 2020; 
22
‘‘(iii) 10 weeks for fiscal year 2021; 
23
‘‘(iv) 10 weeks for fiscal year 2022; 
24
and 
25
250 
•HR 269 EH
‘‘(v) 10 weeks for fiscal year 2023. 
1
‘‘(C) DECREASE.—If the Secretary has 
2
carryover balances for such process in excess of 
3
10 weeks of the operating reserves referred to 
4
in subparagraph (A), the Secretary shall de-
5
crease the fee revenue and fees referred to in 
6
such subparagraph to provide for not more than 
7
10 weeks of such operating reserves. 
8
‘‘(D) RATIONALE
FOR
ADJUSTMENT.—If 
9
an adjustment under this paragraph is made, 
10
the rationale for the amount of the increase or 
11
decrease (as applicable) in fee revenue and fees 
12
shall be contained in the annual Federal Reg-
13
ister notice under paragraph (4) establishing 
14
fee revenue and fees for the fiscal year involved. 
15
‘‘(3) 
ADDITIONAL
DIRECT
COST
ADJUST-
16
MENT.—The Secretary shall, in addition to adjust-
17
ments under paragraphs (1) and (2), further in-
18
crease the fee revenue and fees for purposes of sub-
19
section (b)(2)(D) by an amount equal to— 
20
‘‘(A) $14,000,000 for fiscal year 2019; 
21
‘‘(B) $7,000,000 for fiscal year 2020; 
22
‘‘(C) $4,000,000 for fiscal year 2021; 
23
‘‘(D) $3,000,000 for fiscal year 2022; and 
24
‘‘(E) $3,000,000 for fiscal year 2023. 
25
251 
•HR 269 EH
‘‘(4) ANNUAL FEE SETTING.— 
1
‘‘(A) FISCAL
YEAR
2019.—The Secretary 
2
shall, not later than the second Monday in 
3
March of 2019— 
4
‘‘(i) establish OTC monograph drug 
5
facility fees for fiscal year 2019 under sub-
6
section (a), based on the revenue amount 
7
for such year under subsection (b) and the 
8
adjustments provided under this sub-
9
section; and 
10
‘‘(ii) publish fee revenue, facility fees, 
11
and OTC monograph order requests in the 
12
Federal Register. 
13
‘‘(B) SUBSEQUENT
FISCAL
YEARS.—The 
14
Secretary shall, not later than the second Mon-
15
day in March of each fiscal year that begins 
16
after September 30, 2019— 
17
‘‘(i) establish for each such fiscal 
18
year, based on the revenue amounts under 
19
subsection (b) and the adjustments pro-
20
vided under this subsection— 
21
‘‘(I) OTC monograph drug facil-
22
ity fees under subsection (a)(1); and 
23
252 
•HR 269 EH
‘‘(II) OTC monograph order re-
1
quest fees under subsection (a)(2); 
2
and 
3
‘‘(ii) 
publish 
such 
fee 
revenue 
4
amounts, facility fees, and OTC mono-
5
graph order request fees in the Federal 
6
Register. 
7
‘‘(d) IDENTIFICATION OF FACILITIES.—Each person 
8
that owns an OTC monograph drug facility shall submit 
9
to the Secretary the information required under this sub-
10
section each year. Such information shall, for each fiscal 
11
year— 
12
‘‘(1) be submitted as part of the requirements 
13
for drug establishment registration set forth in sec-
14
tion 510; and 
15
‘‘(2) include for each such facility, at a min-
16
imum, identification of the facility’s business oper-
17
ation as that of an OTC monograph drug facility. 
18
‘‘(e) EFFECT OF FAILURE TO PAY FEES.— 
19
‘‘(1) OTC MONOGRAPH DRUG FACILITY FEE.— 
20
‘‘(A) IN GENERAL.—Failure to pay the fee 
21
under subsection (a)(1) within 20 calendar days 
22
of the due date as specified in subparagraph 
23
(D) of such subsection shall result in the fol-
24
lowing: 
25
253 
•HR 269 EH
‘‘(i) The Secretary shall place the fa-
1
cility on a publicly available arrears list. 
2
‘‘(ii) All OTC monograph drugs man-
3
ufactured in such a facility or containing 
4
an ingredient manufactured in such a facil-
5
ity shall be deemed misbranded under sec-
6
tion 502(ff). 
7
‘‘(B) APPLICATION
OF
PENALTIES.—The 
8
penalties under this paragraph shall apply until 
9
the fee established by subsection (a)(1) is paid. 
10
‘‘(2) ORDER REQUESTS.—An OTC monograph 
11
order request submitted by a person subject to fees 
12
under subsection (a) shall be considered incomplete 
13
and shall not be accepted for filing by the Secretary 
14
until all fees owed by such person under this section 
15
have been paid. 
16
‘‘(3) MEETINGS.—A person subject to fees 
17
under this section shall be considered ineligible for 
18
OTC monograph drug meetings until all such fees 
19
owed by such person have been paid. 
20
‘‘(f) CREDITING AND AVAILABILITY OF FEES.— 
21
‘‘(1) IN GENERAL.—Fees authorized under sub-
22
section (a) shall be collected and available for obliga-
23
tion only to the extent and in the amount provided 
24
in advance in appropriations Acts. Such fees are au-
25
254 
•HR 269 EH
thorized to remain available until expended. Such 
1
sums as may be necessary may be transferred from 
2
the Food and Drug Administration salaries and ex-
3
penses appropriation account without fiscal year lim-
4
itation to such appropriation account for salaries 
5
and expenses with such fiscal year limitation. The 
6
sums transferred shall be available solely for OTC 
7
monograph drug activities. 
8
‘‘(2) 
COLLECTIONS
AND
APPROPRIATION 
9
ACTS.— 
10
‘‘(A) IN
GENERAL.—Subject to subpara-
11
graph (C), the fees authorized by this section 
12
shall be collected and available in each fiscal 
13
year in an amount not to exceed the amount 
14
specified in appropriation Acts, or otherwise 
15
made available for obligation, for such fiscal 
16
year. 
17
‘‘(B) USE
OF
FEES
AND
LIMITATION.— 
18
The fees authorized by this section shall be 
19
available to defray increases in the costs of the 
20
resources allocated for OTC monograph drug 
21
activities (including increases in such costs for 
22
an additional number of full-time equivalent po-
23
sitions in the Department of Health and 
24
Human Services to be engaged in such activi-
25
255 
•HR 269 EH
ties), only if the Secretary allocates for such 
1
purpose an amount for such fiscal year (exclud-
2
ing amounts from fees collected under this sec-
3
tion) no less than $12,000,000, multiplied by 
4
the adjustment factor applicable to the fiscal 
5
year involved under subsection (c)(1). 
6
‘‘(C) COMPLIANCE.—The Secretary shall 
7
be considered to have met the requirements of 
8
subparagraph (B) in any fiscal year if the costs 
9
funded by appropriations and allocated for OTC 
10
monograph drug activities are not more than 15 
11
percent below the level specified in such sub-
12
paragraph. 
13
‘‘(D) PROVISION FOR EARLY PAYMENTS IN 
14
SUBSEQUENT YEARS.—Payment of fees author-
15
ized under this section for a fiscal year (after 
16
fiscal year 2019), prior to the due date for such 
17
fees, may be accepted by the Secretary in ac-
18
cordance with authority provided in advance in 
19
a prior year appropriations Act. 
20
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
21
For each of the fiscal years 2019 through 2023, 
22
there is authorized to be appropriated for fees under 
23
this section an amount equal to the total amount of 
24
fees assessed for such fiscal year under this section. 
25
256 
•HR 269 EH
‘‘(g) COLLECTION OF UNPAID FEES.—In any case 
1
where the Secretary does not receive payment of a fee as-
2
sessed under subsection (a) within 30 calendar days after 
3
it is due, such fee shall be treated as a claim of the United 
4
States Government subject to subchapter II of chapter 37 
5
of title 31, United States Code. 
6
‘‘(h) CONSTRUCTION.—This section may not be con-
7
strued to require that the number of full-time equivalent 
8
positions in the Department of Health and Human Serv-
9
ices, for officers, employers, and advisory committees not 
10
engaged in OTC monograph drug activities, be reduced 
11
to offset the number of officers, employees, and advisory 
12
committees so engaged. 
13
‘‘SEC. 744N. REAUTHORIZATION; REPORTING REQUIRE-
14
MENTS. 
15
‘‘(a) PERFORMANCE REPORT.—Beginning with fiscal 
16
year 2019, and not later than 120 calendar days after the 
17
end of each fiscal year thereafter for which fees are col-
18
lected under this part, the Secretary shall prepare and 
19
submit to the Committee on Energy and Commerce of the 
20
House of Representatives and the Committee on Health, 
21
Education, Labor, and Pensions of the Senate a report 
22
concerning the progress of the Food and Drug Adminis-
23
tration in achieving the goals identified in the letters de-
24
scribed in section 2001(b) of the Over-the-Counter Mono-
25
257 
•HR 269 EH
graph Safety, Innovation, and Reform Act of 2019 during 
1
such fiscal year and the future plans of the Food and 
2
Drug Administration for meeting such goals. 
3
‘‘(b) FISCAL REPORT.—Not later than 120 calendar 
4
days after the end of fiscal year 2019 and each subsequent 
5
fiscal year for which fees are collected under this part, 
6
the Secretary shall prepare and submit to the Committee 
7
on Energy and Commerce of the House of Representatives 
8
and the Committee on Health, Education, Labor, and 
9
Pensions of the Senate a report on the implementation 
10
of the authority for such fees during such fiscal year and 
11
the use, by the Food and Drug Administration, of the fees 
12
collected for such fiscal year. 
13
‘‘(c) PUBLIC AVAILABILITY.—The Secretary shall 
14
make the reports required under subsections (a) and (b) 
15
available to the public on the internet website of the Food 
16
and Drug Administration. 
17
‘‘(d) REAUTHORIZATION.— 
18
‘‘(1) 
CONSULTATION.—In 
developing 
rec-
19
ommendations to present to the Congress with re-
20
spect to the goals described in subsection (a), and 
21
plans for meeting the goals, for OTC monograph 
22
drug activities for the first 5 fiscal years after fiscal 
23
year 2023, and for the reauthorization of this part 
24
258 
•HR 269 EH
for such fiscal years, the Secretary shall consult 
1
with— 
2
‘‘(A) the Committee on Energy and Com-
3
merce of the House of Representatives; 
4
‘‘(B) the Committee on Health, Education, 
5
Labor, and Pensions of the Senate; 
6
‘‘(C) scientific and academic experts; 
7
‘‘(D) health care professionals; 
8
‘‘(E) representatives of patient and con-
9
sumer advocacy groups; and 
10
‘‘(F) the regulated industry. 
11
‘‘(2) 
PUBLIC
REVIEW
OF
RECOMMENDA-
12
TIONS.—After negotiations with the regulated indus-
13
try, the Secretary shall— 
14
‘‘(A) present the recommendations devel-
15
oped under paragraph (1) to the congressional 
16
committees specified in such paragraph; 
17
‘‘(B) publish such recommendations in the 
18
Federal Register; 
19
‘‘(C) provide for a period of 30 calendar 
20
days for the public to provide written comments 
21
on such recommendations; 
22
‘‘(D) hold a meeting at which the public 
23
may present its views on such recommenda-
24
tions; and 
25
259 
•HR 269 EH
‘‘(E) after consideration of such public 
1
views and comments, revise such recommenda-
2
tions as necessary. 
3
‘‘(3) TRANSMITTAL OF RECOMMENDATIONS.— 
4
Not later than January 15, 2023, the Secretary 
5
shall transmit to the Congress the revised rec-
6
ommendations under paragraph (2), a summary of 
7
the views and comments received under such para-
8
graph, and any changes made to the recommenda-
9
tions in response to such views and comments.’’. 
10
Passed the House of Representatives January 8, 
2019. 
Attest: 
Clerk. 
116TH CONGRESS 
1ST SESSION 
H. R. 269 
AN ACT 
To reauthorize certain programs under the Public 
Health Service Act and the Federal Food, Drug, 
and Cosmetic Act with respect to public health 
security and all-hazards preparedness and re-
sponse, to clarify the regulatory framework with 
respect to certain nonprescription drugs that are 
marketed without an approved drug application, 
and for other purposes. 
